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1. REACTIVE OXYGEN SPECIES (ROS) 
The advent of oxygen into the Earth’s atmosphere was a crucial event that 
promoted the evolution of aerobic organisms, which are able to produce energy in 
a very efficient manner. One of the consequences of this improvement was the 
appearance of novel reactive molecules derived from oxygen, the reactive oxygen 
species (ROS) (Figure I). 
 
 
ROS include the superoxide (O2•-), hydrogen peroxide (H2O2) and hydroxyl 
radical (•OH). These species present higher chemical reactivity than oxygen and 
they are able to trigger both physiological and pathological processes. In general 
terms, under normal conditions, the level of cellular ROS is constant in a dynamic 
equilibrium, and this balance is modulated by cellular processes that produce ROS 
and eliminate them (Zhang et al., 2016). However, under certain circumstances, 
Figure I: Main mechanisms of cellular ROS production. Due to the high ROS 
reactivity, the interaction between different pathways is possible, in which the 
product of a reaction is used to generate new ROS. SOD: superoxide dismutase. 
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the rate of ROS production exceeds the ability of the antioxidant systems to 
eliminate them. This excess ROS, commonly called “oxidative stress”, results in 
the oxidation of proteins, nucleic acids and lipids (Poyton et al., 2009; Temple et 
al., 2005). Oxidative stress can trigger damage that can lead to the activation of 
autophagy of certain organelles, even leading to cell death (Brand, 2010). Indeed, 
in post-mortem brain samples of neurological diseases, there are signs of 
oxidative stress in neurons within the degenerating brain areas (Cannon and 
Greenamyre 2013; Federico et al., 2012). Thus, oxidative stress appears to be 
associated with the cause of neurodegenerative diseases. However, all clinical 
trials based on an antioxidant strategy performed so far in several 
neurodegenerative diseases were not conclusive (Halliwell 2013; Heyland et al., 
2013; Kamat et al., 2008; Snow et al., 2010), hence arguing against a pathological 
role of ROS. The reason is yet unknown, although has been suggested to be 
ascribed to the wrong design of the treatment with the antioxidants (Halliwell 
2013; Kamat et al., 2008). However, the option that ROS physiologically 
modulate survival pathways, hence antioxidant will be deleterious, has received 
none or very little attention. 
1.1.  Intracellular sources of ROS 
Various organelles within the cell can generate ROS physiologically. These 
include mitochondria, the endoplasmic reticulum and peroxisomes. In addition, 
various enzymes, including oxidases and oxygenases, generate ROS as part of 
their reaction cycles (Holmström and Finkel, 2014). Furthermore, ROS generation 
is species-, cell- and tissue-specific and also depends on the physiopatological 
state of the cells. For these reasons, defining the major intracellular source of ROS 
is complex. The best-characterized intracellular sources of ROS are described in 
the successive sections. 
1.1.1 Mitochondria 
From a quantitative perspective, mitochondria are the largest sources of 
ROS within most mammalian cells (Murphy, 2009). These organelles generate 
ATP in an oxygen-dependent manner, during which the flow of electrons 
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culminates at complex IV of the electron transport chain (ETC), with the 
reduction of oxygen to water. Throughout this process, 1-3% oxygen can also 
undergo a one-electron reduction to generate superoxide (Green et al., 2011; 
Murphy, 2009). Within the mitochondria eight sites of superoxide production 
have been identified (Figure II). The major sites of superoxide production are 
complexes I and III of the ETC (Brand, 2010). Superoxide is rapidly converted 
into hydrogen peroxide by superoxide dismutase 2 (SOD2 or MnSOD), located 
within the mitochondria. 
 
 
1.1.2 NADPH oxidases 
The family of the NADPH oxidases is another important intracellular 
source of ROS. NADPH oxidases, known as NOX enzymes, are multi-subunit 
enzymes which primary catalytic function is the generation of ROS (Belarbi et al., 
2017). The major source of ROS generation is a flavin- and haem-containing 
protein complex that transfer electrons from cytosolic NADPH to oxygen to 
Figure II: Superoxide production within the mitochondria. Mitochondria are the largest source of ROS in 
most of mammalian cell types. Complexes I and III are the major sites of superoxide production. Other 
contributors include metabolic enzymes in the mitochondrial matrix, such as OGDH (2-oxoglutarate 
dehydrogenase) and PDH (pyruvate dehydrogenase), and the mitochondrial membrane forms of GPDH 
(Glycerol 3-phosphate dehydrogenase) and the FQR (electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial) system. Obtained from Holmström and Finkel, 2014. 
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purposely produce superoxide or hydrogen peroxide (Holmström and Finkel, 
2014). 
Seven members of the NOX family were described in humans, NOX1-5 and 
Duox1-2, which they differ for the specific ROS produced and for the sub-cellular 
localization. NOX1, -2, -3 and -5 and Duox1 and -2 are anchored to the plasma 
membrane and they release superoxide in the extracellular space, participating in 
processes like the innate immunity (NOX2) or in the control of the arterial 
pressure (NOX1) (Altenhöfer et al., 2012). NOX4 mainly produce hydrogen 
peroxide and is localized in the mitochondrial and endoplasmic reticulum 
membranes (Block et al., 2009; Petry et al., 2006). Therefore, depending on the 
cell state, the subcellular localization, the cell type and the specific NOXs 
isoforms expressed, NOX-derived ROS could participate differently in redox 
signaling (Lambeth and Neish, 2014). The distribution of NOXs in the brain 
shows that neurons express NOX1, -2 and -4, whereas astrocytes mostly NOX2, 
but also NOX1 and -4 (Belarbi et al., 2017; Nayernia and Jaquet, 2014). The 
majority of studies on the physiological roles of NOXs in the central nervous 
system have focused on their participation in the host defense. However, under 
basal conditions, NADPH oxidases produce small amounts of ROS, which the 
most probable function is redox signaling (Nayernia and Jaquet, 2014). 
1.1.3 Other intracellular sources of ROS 
In addition to mitochondria and the NOX family, there are a wide range of 
enzymes, such as xanthine oxidase, nitric oxide synthase, cyclooxygenases, 
cytochrome P450 enzymes and lipoxygenases, that are able to produce ROS 
(Holmström and Finkel, 2014). Furthermore, organelles like peroxisome and the 
endoplasmic reticulum can produce oxidants. The relative contribution of these 
additional sources of ROS varies according to cell type, but, in basal conditions, 




1.1.4 ROS production in the brain 
Within the central nervous system the production of ROS differs between 
the cell types. Neurons and astrocytes, the two most abundant cell types in the 
brain, present a differential pattern of mitochondrial ROS (mROS) production, 
with glial cells producing mROS severalfold faster than neurons (Lopez-Fabuel et 
al., 2016). However, the physiological role of this major mROS production by 
astrocytes is still elusive. These differences are explained by the different 
organization of the mitochondrial respiratory chain between the two cell types. 
Astrocytes present less complex I assembled in supercomplexes and more free 
complex I compared to neurons (Lopez-Fabuel et al., 2016). These data confirm 
the higher mROS production by free complex I, compared to the complex I 
assembled in supercomplexes, previously seen in liposomes (Maranzana et al., 
2013). Furthermore, this different assembly of complex I into supercomplexes 
between neuronal and glial cells could explain their bioenergetic differences. 
Neurons present a higher respiration rate compared with astrocytes (Lopez-Fabuel 
et al., 2016), which is consistent with the dependency of neural cells on oxidative 
phosphorylation for neurotransmission and survival (Almeida et al., 2001; 
Almeida et al., 2004; Herrero-Mendez et al. 2009) and with the glycolytic 
metabolism of astrocytes (García-Nogales et al., 2003; Herrero-Mendez et al., 
2009). 
1.2. Antioxidant systems in the central nervous system 
To maintain the redox homeostasis, and therefore to counteract the deleterious 
effects of excess ROS, brain cells have developed several enzymatic antioxidant 
systems (Figure III). Superoxide is rapidly inactivated and converted to hydrogen 
peroxide by superoxide dismutase (SOD). There are three isoform of this enzyme, 
depending on its localization: SOD1 or Cu/Zn-SOD (cytosolic), SOD2 or Mn-
SOD (mitochondrial) and SOD3 (extracellular). 
Considering its pro-oxidant properties and its role in cell signaling, the levels of 
hydrogen peroxide need to be tightly regulated, for which cells use different 
enzymatic systems that neutralize it to water. The most important are 
peroxiredoxins (Prxs), glutathione peroxidases (GPxs) and catalase. 
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Catalase is an haem-containing enzyme localized in the peroxisomes that converts 
hydrogen peroxide to water in a direct manner (Dringen et al., 2005). 
Peroxiredoxins are a family of peroxidases that contribute to the elimination of 
organic hydroperoxides and hydrogen peroxides (Circu and Aw, 2010). To do so, 
peroxiredoxins posess an active site containing cysteines able to oxidize 
themselves at sulphenic acid (Cys-SOH) and subsequently to condense with a 
cysteine localized in the C-terminal subunit to form a disulphide (D’Autréaux and 
Toledano, 2007). This disulphide is then reduced by the thioredoxin 
(Trx)/thioredoxin reductase (TrxR) system at the expense of an equivalent of 
NADPH to regenerate cysteine moieties of peroxiredoxin (Patenaude et al., 2005). 
Glutathione peroxidases (GPx) convert hydrogen peroxide to water at the expense 
of the tripeptide glutathione (GSH, g-glutamyl-cysteinyl-glicine) which become 
oxidized to its disulphide form GSSG (Flohé et al., 2011). GSH is then 
regenerated by glutathione reductase (GR), which transfers electrons from 
NADPH to GSSG (Dringen et al., 2005). Since it provides reducing equivalents 
for the regeneration of GSH, NADPH plays a pivotal role in the redox 
homeostasis of the brain, especially in neurons (Bouzier-Sore and Bolaños, 2015). 
These cells contains very low amounts of glutathione (Bolaños et al., 1995; 
Dringen et al., 1999), hence the recycling of GSH from GSSG is critical for their 
survival. Most of the cytosolic pool of NADPH is produced in the pentose 
phosphate pathway (PPP) (Wamelink et al., 2008), underlying the 
interconnections between the glucose metabolism and redox homeostasis within 
the central nervous system.  
Considering that the hydrogen peroxide concentration needs to be strictly 
regulated spatially and temporarily, mammalian cells express several isoforms of 
peroxiredoxins, thioredoxins and glutathione peroxidases in the cytosol, nucleus, 
endoplasmic reticulum and mitochondria (Hekimi et al., 2011; Marí et al., 2009; 





It is a remarkable fact that numerous antioxidant enzymes depend on GSH and 
other thiols as cofactors. Considering that glutathione is the most abundant 
mammalian thiol-containing antioxidant (Dringen, 2000), its importance in the 
redox homeostasis is crucial. For this reason, glutathione metabolism receives a 
detailed analysis in successive sections. 
Besides the enzymatic antioxidant systems, the brain contains ascorbic acid and 
vitamin E, which act as direct radical scavengers through their hydroxyl moieties. 
The ascorbate is especially abundant in neurons (Shimizu et al., 1960). 
Nevertheless, astrocytes possess more vitamin E, compared with neurons, which 
protects glial cells against mitochondrial oxidative damage (Heales et al., 1994). 
1.3. ROS functions in cellular signaling 
Traditionally ROS are considered as harmful and unregulated agents, with random 
intracellular targets. Indeed, due to their greater chemical reactivity, ROS oxidize 
Figure III: Main antioxidant systems within the cell. Superoxide is converted to hydrogen peroxide by 
superoxide dismutase (SOD). Hydrogen peroxide is neutralized to water by several enzymes, including 
catalase (CAT), peroxiredoxins (Prx) or glutathione peroxidase (GPx). The thioredoxin (Trx) / thioredoxin 
reductase (TrxR) system regenerates the reduced form of peroxiredoxin (Prxred). GR: glutathione reductase, 
GSH: glutathione reduced form, GSSG: glutathione disulphide form, NADP+: nicotinamide adenine 
dinucleotide phosphate oxidized form, NADPH: nicotinamide adenine dinucleotide phosphate reduced form. 
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lipids, DNA and proteins and this may lead to the accumulation of damaged 
biomolecules, and contribute to a range of pathologies. Although this nonspecific, 
random and damaging aspect of ROS biology persists, a growing body of 
evidence now suggests that ROS act as signaling molecules in several 
physiological processes (D’Autréaux and Toledano, 2007; Holmström and Finkel, 
2014; Wang and Hai, 2016). However, this view is not free from controversy. 
1.3.1 ROS chemistry sets target specificity 
The scepticism about the physiological functions of ROS as second 
messenger stems from the idea that they lack of the specificity required for 
signaling processes. While this might be true for hydroxyl radical, which has 
indiscriminate reactivity toward biomolecules (D’Autréaux and Toledano, 2007), 
superoxide and hydrogen peroxide have specific biological targets. This 
specificity comes from their chemical proprieties, which include reactivity, half-
life and lipid solubility (D’Autréaux and Toledano, 2007). 
The instability of superoxide and its inability to cross membranes make this ROS 
a poor signaling molecule (D’Autréaux and Toledano, 2007). In contrast to 
superoxide, the chemical characteristics of hydrogen peroxide make this ROS 
more suitable for signaling. First of all, hydrogen peroxide is able to cross 
membranes by diffusion or, more rapidly, transported by a specific aquaporin, the 
peroxiporin (Bienert et al., 2007). Moreover, its relative stability compared to 
other ROS (cellular half life ~1 ms, in vivo concentration ~10-7 M) supports its 
role in redox signaling (Giorgio et al., 2007). Last, but not less important, 
hydrogen peroxide is a poor oxidant and reacts mildly with [Fe-S] clusters, very 
slowly with glutathione and free cysteine (Cys) and methionine (Met), and it 
loosely binds metals. However, its reactivity towards Cys residues can 
significantly increase, depending on the protein environment (D’Autréaux and 
Toledano, 2007). In addition, the ability of Cys residues to cycle between 
different stable redox forms, makes them the ideal hydrogen peroxide target for 
redox signaling (Holmström and Finkel, 2014). It should to be noted that only the 
forms of Cys that can be reversibly oxidized operate in redox signaling. An 
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irreversible oxidation of Cys result in permanent protein damage that might lead 
to oxidative stress (Schieber and Chandel, 2014). 
Cysteines residues are not equally reactive, providing the basis for selectivity and 
specificity. Their reactivity is dictated by their solvent-exposed localization, 
ionization state and protein environment (D’Autréaux and Toledano, 2007). 
Depending on their pKa, Cys might exist as a thiolate anion (Cys-S-) at 
physiological pH and they are more susceptible to oxidation compared with the 
protonated cysteine thiol (Cys-SH) (Finkel, 2012). During redox signaling, 
hydrogen peroxide oxidizes the thiolate anion to the sulphenic form (Cys-SOH), 
causing allosteric changes within the protein that modulates its function 
(Holmström and Finkel, 2014) (Figure IV).  
 
 
Aside from the specificity and selectivity of ROS on their targets, the 
compartmentalization of ROS production within cells is an important determinant 
of whether damage or redox signaling occurs. In order to obtain an effective redox 
Figure IV: Reversible modulation of reactive Cys residues. Redox-sensitive target proteins present 
reactive Cys residues that could form thiolate anions (-S-) at physiological pH. Oxidation of this residue 
results in a sulphenic acid moiety (-SOH) that leads to a change in function of the target protein. The 
sulphenic acid form could form an intramolecular disulphide bond or conjugate with glutathione (GSH) to 
form an S-glutathionylated (-SSG) intermediate. Obtained from Holmström and Finkel, 2014. 
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signaling, the hydrogen peroxide-dependent oxidation of a given protein is likely 
to occur close to the source of hydrogen peroxide production (Schieber and 
Chandel, 2014). For example, mitochondria are very dynamic organelles that 
move to their targets, allowing mitochondrially generated hydrogen peroxide to 
activate specific pathways (Al-Mehdi et al., 2012). 
1.3.2 ROS modulate crucial pathways 
Reactive oxygen species, in particular hydrogen peroxide, are second 
messengers able to modulate pathways involved in nuclear transcription, cellular 
differentiation, cell death and ageing, among others. 
1.3.2.1. ROS modulate the HIF-1a pathway 
Mammalian cells possess several redox-sensitive transcription factors, 
which modulate the transcription of genes involved in different biological 
processes following a ROS-mediated activation. The family of the hypoxia-
inducible factors (HIFs) orchestrates the transcriptional response to hypoxia, 
promoting expression of erythropoietin to enhance red blood cell production, 
vascular endothelial growth factor to promote new blood vessel formation, and 
glycolytic enzymes to maintain ATP levels. Under normal oxygen conditions, 
prolyl hydroxylase domain protein 2 (PHD2) hydroxylates HIF-1a at two proline 
residues (Pro402 and Pro564), which targets the transcription factor for pVHL-
dependent proteasomal degradation (Kaelin and Ratcliffe, 2008). When oxygen 
levels decrease below 5%, PHD2 is inhibited, allowing the HIF-1a stabilization 
and its translocation to the nucleus where it forms a heterodimer with HIF-1b, 
which binds the hypoxia response elements (HRE) to initiate gene transcription. 
Early evidences that suggest that mROS modulate HIF-transcription activity came 
from the observations that cells depleted of mitochondrial DNA (rº cells) do not 
stabilize HIF-1a during hypoxia (Chandel et al., 1998). These rº cells lack a 
functional electron transport chain (ETC) and could not increase mROS under 
hypoxia. Wild type cells treated with ETC inhibitors phenocopied the rº cells 
(Chandel et al., 2000). The critical experiment that demonstrates that mROS, and 
not oxidative phosphorylation, stabilize HIF-1a under hypoxia was performed in 
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cells lacking the complex III subunit cytochrome b (Bell et al., 2007). These 
cytochrome b null cells cannot perform oxidative phosphorylation but can 
produce mROS and stabilize HIF-1a during hypoxia. 
1.3.2.2. ROS modulate the NRF2 pathway 
The transcriptional activity of the nuclear factor (erythroid-derived-2)-like 
2 (NRF2), the master regulator of the antioxidant response, is modulated similarly 
to HIF-1a. Under basal conditions, NRF2 is kept in the cytosol by associating 
with Kelch-like ECH-associated protein 1 (KEAP1) and the E3 ubiquitin ligase 
cullin 3 (CUL3), forming a complex that facilitates the ubiquitination and the 
subsequent proteasomal degradation of NRF2 (Kobayashi et al., 2004). Acting as 
a stress sensor, KEAP1 presents multiple thiols, which are direct targets of 
oxidants and electrophiles. Modifications of these thiols result in a conformational 
change of KEAP1 leading to the nuclear accumulation of NRF2 (Taguchi et al., 
2011). Once in the nucleus, NRF2 binds the antioxidant response element (ARE, 
5’-TGACnnnGC-3’) and promotes the transcription of a plethora of genes 
involved in the response to different cellular stresses (Taguchi et al., 2011). 
Considering the crucial role of this pathway in the redox homeostasis, NRF2 
receives a detailed analysis in successive sections. 
1.3.2.3. ROS modulate the cellular growth 
Hydrogen peroxide is required for activation of a number of cellular 
pathways involved in physiological and oncogenic cellular growth. The induction 
of cell proliferation by several growth factors (such as epidermal growth factor, 
platelet-derived growth factor, nerve growth factor and insulin) correlates with a 
transient increase of intracellular hydrogen peroxide, whereas antioxidant 
treatments prevent DNA synthesis (Finkel, 2000). Similarly, cellular 
transformation following the expression of activated oncogenes (such as Ras or 
overexpressed myc) is associated with increased intracellular hydrogen peroxide 
and is prevented by antioxidants (Giorgio M, et al., 2007). 
1.3.2.4. ROS modulate cellular differentiation 
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ROS are also essential for stem-cell differentiation. Scavenging ROS by 
overexpression of glutathione peroxidase retards differentiation of Drosophila 
multipotent hematopoietic progenitors, while increasing mROS by depletion of 
the mitochondrial complex I protein ND75 or deletion of SOD2 increased 
differentiation (Owusu-Ansah and Banerjee, 2009). Another evidence of the 
importance of redox signaling in stem-cell differentiation comes from the 
observation that in murine cardiomyocytes the arrest of the cell-cycle through 
activation of the DNA damage response, was subsequent of a mROS rise (Puente 
et al., 2014). This increase of mROS is consequent of a shift from glycolytic to 
oxidative metabolism, which occurs within the first week of the mouse life. 
Scavenging ROS by expressing a mitochondrial form of catalase (mCAT) 
specifically in cardiomyocites increases the undifferentiated cell number, 
confirming the critical role of mROS in cell differentiation (Puente et al., 2014). 
Another study shows that the increase of ROS early in neuronal development, due 
to a NRF2 decline, helps to establish a mildly oxidant environment, which is 
permissive for signaling pathways sensible to redox modulation involved in 
neuronal maturation, such as the Wnt pathway (Bell et al., 2015). 
1.3.2.5. ROS and aging 
In the middle of the past century, Denham Harman proposed the “Free radical 
theory of aging” as a molecular explanation why aging occurs (Harman, 1956). 
The theory proposes that free radicals, as by-product of oxidative metabolism, 
cause cumulative cellular damage resulting in overall loss of organismal fitness 
over time. However, longevity studies in multiple model organisms have not 
consistently demonstrated that antioxidants prevent aging. Early studies in 
Drosophila suggested that increasing SOD and catalase activity in the cytosol 
extend longevity (Orr and Sohal, 1994), although other investigators could not 
replicate these results (Mockett et al., 2010). Furthermore, careful measurements 
of ROS in Drosophila have not found any correlation between ROS levels and 
longevity (Schieber and Chandel, 2014). In mice, overexpression of SOD1 
together with catalase or SOD2, does not increase lifespan (Pérez et al., 2009). By 
contrast, the expression of mCAT, but not cytosolic or nuclear catalase, extends 
the longevity in mice (Schriner et al., 2005). The conventional interpretation is 
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that mCAT detoxifies mitochondrial matrix-generated hydrogen peroxide, 
preventing hydrogen peroxide-induced damage to mitochondria. An alternative 
explanation is that detoxification of matrix-generated hydrogen peroxide prevents 
leakage of hydrogen peroxide into the cytosol, interfering with normal ROS 
signaling pathways that prevent pathologies such as cancer, a major cause of 
death in laboratory mice (Schieber and Chandel, 2014). Studies carried out in 
several model organisms show that a mild increase of ROS could extend lifespan. 
In yeast, inhibition of target of rapamycin (mTOR) or caloric restriction extends 
chronological lifespan by increasing mROS (Mesquita et al., 2010; Pan et al., 
2011). In C. elegans, loss of mitochondrial SOD but not cytosolic SOD, extend 
lifetime (Schaar et al., 2015). The increased lifespan ROS-mediated has been 
found also in mammals. Mice heterozygous for mclk1, which is required for 
proper electron transport, show increased mROS (Lapointe et al., 2009). 
Furthermore, these mice present less oxidative damage to cytosolic proteins, 
supporting a model whereby elevated ROS levels are paradoxically protective 
through the induction of stress response pathways (Liu et al., 2005). 
ROS signaling is essential for homeostasis and adaption to stress. Hence, ROS 
concentration needs to be tightly regulated to maintain an optimal oxidative 
environment for cellular signaling which is ideal to maintain homeostasis. ROS 
levels below this range lead to a disruption on redox signaling and loss of 
homeostasis; by contrast, ROS level above the optimal range cause oxidative 
stress and aberrant cell signaling, that might results in pathologies such as cancer 




2. NRF2 PATHWAY 
During its life, every organism is challenged to fight against a variety of stressors, 
both endogenous (such as mROS) and exogenous (such as toxins), that disrupt 
cellular homeostasis. With the purpose to counteract these insults and survive, 
organisms evolved several mechanisms to maintain ROS homeostasis. One 
example is NRF2 or NFE2L2 (Nuclear factor erythroid-derived 2 like 2) pathway, 
which regulates more than 1% of the human genome encoding metabolic, 
detoxification, antioxidant and anti-inflammatory cytoprotective proteins 
(Malhotra et al., 2010). 
Figure V: ROS signaling. Depending on the ROS levels, redox signaling could be 
ideal to maintain homeostasis and to adapt to stress. ROS levels above the optimal 
range cause oxidative stress and aberrant cell signaling resulting in pathologies;, 
however, ROS levels below this optimal range lead to a disruption of redox signaling 
resulting in loss of homeostasis.  
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2.1. Structure and functions of NRF2 
NRF2 is encoded by the gene NFE2L2 and belongs to the family of basic leucine 
zipper (bZIP) transcription factors (Moi et al., 1994). In vertebrates, other 
members of the CNC-bZIP family include the nuclear factor erythroid-derived 2 
like 1 (NRF1) and the nuclear factor erythroid-derived 2 like 3 (NRF3) (Andrews 
et al., 1993; Chan et al., 1993; Kobayashi et al., 1999) In mammals, NRF1 and 
NRF2 are well known for their role in the transcriptional modulation of 
cytoprotective genes in response to stress (Biswas and Chan, 2010; Venugopal 
and Jaiswal, 1998), although NRF2 appears to be more potent in activating ARE-
regulated genes that NRF1 (Jaiswal, 2004). In contrast, NRF3 has been linked to 
differentiation, inflammation and carcinogenesis (Chevillard and Blank, 2011).  
2.1.1 Structure of NRF2 
The NRF2 protein in humans is 605 amino acids long and contains seven 
highly conserved regions known as NRF2-ECH homology (Neh) domains 
(Figure VI), where each fulfills distinct functions: 
• Neh2 contains two degrons, DLG and ETGE motifs, essential for 
the interaction with KEAP1 (Tong et al., 2006). 
• Neh4 and Neh5 are transcriptional activation domains that 
cooperatively bind to the co-activator cAMP-responsive element-
binding protein and facilitate NRF2 transcription (Xiang et al., 
2014). 
• Neh7 is involved in the NRF2 repression by linking up with the 
retinoic X receptor a (Wang et al., 2013). 
• Neh6 contains two further redox-independent degrons, DSGIS and 
DSAPGS, which are targeted for degradation by the E3 ubiquitin 
ligase b-TrCP (McMahon et al., 2004). 
• Neh1 mediates the dimerization with Maf (musculoaponeurotic 
fibrosarcoma oncogene homolog) necessary for the NRF2 
transactivation function (Motohashi et al., 2004). 
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• Neh3 interacts with the co-activator known as CHD6, which is 




2.1.2 Functions of NRF2 
The NRF2 pathway modulates the transcription of a large number of genes 
involved in metabolism, detoxification, antioxidant defenses and anti-
inflammatory processes (Hayes and Dinkova-Kostova, 2014). Considering its role 
in the modulation of key genes involved in the antioxidant defenses, such as 
thioredoxines, peroxiredoxins and genes involved in the glutathione homeostasis, 
NRF2 is defined as the master regulator of the antioxidant response (Hayes and 
Dinkova-Kostova, 2014). Besides the up-regulation of the antioxidant defenses, it 
was recently reported that NRF2 modulates the redox environment repressing the 
expression of the ROS producer NOX2, while enhances the expression of NOX4 
(Kovac et al., 2015; Wei et al., 2016), although the mechanisms are still elusive. 
In addition to its importance in the redox and xenobiotic response, NRF2 
modulates the metabolism and the mitochondrial function (Esteras et al., 2016), 
up-regulating the transcription of enzymes such as the malic enzyme 1 (Wu et al., 
2011) or the Peroxisome Proliferator-Activated Receptor g (PPARg) (Pi et al., 
2010). Another important mechanism by which NRF2 can modulates metabolism 
Figure VI: NRF2 structure. NRF2 contains seven domains, called Neh, where each fulfils distinct 
functions. It should be noted that the Neh2 domain contains two motifs, DLG and ETGE, necessaries for the 




or mitochondrial function is by preventing the oxidative thiol modifications, 
through the expression of several antioxidant enzymes, that can modulate the 
function of proteins implicated in metabolic pathways. mROS can reversibly 
modify thiol groups present in several enzymes implicated in carbohydrates and 
lipid metabolism, regulating their activity (Hurd et al., 2007). Most of these 
enzymes are involved in fatty acid oxidation (carnitine acetyltransferase, very 
long chain acyl CoA dehydrogenase, propionyl-CoA carboxylase) and in the 
regulation of the pyruvate dehydrogenase, through the pyruvate dehydrogenase 
kinase 2 (Hurd et al., 2007). Furthermore, transcription of PPP-related genes are 
indirectly regulated by NRF2 through an epigenetic mechanism that involves the 
oxidation of Cys of a specific redox-sensitive histone deacetylase, HDAC4 (Singh 
et al., 2013). 
Besides the modulation of its target genes, NRF2 regulates itself, both directly 
and indirectly. The NFE2L2 gene contains two ARE-like sequences, which enable 
NRF2 to modestly auto up-regulates its own expression (Kwak et al., 2002). 
Moreover, KEAP1, the major NRF2 repressor, contains an ARE domain (Lee et 
al., 2007), creating a tight auto-regulatory loop necessary to avoid an aberrant 
activation of the NRF2 pathway, which could be lethal (Wakabayashi et al., 
2003). 
Furthermore, the role of the NRF2 pathway in cancer is dual: although the 
activation of cytoprotective genes can suppress carcinogenesis in the earliest 
stages (Hayes et al., 2010; Hu et al., 2010; Kensler and Wakabayashi, 2010), the 
aberrant up-regulation of its target genes cause chemotherapy resistance (Ohta et 
al., 2008; Shibata et al., 2017; Zhang et al., 2010) and a more favourable 
intracellular environment for the survival of tumour cells (DeNicola et al., 2011; 
Ohta et al., 2008; Singh et al., 2008). 
2.2. Regulation of the NRF2 pathway 
Considering the crucial role of NRF2 in maintaining the cellular homeostasis and 
how its aberrant activation might be lethal, the NRF2 pathway has to be very 
tightly regulated. The canonical regulation of the NRF2 pathway involves the 
complex formed by Kelch-like ECH-associated protein 1 (KEAP1), Cullin 3 
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(Cul3), an E3 ubiquitin ligase, and RING (really interesting new gen)-box protein 
1 (Rbx1). 
2.2.1 Models of NRF2-KEAP1 regulation 
Under basal conditions, NRF2 is constitutively expressed but its 
intracellular levels are kept low by the KEAP1-Cul3 complex, which degrades it 
rapidly, with a half-life of less than 20 minutes (Katoh et al., 2005). The 
homodimer KEAP1 binds NRF2 sequestering it in the cytoplasm, inhibiting its 
activation and its nuclear translocation (Kang et al., 2004). Moreover, KEAP1 
regulates the turnover of NRF2 interacting with the Cul3-Rbx1 complex, which 
ubiquitinates and targets the transcription factor for its degradation by the 26S 
proteasome (Itoh et al., 1999). This mechanism ensures low intracellular levels of 
NRF2 in unstressed conditions. Nevertheless, under stress conditions, NRF2 can 
rapidly accumulate in the nucleus where it up-regulates the expression of its target 
genes. The prevailing model by which KEAP1 regulates NRF2 is called the 
“Hinge and Latch model” (Tong et al., 2006). However, live cell imaging based 
on the Förster resonance energy transfer (FRET) system suggests a new model 
called “Cyclic sequential attachment and regeneration model of KEAP1-mediated 
degradation of NRF2” (Baird et al., 2013). De novo synthetized NRF2 binds to a 
single member of a free KEAP1 homodimer through its ETGE (high affinity) 
motif to form the open conformation. When the ETGE domain alone is bound to 
KEAP1, NRF2 is not ubiquitinated (McMahon et al., 2006). After a period in the 
open conformation, the cycle progresses to form the closed conformation through 
the binding of the low affinity motif DLG to the other member of the KEAP1 
homodimer. In the closed conformation, the Cul3-Rbx1 complex polyubiquinates 
seven lysines located between the ETGE and DLG motifs of NRF2, which is 
subsequently released for the proteasomal degradation (Figure VII A). The 
regenerated free KEAP1 dimer is then able to bind to a de novo synthetized NRF2 
to start a new cycle (Baird et al., 2013). In presence of inducers (i.e. compounds 
that modifies the reactive Cys of KEAP1, such as oxidants or electrophiles), 
Cys151, Cys273 and Cys288 are chemically modified resulting in a 
conformational change in the KEAP1-Cul3-NRF2 complex, blocking it in the 
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induced closed conformation and preventing the regeneration of free KEAP1. 
This allows the de novo synthetized NRF2 to translocate to the nucleus and to 
start the transcription of its target genes (Figure VII B). 
 
 
It was suggested that this induced closed conformation orientates the lysines 
moieties in a manner that they are no longer aligned with the Cul3-Rbx complex, 
thus the ubiquitination does not occurs (Baird et al., 2013). 
This model suggests that the KEAP1-NRF2 complex might exist in the open 
conformation, which is compatible with other types of regulation of the NRF2 
pathway, called non-canonical regulation of the NRF2 pathway. 
2.2.2 Non-canonical regulation of the NRF2 pathway 
In addition to the canonical regulation, the NRF2 pathway could be 
modulated through different mechanisms. Recent studies have identified 
numerous proteins with motifs that are very similar to the ETGE present in NRF2. 
Figure VII: Cyclic sequential attachment and regeneration model of KEAP1-mediated degradation of 
NRF2. A) In unstressed conditions, de novo synthetized NRF2 first interacts with one member of the KEAP1 
homodimer through its ETGE (high affinity) motif and forms the open conformation. Subsequently, the low 
affinity DLG motif binds the other KEAP1 member to form the close conformation, which allows the NRF2 
polyubiquitination and its proteasomal degradation. Free KEAP1 homodimer is regenerated, allowing the 
cycle to start again. B) Inducers (such as oxidants or electrophiles) block the cycle of KEAP1-mediated 
degradation of NRF2 by chemically modifying cysteine sensors of KEAP1 and disabling its substrate adaptor 
function, leading to accumulation of the protein complex in the closed conformation. As a result, NRF2 is not 
released for its degradation and KEAP1 is not regenerated. This allows the de novo synthesized NRF2 to 
accumulate, to translocate to the nucleus, to bind a small Maf protein and to initiate the transcription of its 
downstream target genes. Obtained from Dinkova-Kostova et al., 2016. 
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These proteins can compete with NRF2 for KEAP1 binding, thus stabilizing 
NRF2 (Hast et al., 2013). The most recognized positive regulator of NRF2 is 
SQSTM1/p62, an autophagosome cargo protein, which binds KEAP1 through its 
(E/S)TGE motif stabilizing NRF2 (Lau et al., 2010). Furthermore, the directly 
repression of the NRF2 activity is obtained by the phosphorylation of the Neh6 
domain mediated by the glycogen synthase kinase-3b (GSK-3b) (Chowdhry et al., 
2013; Rada et al., 2011; Rada et al., 2012). This phosphorylation of NRF2 leads 
to its recognition by an E3 ligase receptor, its subsequent ubiquitination and its 
proteasomal degradation. This regulation has been largely overlooked because 
GSK-3b is inhibited under conventional cell culture conditions (i.e. in medium 
containing 10% fetal bovine serum) by growth factor signaling (Hayes and 
Dinkova-Kostova, 2014). Nevertheless, NRF2 phosphorylation not only represses 
its activity. Active protein kinase Cd (PKCd) in astrocytes promotes, by 
phosphorylation, the stabilization of p35, a cyclin-dependent kinase-5 (Cdk5) co-
factor. Active p35/Cdk5 complex phosphorylates NRF2 at Thr395, Ser433 and 
Thr439 which is sufficient to promote the NRF2 nuclear translocation (Jimenez-
Blasco et al., 2015). 
2.2.3 The NRF2 pathway in the central nervous system 
The NRF2 pathway plays a crucial role maintaining the cellular homeostasis and 
in the pathogenesis of several diseases, hence it needs to be tightly regulated at 
different levels. This implies that, depending on the cell type, there are different 
patterns of the NRF2 modulation. In the brain, neurons and astrocytes express 
different activity of the NRF2 pathway (Bell et al., 2015; Jimenez-Blasco et al., 
2015). The transcription of antioxidant genes in neurons is repressed as a 
consequence of the continuous protein destabilization of NRF2 by the high levels 
of its repressors KEAP1 and Cul3 (Jimenez-Blasco et al., 2015). Furthermore, 
there is an epigenetic repression of the NRF2 promoter in neurons (Bell et al., 
2015), that maintains low levels of functional NRF2 pathway. Forcing the 




The extreme neuronal vulnerability to oxidative damage and the need to maintain 
low levels of NRF2 for their proper development, explain the neuronal reliance on 
astrocytic support to maintain the redox homeostasis (Bolaños, 2016). 
3. GLUTATHIONE IN THE BRAIN 
The tripeptide g-L-glutamyl-L-cysteinylglycine (glutathione or GSH) (Figure 
VIII) is the most abundant mammalian thiol-containing antioxidant (Dringen, 
2000). Its concentration varies in the range of 1–10 mM, depending on the cell 
type. The highest levels of glutathione are found in liver, spleen, kidney, lens, 
erythrocytes and leukocytes (Njålsson, 2005). Concentrations in brain are on the 
order of 1–3 mM (Dringen, 2000), however its distribution in brain cells is not 
uniform. In vivo measurement of intracellular levels of glutathione show that in 
neurons its concentration is estimated to be 2.5 mM, whereas astrocytes have a 




Most of the intracellular GSH is localized in the cytosol (80–85%), where it 
presents a half-life of 2-3 hours. The rest of the glutathione is present in the 
Figure VIII: Glutathione structure. The tripeptide glutathione consists of an unusual 
gamma peptide linkage between the carboxyl group of the glutamate side-chain and the 
amine group of the cysteine, and a usual peptide bond among cysteine and glycine. 
Adapted from Lash, 2006.  
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mitochondria (10–15%) and a small percentage in the endoplasmic reticulum, 
peroxisomes and nucleus (Lu, 2009; Meredith and Reed, 1982; Wu et al., 2004). 
The glutathione exists mainly in its reduced form (GSH); only about 1-5% is in 
the oxidized form as glutathione disulphide (GSSG) (Lu, 2009), or as mixed 
disulphide with xenobiotic (GSSX) or thiol-containing protein (GSSPr) (Njålsson, 
2005).  
3.1. Functions of glutathione 
Glutathione serves several crucial functions including antioxidant defense, 
detoxification of xenobiotics and/or their metabolites, modulation of redox 
signaling, regulation of cell cycle progression and cell death, storage of cysteine, 
among the others. 
The most important cellular function of GSH is the antioxidant defense, 
accomplished largely by GPx-catalyzed reactions, which reduce hydrogen 
peroxide and lipid peroxides as GSH is oxidized to GSSG. In turn, GSH is 
regenerated by glutathione reductase at the expenses of NADPH, forming a redox 
circle (Figure III) (Lu, 2009). Besides the antioxidant function, glutathione is 
involved in several crucial processes to maintain the cellular viability. The main 





Main functions of glutathione 
• Antioxidant defense (Dringen, 2000) 
• Detoxification of electrophiles and xenobiotics (Lu, 2009; Meister, 1988) 
• Modulation of intracellular thiols (Kumar et al., 2011; Lu, 2009) 
• Post-translational modifications of proteins (Ballatori et al., 2009; Wu et al., 
2004) 
• Cysteine reservoir (Lu, 2009; Meister, 1988) 
• Modulation of cellular growth (Holmgren, 1981; Lu, 2009) 
• Modulation of cellular death (Anathy et al., 2009; Ballatori et al., 2009; Diaz-
Hernandez et al., 2005; Garcia-Ruiz and Fernández-Checa, 2007; Huang et al., 2008) 
Table I: Functions of glutathione. The main functions directly or indirectly modulated by the GSH are 
resumed in this table. 
 
3.2. Synthesis of glutathione 
The synthesis of glutathione from its constituent amino acid involves two ATP-
requiring enzymatic steps: formation of g-glutamylcysteine (g-GC) from 
glutamate and cysteine and formation of GSH from g-GC and glycine (Figure IX) 
(Lu, 2013). The first step of GSH biosynthesis is rate limiting and catalysed by g-
glutamylcysteine synthetase or glutamate-cysteine ligase (GCL), while the second 




GCL is an heterodimer composed of a heavy or catalytic (GCLC, ~73 kDa) and a 
light or modifier (GCLM, ~31 kDa) subunit, which are encoded by different genes 
in Drosophila, rodents and humans (Dalton et al., 2004; Gipp et al., 1992; Huang 
et al., 1993; Yan and Meister, 1990). GCLC exhibits all of the catalytic activity of 
the isolated enzyme and feedback inhibition by GSH (Seelig et al., 1984). GCLM 
is enzymatically inactive, however plays an important regulatory function by 
lowering the Km of GCL for glutamate and raising the Ki for GSH (Huang et al., 
1993a; Huang et al., 1993b). 
The GS is an homodimer and is not subject to feedback inhibition by GSH 
(Oppenheimer et al., 1979). Considering that g-GC, the product of GCL, is present 
exceedingly low concentrations when GS is present, GCL is considered rate 
limiting (Dalton et al., 2004). Supporting this evidence, the overexpression of GS 
failed to increase GSH levels, whereas overexpression of GCL does it (Grant et 
al., 1997). 
The structure of glutathione is unique (Figure VIII). The peptide bond linking 
glutamate and cysteine, formed in the first step catalized by GCL, is through the 
g-carboxyl group of glutamate rather than the conventional a-carboxyl group. 
This characteristic confers intracellular stability to GSH, considering that the only 
enzyme that can hydrolyses this unusual bond is the g-glutamyltranspeptidase (g-
GT), which is only present on the external surfaces of specific cell types (Meister 
and Anderson, 1983), such as astrocytes (Cambier et al., 2000). 
Figure IX: Glutathione synthesis. GSH is synthesized in the cytosol from its constituent amino acids 
by the sequential action of two ATP-requiring enzymes: g-glutamylcysteine synthetase (GCL) and 
glutathione synthetase (GS). 
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3.3. Regulation of glutathione biosynthesis 
The glutathione biosynthesis occurs in the cytoplasm and it is regulated by three 
major factors: a) the expression of the rate-limiting enzyme GCL, b) the 
availability of L-cysteine, and c) the nonallosteric feedback competitive inhibition 
(with glutamate) by GSH (Lu, 2013; Meister and Anderson, 1983; Richman and 
Meister, 1975). 
The expression of many genes involved in the GSH homeostasis is regulated by 
several transcription factors. Among all, NRF2 up-regulates the expression of 
genes involved in the supply of precursors (xc-), the biosynthesis (GCLC, GCLM 
and GS), the recycling (GR), the transport (MRP1), and the specific extracellular 
hydrolization (g-GT) of glutathione (Hayes and Dinkova-Kostova, 2014). The 
promoter region of these genes contains an ARE sequence, which allows NRF2 to 
increase their expression, both in basal and stressed conditions (Hayes and 
Dinkova-Kostova, 2014; Lee et al., 2004). 
Post-transcriptional regulation of GCL is mainly based on its mRNA stabilization 
and post-translational modifications. The directly phosphorylation of GCLC, 
mediated by protein kinase A (PKA), protein kinase C (PKC) or Ca2+-calmodulin 
kinase II (CAMK), decrease its activity (Sun et al., 1996). Furthermore, GCL 
could be inhibited by nitric oxide through nitrosylation (Griffith, 1999). Another 
post-translational modification of GCL is the cleavage mediated by caspase-3 
(Franklin et al., 2002), which regulates GSH biosynthesis during apoptosis. 
3.4. Astrocyte-neuron glutathione shuttle 
Oxidative stress is a hallmark of neurodegenerative diseases, stroke and traumatic 
brain injuries, highlighting the particularly susceptibility of the brain to oxidative 
damage (Dringen, 2000; Bélanger et al., 2011). Paradoxically, despite the fact that 
the greater part of the brain’s oxidative metabolism occurs in neurons and the 
neurotransmission unavoidably increases mROS, the neuronal antioxidant 
machinery is generally weak (Bolaños et al., 1995; Bolaños et al., 1996), dues to 
the continuous NRF2 degradation (Bell et al., 2015; Jimenez-Blasco, et al., 2015). 
In contrast, NRF2 is highly stable in neighbor astrocytes, which present a greater 
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antioxidant potential compared to neurons (Jimenez-Blasco et al., 2015). 
Accordingly, astrocytes are much more resistant than neurons to cellular damage 
induced by pro-oxidant compounds (Almeida et al., 2001; Bolaños et al., 1995; 
Dringen, 2000; Wilson, 1997). One reason for the higher vulnerability of neurons 
appears to be a lower glutathione content compared to astrocytes (Bolaños et al., 
1995; Dringen et al., 1999). 
Evidence is growing that especially between neurons and astrocytes, intensive 
metabolic and redox exchanges occur, both in vitro and in vivo (Bolaños, 2016; 
Fernandez‑Fernandez et al., 2012; Mächler et al., 2016; Pellerin and Magistretti, 
2012). In co-culture systems, astrocytes protect neighbour neurons from harmful 
doses of hydrogen peroxide, nitric oxide iron or hydroxydopamine (Bélanger and 
Magistretti, 2009; Dringen, 2000; Vargas and Johnson, 2009; Wilson, 1997), 
suggesting that neural cells are dependent upon the high antioxidant potential of 
astrocytes for their own defense against oxidative stress.  
To prevent competition, neurons and astrocytes display differential preference for 
extracellular GSH precursors. Neural cells rely on the presence of extracellular 
cysteine for GSH synthesis, since they cannot use cystine (Dringen et al., 1999; 
Kranich et al., 1996; Sagara et al., 1993), while the best extracellular precursor for 
the glutamate moiety of glutathione is glutamine (Kranich et al., 1996). In 
contrast, astrocytes prefer glutamate and cystine as extracellular GSH precursors 
(Dringen and Hamprecht, 1998; Kranich et al., 1996; Kranich et al., 1998). 
However, since neurons cannot use extracellular cystine, they depend for their 
glutathione synthesis on the supply of cysteine or a cysteine precursor from 
neighbour astrocytes (Dringen et al., 2000). The presence of astrocytes increases 
glutathione levels in co-cultured neurons (Bolaños et al., 1996; Dringen et al., 
1999), suggesting the existence of a GSH precursors supply from astrocytes to 
neurons (Dringen et al., 1997), called astrocyte-neuron glutathione shuttle 





Cultured astrocytes export about 10% of their intracellular GSH per hour 
(Dringen et al., 1997), which has continuously to be resynthesized from its 
precursors in order to maintain a constant cellular concentration. These data and 
the reported half life of about 5 hours for astroglial GSH (Devesa et al., 1993) 
indicate that the export of GSH is quantitatively the most important process 
consuming astrocytic glutathione. Indeed, treatments that increase the glutathione 
concentration in glial cells lead to an increase in the rate of cellular GSH export 
(Dringen et al., 2015). The GSH export from astrocytes is predominately 
mediated by multidrug resistance-associated protein 1 (MRP1) (Minich et al., 
2006). GSH that has been exported from astrocytes is a substrate of the g-glutamyl 
transpeptidase (g-GT) (Dringen et al., 1997). One product of this reaction is the 
dipeptide CysGly, which is cleaved by the neuronal aminopeptidase N (APN) 
(Dringen et al., 2001) to provide cysteine and glycine to neurons. 
Astrocytes are therefore necessary for maintaining neuronal GSH through the 
ANGS; however, they may not be sufficient. Knockdown of GCL in neurons 
triggers GSH depletion and neuronal death, both in vitro and in vivo (Chinta et al., 
2007; Diaz-Hernandez et al., 2005; Garrido et al., 2011). Hence, intact 
Figure X: Astrocyte-neuron glutathione shuttle (ANGS). Astrocytes export, through MRP1, up to 10% 
about their intracellular GSH per hour, which is cleaved into CysGly by the g-GT. The APN on the neuronal 
surface cleaves CysGly into cysteine and glycine, which are uptake by neurons. Meanwhile, astrocytes also 
export glutamine, which is uptake by neurons and converted to glutamate. Modified from 
Fernandez‑Fernandez et al., 2012. 
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biosynthetic enzymatic machinery for de novo synthesis of glutathione in neurons 
is necessary for their survival, even in presence of neighbour astrocytes. 
4. PENTOSE PHOSPHATE PATHWAY (PPP) 
The vast majority of glucose that enters in the cells is oxidized by glycolysis to 
provide ATP and metabolic intermediates. However, a percentage of glucose that 
varies from 5 to 30% in a tissue-dependent manner, is oxidized through the PPP to 
yield ribose-5-phosphate for nucleic acid synthesis and NADPH for redox 
homeostasis or biosynthetic processes (Riganti et al., 2012). The basal flux 
through the PPP reaches the maximal percentage in lipid- and steroid-synthetizing 
tissues (such as liver, white adipose tissue, lactating mammary glands, adrenal 
glands and gonads) and in erythrocytes. Nevertheless, the rate of PPP may widely 
vary. Cells exposed to oxidative stress increase the PPP activity in order to 
regenerate GSH and restore the redox homeostasis (Riganti et al., 2012). 
Moreover, PPP sustains glycolytic cancer cells to meet their anabolic demands 
and combat oxidative stress increasing their survival (Patra and Hay, 2014). 
The PPP can be divided into two branches: the oxidative and the non-oxidative 
phase (Figure XI) (Wamelink et al., 2008). 
The oxidative branch of the PPP starts with the dehydrogenation of glucose-6-
phosphate, catalysed by the rate limiting enzyme glucose-6-phosphate 
dehydrogenase (G6PD). The product 6-phosphogluconolactone is rapidly and 
irreversibly hydrolysed by the 6-phosphogluconolactonase to yield 6-
phosphogluconate. The lately is oxydatively decarboxylated by the 6-
phosphogluconate dehydrogenase (6PGD) to produce ribulose-5-phosphate and 
CO2. The effectiveness of the oxidative branch of the PPP is favored by the 
localization of G6PD and 6PGD next to the glucose transporters (Kletzien et al., 
1994). The net result of the oxidative phase of the PPP is the formation of one 
mole of ribulose-5-phosphate, two moles of NADPH and one mole of CO2 per 
mole of glucose-6-phosphate. 
In the non-oxidative branch of the PPP, ribulose-5-phosphate can be epimerized 
to xylulose-5-phosphate by ribulose-5-phosphate epimerase, or isomerized by the 
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ribulose-5-phosphate isomerase to ribose-5-phosphate and incorporated into 
nucleotides (Wamelink et al., 2008). Depending on the cellular requirements, the 
pentose phosphates generated in the non-oxidative branch could be transformed in 
the glycolytic intermediates glycealdehyde-3-phosphate and fructose-6-phosphate 
(Baquer et al., 1988), or can be recycled into glucose-6-phosphate and re-enter in 




Figure XI: Pentose phosphate pathway. Abbreviations used: HK: hexokinase; G6PD: glucose-6-
phosphate dehydrogenase; 6PGL: 6-phosphoglucolactonase; 6PGD: 6-phosphogluconate dehydrogenase; 
RPI: ribulose-5-phosphate isomerase; RPE: ribulose-5-phosphate epimerase; R5P: ribose-5-phosphate; EPI: 
epimerase; X5P: xilulose-5-phosphate; TKT: transketolase; S7P: sedoheptulose-7-phosphate; GAP: 
glyceraldehyde-3-phosphate; TALDO: transaldolase; F6P: fructose-6-phosphate; E4P: erythrose-4-
phosphate; PGI: phosphoglucose isomerase; G6P: Glucose-6-phosphate. 
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4.1. Functions of the PPP in the brain 
The two major functions of the PPP are the production of NADPH and the 
synthesis of ribose-5-phosphate. Most of the cytosolic NADPH is produced by 
G6PD and 6PGD (Wamelink et al., 2008). This coenzyme plays a pivotal role in 
redox homeostasis, since it provides reduced equivalents for the GSH and 
thioredoxin regeneration (Stincone et al., 2015). Besides its importance in the 
antioxidant systems, NADPH is required as electron donor in many anabolic 
pathways, such as fatty acid oxidation, lipid and cholesterol synthesis (Dringen et 
al., 2007). Among the various NADPH-consuming processes in the adult brain, 
the regeneration of GSH is likely to be quantitatively the most important one, 
especially in neurons (Bouzier-Sore and Bolaños, 2015). These cells contains very 
low amounts of glutathione (Bolaños et al., 1995; Dringen et al., 1999), hence it 
regeneration is critical for their survival. Since NADPH is essential for this 
process, the re-cycling version of the PPP, which recovers a considerable 
proportion of glucose-6-phosphate, explains both the low glucose consumption 
and the efficient GSH regenerating activity of neurons compared to astrocytes 
(Bouzier-Sore and Bolaños, 2015). Metabolic switch from PPP to glycolysis 
overexpressing 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(PFKFB3), cause neuronal death by nitrosative stress (Herrero-Mendez et al., 
2009), confirming the importance of the PPP in the redox homeostasis of neurons. 
In contrast, astrocytes express higher PPP-rate limiting enzyme G6PD, have 
higher basal PPP activity rate and a better capability to stimulate this pathway in 
response to oxidative stress, compared to neurons (Ben-Yoseph et al., 1996; 
García-Nogales et al., 1999; Herrero-Mendez et al., 2009). However, the 
production of NADPH by G6PD and 6PGD plays a dual role in the regulation of 
the redox homeostasis: on the one hand, these enzymes supply reducing 
equivalent for the glutathione regeneration, but on the other hand, they provide 
cytoplasmic substrate for ROS generation by NADPH-oxidases (Park et al., 
2005). 
The synthesis of ribose-5-phosphate, fundamental for dividing cells, occurs both 
in the oxidative and in the non-oxidative branch of PPP (Wamelink et al., 2008). 
With the exception of processes such as DNA repair (Brooks, 2002), proliferation 
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of stem cells (Baizabal et al., 2003) and the growth of brain tumors (Loreck et al., 
1987; Spence et al., 1997), low amounts of ribose-5-phosphate are required for 
the generation of nucleotides in the adult brain. Hence, synthesis of ribose-5-
phosphate does not appear to be a major function of the PPP in the central nervous 
system (Dringen et al., 2007). 
4.2. Regulation of the PPP 
The activity of the PPP varies in a tissue-specific manner. Moreover, the basal 
flux of PPP depends on the cell state. The activity of G6PD, the rate limiting 
enzyme of the PPP, is directly related to the NADPH/NADP+ ratio (Barcia-
Vieitez and Ramos-Martínez, 2014). Situations in which this ratio drops, boost the 
activity of the G6PD enzyme increasing the glucose flux through the PPP, with 
the aim to restore physiological values of the NADPH/NADP+ ratio (Stincone et 
al., 2015). 
Besides the post-translational regulation of the G6PD enzyme, there is a 
transcriptional regulation of several enzymes involved in the PPP. The rate 
limiting enzyme, G6PD, is transcriptionally induced upon oxidative stress and by 
the need for NADPH and PPP intermediates for anabolic reactions such as lipid 
and nucleotide synthesis (Stincone et al., 2015). A recent study suggests that the 
mRNA levels of the G6pd, 6Pgd and transketolase (Tkt) were indirectly regulated 
by NRF2 (Singh et al., 2013). The targeted deletion of the ARE sequence from 
these genes demonstrates that they are not directly regulated by NRF2 (Singh et 
al., 2013). The suggested indirect modulation of several PPP-related genes by 
NRF2, involves an epigenetic mechanism. Histone deacetylase 4 (HDAC4) is a 
redox-sensitive protein which nuclear localization depends on the reduced state of 
two cysteines, Cys-667 and Cys-669 (Ago et al., 2008). In its reduced state, 
HDAC4 accumulates in the nucleus, deacetylates chromatin causing its 
compaction and represses the transcription of two micro-RNAs, miR-1 and miR-
206. These two micro-RNAs target the newly synthesized G6pd, 6Pgd, Tkt and 
Hdac4 mRNA interfering with their ribosomic translation (Chen et al., 2010; 
Coda et al., 2015; Hak et al., 2006; Singh et al., 2013). Decreased antioxidant 
potential results in the oxidation of the Cys residues, nuclear exportation of 
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HDAC4 and increased transcription of miR-1 and miR-206, which in turn leads to 
lower levels of G6PD, 6PGD, TKT and HDAC4 itself (Singh et al., 2013) 
(Figure XII). Thioredoxin-1 (Trx-1) overexpression preserves the Cys moieties in 
their reduced state, maintaining HDAC4 in the nucleus repressing the 
transcription of miR-1 and miR-206 (Ago et al., 2008). Modulating the redox 
environment through the transcription of several antioxidant genes, among them 
Trx-1, NRF2 indirectly controls the HDAC4 subcellular localization. 
 
 
Figure XII: Epigenetic model of PPP-related genes modulation by a ROS-mediated mechanism. A 
mechanism involving ROS, HDAC4 and miRNAs modulates the expression of several PPP genes. A) With 
low ROS levels, the two Cys residues of HDAC4 are in their reduced state. HDAC4 could accumulate in 
the nucleus, deacetylates the chromatin causing its condensation and suppresses miR-1 and miR-206 gene 
expression, leading to an enhanced expression of metabolic genes. B) A ROS increase causes the Cys 
oxidation leading to nuclear export of HDAC4 and relaxation of chromatin, which leads to miR-1 and miR-
206 expression. Newly formed miRNAs target specific mRNAs (G6PD, 6PDG, TKT and HDAC4) leading 
to a decreased gene expression. Abbreviations used: HDAC4: histone deacetylase-4; G6PD: glucose-6-














1. HYPOTHESIS  
Reactive oxygen species (ROS) have been associated with oxidative stress 
conditions and to participate in the etiology of human pathologies, including 
neurodegenerative diseases. Whilst antioxidant treatments in in vitro and in vivo 
models of neurodegenerative diseases have shown neuronal protection, translation 
to human has not been conclusive (Halliwell 2013; Heyland et al., 2013; Kamat et 
al., 2008; Snow et al., 2010), which argues against the notion of a pathological 
role for ROS. 
Recent evidences from our laboratory show that, under basal conditions, 
astrocytes produce higher mitochondrial ROS (mROS) compared to neurons 
(Lopez-Fabuel et al., 2016). This seems to be paradoxical, considering that 
astrocytes express a robust antioxidant machinery, reliable to a major NRF2 
activity, compared to neurons (Jimenez-Blasco et al., 2015). Furthermore, 
astrocytes support neuronal antioxidant defenses by shutting glutathione (GSH) 
precursors. This shuttle is maintained by NRF2 activity in astrocytes. However, 
the factor(s) responsible for such a high NRF2 activity in astrocytes is unknown.  
In the view of the previously described premises, we hypothesize that endogenous 
mROS maintain active the NRF2 pathway in astrocytes. If so, mROS-NRF2 





To address the above-mentioned hypotheses, we planned the following objectives:  
 
1. To generate a mouse model able to down modulate endogenous mROS in 
astrocytes. 
 
2. To investigate whether endogenous mROS modulate the redox 
homeostasis in astrocytes. 
 
3. To investigate whether astrocytic mROS modulate neuronal redox 

















1.1. +/mCAT mouse line generation 
To down-modulate endogenous mitochondrial ROS (mROS) abundance, a knock-
in mouse model harbouring a mitochondrial-tagged form of Catalase (mCAT) was 
generated (Genoway, France). 
The mCAT cDNA, generously supplied by J.A. Enríquez (CNIC, Madrid), 
contains the N-terminal mitochondrial-leading cDNA sequence of cytochrome c 
oxidase VIII (C8), followed by the full-length cDNA sequence of catalase and the 
cDNA sequence of the human influenza hemagglutinin (HA) (Scheme 1). 
 
 
The mCAT construct was inserted in the Rosa26 locus of C57Bl/6 embryonic 
stem cells by homologous recombination. The Rosa26 locus strategy has several 
advantages over random integration transgenesis: 
• Only one copy of the transgene is inserted in a defined locus 
• A reliable and predictable expression pattern of the transgene 
• The endogenous (cytosolic) catalase is kept intact. 
Furthermore, a floxed (loxP flanked) transcriptional STOP cassette was 
Scheme 1: mitochondrial catalase (mCAT) construction. C8: cytochrome c oxidase 




incorporated between mCAT and the CAG promoter, in order to eventually obtain 
tissue- and time-specific expression of mCAT in vivo. This strategy allows the P1 
phage-derived Cre recombinase to site-specifically recombine DNA flanked by 
LoxP sites (5’-ATAACTTCGTATAATGTATGCTATACGAAGTTAT-3’) 
(Branda and Dymecki, 2004). 
Thus, the mouse line harbouring the floxed mCAT construct does not express 
mitochondrial catalase unless Cre recombinase is present. This can be obtained by 
crossbreeding the floxed mCAT mice with mice harbouring the Cre recombinase 
gene. 
To obtain ubiquitous constitutive mCAT expression, the floxed mCAT mice were 
crossbred with the human cytomegalovirus minimal promoter (CMV)-Cre 
recombinase mice under a C57Bl/6 genetic background (C57Bl/6+/mCAT, 
henceforth +/mCAT). (Scheme 2). +/mCAT was bred in heterozygosis. 
 
Animals were bred at the Animal Experimentation Facility of the University of 
Salamanca in cages (maximum 5 animals/cage) and a light-dark cycle was 
maintained for 12 hours. Humidity was between 45% and 65% and temperature 
Scheme 2: Strategy used to express ubiquitously the mCAT. pA: poly-A tail; 
mCAT: mitochondrial catalase; CAG: cytomegalovirus enhancer fused to chicken b-
actin promoter; CMV: cytomegalovirus. 
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between 20ºC and 25ºC. Animals were fed ad libitum with a standard solid diet 
(17% proteins, 3% lipids, 58.7% glucidic component, 4.3% cellulose, 5% 
minerals and 12% humidity) with free access to water. 
Gestational stage was controlled by limiting the cohabitation of female mice with 
males to one night. At 9:00 hours of the following day, mice that had the presence 
of spermatozoids in the vaginal smear accompanied by epithelial cells from the 
vagina (indicator of the successful copulation) were isolated. Under these 
conditions, gestational period of the mouse is assumed to be 19.5 days. 
All animal handlings and procedures are in agreement with the current and 
Spanish legislation (Law 6/2013) related to accommodation and experimental 
animals care. All the protocols performed in this thesis were approved by 
Bioethics Committee of the University of Salamanca. 
1.2. Tissue extraction 
Mice were anesthetized with CO2, euthanized by cervical dislocation and the 
brain, liver, heart and kidney were extracted within the following 5 min and 
processed to obtain a cytosolic and nuclear fractionation (see Section 7.3). 
1.3. DNA extraction 
DNA was extracted from tails (2-5 mm long) of newborn mice. Tails were 
incubated with 120 µl of TENS buffer (100 mM Tris, 5 mM EDTA, 200 mM 
NaCl, 0.2% SDS, pH 8) and 1.2 µl of Proteinase K (800 U/µl; Sigma-Aldrich) and 
left overnight at 55ºC for complete digestion. Subsequently, 410 µl of Phenol-
Chloroform-Isoamilic acid (PCI) mix (25:24:1) was added and centrifuged at 
13,000 rpm for 5 minutes. The aqueous phase was transferred to a new tube, to 
which an equal volume of isopropanol was added, kept at 4 ºC for at least 30 
minutes, and centrifuged at 13,000 rpm for 5 minutes at 4 ºC. Tubes were left to 
dry for no more than 5 minutes, and 50 µl of TE buffer solution (10 mM Tris-HCl, 
1 mM EDTA, pH 8) was added. Tubes were left 24 hours at room temperature, 




mCAT mice were genotyped by PCR. Forward (124540-BOL1) and reverse  
(124541-BOL1) oligonucleotides used were, respectively, 5’-
CTCCCAAAGTCGCTCTGAGTTGTTATCA-3’ and 5’-
CGATTTGTGGTGTATGTAACTAATCTGTCTGG-3’, which generated a 778 
bp band in the wild type allele and a 5949 bp band in the mCAT allele (due to the 
large size of this PCR product, the amplification will not occur). Hence, to detect 
the mCAT construction, a third oligonucleotide (0034-Kin-ROSA) was used, 5’-
GCAGTGAGAAGAGTACCACCATGAGTCC-3’, which generated a 245 bp 
band (Scheme 3). 
 
 
PCR conditions were: 5 minutes at 94°C, 35 cycles of 30 seconds at 94°C 
followed by 30 seconds at 65°C and 3 minutes at 60°C and a final step 8 minutes 
at 68°C. Final concentrations of PCR components were 0.5 mM dNTPs mix 
(Roche), 0.3 µM of primers (Sigma-Aldrich), 0.042 U/µl of Taq polymerase 
(Biotools) and 1X reaction buffer containing MgCl2. The total amount of DNA 
added was 30 ng. 
Scheme 3: +/mCAT identification strategy by PCR. Red lines illustrate the primers localization 
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1.5. Gel electrophoresis 
PCR products were run in a 2% (w/v) agarose gels (Sigma-Aldrich). Gels were 
pre-stained with MidoriGreen (1:20,000) and run in TAE buffer (200 µM Trizma-
Base, 100 mM Glacial Acetic Acid, 5 mM Na2EDTA·2H2O), using a 6X loading 
dye (10 mM Trizma-Base, 0.03% Bromophenol blue, 0.03% (v/v) Xylene 
cyanole, 60% (v/v) Glycerol, 60 mM Na2EDTA·2H2O, pH 7.6) for DNA input. 
Images were taken using Bio-Rad Chemidoc. 
2. CELL CULTURES 
2.1. Mouse embryonic fibroblasts (MEFs) immortalization  
MEFs were prepared from fetal +/mCAT mice (E13.5), using the wild type (WT 
or +/+) littermates as control. Embryos were processed individually, and the liver 
and brain tissue were disregarded. The carcass was mechanically disaggregated in 
0.25 g/ml of trypsin/1 mM EDTA and seeded in a 60 cm2 cell culture dish 
containing Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich) 
supplemented with 10% v/v fetal bovine serum (FBS, GE Healthcare Life 
Sciences) and 25 mM D-glucose. Confluent cells were split 1:3 during 2 weeks, 
until the immortalization crisis occurred, which lasted for a further 2 weeks. 
During this period, medium was renewed every 3 days. One week after the 
immortalization crisis, single cell colonies were spotted, picked and grew. Cells 
were placed in a thermostatized cell-culture incubator at 37ºC (Thermo Forma 
310, Thermo Fisher) and 5% CO2 atmosphere. MEFs were frozen in a mixture of 
FBS and DMSO (9:1).  
2.2. Neurons in primary cultures 
Neurons in primary culture were obtained from fetal embryos of 15.5 days 
(E15.5) C57Bl/6 mice according to standard procedure (Almeida et al., 1998). In 
brief, pregnant mice were anesthetized with CO2, euthanized by cervical 
dislocation and the embryos were removed by hysterectomy. Embryos were 
transferred to a laminar flux cabin (TC48, Gelaire Flow Laboratories) in order to 
maintain the sterile conditions of the culture. Cerebral hemispheres were removed 
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using scissors, forceps and 70% ethanol impregnates handkerchiefs. The brain 
tissue was then placed in a polystyrene Petri plate containing the disintegration 
solution (EBSS (Eagle’s Basal Salt Solution): 116 mM NaCl, 5.4 mM KCl, 1.01 
mM NaH2PO4, 1.5 mM MgSO4, 26 mM NaHCO3, 4 mM glucose, 10 mg/ml 
phenol red, with 2.94 mg/ml BSA (Bovine Serum Albumin) and 20 µg/ml 
DNAse, pH 7.15) and very smoothly chopped with a scalpel. After this, it was 
placed in a tube and left for 4 minutes for sedimentation. The pellet was re-
suspended in trypsinization solution (EBSS; 50 µg/ml DNAse, 3.15 mg/ml BSA, 
10mg/ml trypsin, pH 7.15) and incubated at 37ºC for 15 minutes in a thermostatic 
bath. Trypsinization was stopped by adding FBS at a final concentration of 10 % 
v/v, and the tissue was centrifuged at 500 g for 5 minutes (Eppendorf 5702R, 
Eppendorf). The pellet was re-suspended in 12 ml of disintegration solution and 
triturated with a silicon-coated Pasteur pipette for 9 strokes. After letting the 
cellular solution stand for 4 minutes, the supernatant containing the dissociated 
cells was carefully removed and placed in a fresh tube. This process was repeated 
once more in order to increase yield. The supernatants were then centrifuged at 
500 g for 5 minutes. The cellular sediment was re-suspended in specific medium 
for neuronal growth (Neurobasal-A (Life Technologies) supplemented with 2% 
B27 MAO (Minus AntiOxidants, Life Technologies), 2 mM glutamine, 5.5 mM 
glucose, 0.22 mM pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin and 
0.25 µg/ml amphotericin B (Sigma Aldrich). 10 µl of the cellular suspension was 
diluted four times and mixed with an equal volume of trypan blue 0.4 % (Sigma-
Aldrich) for alive cellular counting using a Neubauer chamber (Zeiss) and a phase 
contrast microscope (CK30 model, Olympus). The cell suspension was diluted in 
culture medium and seeded at 200,000 cells/cm2 in plastic culture plates (Corning 
Incorporate), previously coated with poly-D-lysine (10 µg/ml; Sigma-Aldrich). 
Plates were placed in a thermostatized cell-culture incubator at 37ºC and 5% CO2 
atmosphere. The medium was renewed at DIV3 (days in vitro). Neurons were 
used for experiments at DIV7. 
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2.3. Astrocytes in primary culture 
Astrocytes in primary culture were obtained from +/mCAT newborn mice (from 0 
to 24 hours of age), using the WT littermates as control (Almeida et al., 1998). 
Animals were cleaned with 70% ethanol, decapitated and the whole brain was 
removed under a laminar flux cabin. Cerebellum and olfactory bulb were removed 
using forceps and cerebral hemispheres were cleaned from meninges and blood 
vessels. The tissue was then placed in a Petri dish with the disintegration solution. 
Every brain was processed individually. Cellular suspension was obtained as 
previously described for neurons. 
Individual cellular suspension was seeded in DMEM supplemented with 10% v/v 
FBS in a 75 cm2 culture flask. Cells were incubated in a thermostatic cell-culture 
incubator at 37 ºC and 5% CO2 atmosphere. Culture medium was renewed twice 
per week. To detach non-astrocytic cells, at DIV7 the flasks were shaken at 180 
rpm overnight. The supernatant was discarded, and the attached, astrocyte-
enriched cells, were reseeded at 100,000 cells/cm2 in DMEM supplemented with 
10% v/v FBS in different plate size. At DIV11 the medium was replaced with 
Neurobasal A supplemented with 2% B27 MAO, 2 mM glutamine, 5.5 mM 
glucose, 0.22 mM pyruvate. A glucose control was made at DIV13 with a 
glucometer (Glucocard G+ meter, Angelini) and the glucose concentration was 
adjusted to 5.5 mM. Astrocytes were used for experiments at DIV15. 
2.4. Astrocyte-neuronal co-culture 
To obtain astrocyte-neuronal co-culture, the cells were obtained as previously 
described. Neurons were seeded on plastic culture plates (Corning) previously 
coated with poly-D-lysine. At DIV8, astrocytes were re-seeded on semipermeable 
inserts (0.4 µm pore size, Corning). At DIV11 of astrocytes, corresponding at 
DIV3 for neurons, medium was renewed and the inserts were placed over the 
neurons. Cells were co-cultured and harvested at DIV7 of neurons, corresponding 
at DIV15 for astrocytes. 
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3. CELL TRANSFECTION 
Cells were transfected with the aim to overexpress cDNA (complementary DNA) 
24 or 96 hours before cell recollection. Transfection of cells with plasmid vectors 
was carried out using a final concentration of 1.6 µg/ml of DNA. 
To transfect MEFs, a previously described protocol (Boussif et al., 1995) with 
some variations was used. Thus, after incubation of the plasmid with 1 µM 
polyethylenimine (PEI, Sigma-Aldrich) for 10 min at room temperature, the 
mixture was added to the cells, which were incubated in OptiMEM medium 
(Invitrogen) for 1h. After washing with phosphate buffer saline (PBS, 136 mM 
NaCl, 2.7 mM KCl, 7.8 mM Na2HPO4·2H2O, 1.7 mM KH2PO4, pH 7.4) the cells 
were incubated in DMEM with 10% v/v FBS and 25 mM D-glucose. 
Astrocytes were transfected using the cationic reagent Lipofectamine LTX with 
Plus ReagentTM (Invitrogen), following manufacturer’s instructions. The protocol 
is based on the incubation of the plasmid DNA with Lipofectamine and the Plus 
Reagent in OptiMEM medium. The expression of the proteins encoded by the 
plasmid DNA was confirmed by immunoblotting. 
Plasmid vectors used (Table 1) were obtained following transformation of E. coli 
competent cells, strain DH-5α, by heat shock. Bacteria culture mediums (LB, LB-
agar and 2 x YT) were prepared with bactotriptone, yeast extract and agar from 
DIFCO Laboratories. Extraction and purification of the plasmids after the 





4. ROS MEASUREMENTS 
4.1. Hydrogen peroxide 
The production of hydrogen peroxide (H2O2) in whole cells or in fresh isolated 
mitochondria was assessed using the Amplex RedTM dye (Life Technologies). In 
presence of horseradish peroxidase (HRP), the Amplex RedTM reagent reacts with 
hydrogen peroxide in a 1:1 stoichiometry to produce the red-fluorescent oxidation 
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Table 2: Plasmid vectors used. Name of the plasmid vector, protein encoded and 
origin are specified. NRF2 PM: Nuclear factor (erythroid-derived 2)-like 2 





For the hydrogen peroxide measurement, cells or fresh isolated mitochondria were 
incubated with the Amplex RedTM dye (9.45 µM) in Krebs Ringer Phosphate 
Glucose Buffer (KRPG: 145 mM NaCl, 5.7 mM Na2HPO4, 4.86 mM KCl, 0.54 
mM CaCl2, 1.22 mM MgSO4, 5.5 mM glucose, pH 7.35) in presence of HRP (0.1 
U/ml). Luminescence was recorded for 2 hours at 30 minutes intervals using a 
Fluoroskan Ascent FL (Thermo Fisher) (lexc 538 nm; lem 604 nm). Hydrogen 
peroxide release rate was calculating extrapolating the slopes to those obtained 
from a hydrogen peroxide standard curve and the results were expressed as 
arbitrary unit (fold) between the control, to which is assigned the value of 1, and 
the sample condition. 
4.2. mROS 
mROS were measured using the fluorescent probe MitoSOXTM Red (Life 
Technologies). This probe is live-cell permeant and is rapidly and selectively 
targeted to the mitochondria. Once in the mitochondria, MitoSOXTM Red reagent 
is oxidized by mROS and it exhibits red fluorescence. The oxidation product 
becomes highly fluorescent upon binding to nucleic acids. Cells were incubated 
with 2 µM MitoSOXTM Red for 30 min at 37°C in a 5% CO2 atmosphere in 
Hank’s Balanced Salt Solution (HBSS) (134.2 mM NaCl, 5.26 mM KCl, 0.43 
mM KH2PO4, 4.09 mM NaHCO3, 0.33 mM Na2HPO4·2H2O, 5.44 mM glucose, 
20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 4 mM 
Amplex Red Resorufin 
H2O2 H2O 
HRP 
Scheme 4: Amplex RedTM reaction. Amplex RedTM dye is oxidized by H2O2 in presence of the 
horseradish peroxidase, liberating the fluorescent molecule Resorufin. 
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CaCl2·2H2O, pH 7.4). Cells were then washed with PBS and trypsinized. 
MitoSOXTM red fluorescence was detected in channel FL3 in a FACScalibur (BD, 
Biosciences) flux cytometer equipped with a 15 mW argon ion laser tuned at 488 
nm and analysed using CellQuestTM PRO and Paint-a-GateTM PRO (BD, 
Biosciences) software. Results were expressed in arbitrary units. 
4.3. Extracellular superoxide 
The production of extracellular superoxide was measured following a previous 
published protocol (Li et al., 2016) with some modifications. This method is 
based on the reduction of the oxidized cytochrome C (Cyt C) to its reduced form 
by the superoxide. Reduced Cyt C absorbs light at l=550 nm and the value of 
absorbance is directly proportional to its concentration. To determine the 
extracellular superoxide production, intact astrocytes in a 96-well plate were 
washed twice with KRPG and incubated with 120 µM oxidized Cyt C (Sigma-
Aldrich), for 4 hours at 37°C. Thus, absorbance at 550 nm was recorded using a 
Fluoroskan Ascent FL (Thermo Fisher). Superoxide concentration was calculated 
using the extinction coefficient of the reduced form of Cyt C and normalized to 
the amount of proteins. Results are expressed as arbitrary unit (fold) between the 
control, to which is assigned the value of 1, and the sample condition. 
5. MITOCHONDRIAL MEMBRANE POTENTIAL 
MEASUREMENT 
The mitochondrial membrane potential (DY ) was assessed using the cyanine dye 
DiIC1(5) (1,1′,3,3,3′,3′-hexamethylindodicarbo-cyanine iodide) (Life 
Technologies). DiIC1(5) is a cationic probe that accumulates primarily in 
mitochondria with active membrane potentials, hence the fluorescence intensity is 
directly proportional to the DY . Cells were incubated with DiIC1(5) dye (50 nM) 
in PBS at 37°C for 30 minutes in a bath with soft agitation. DY  intensity signal 
was detected in channel FL4 in a FACScalibur (BD, Biosciences) flux cytometer 
and analysed using CellQuestTM PRO and Paint-a-GateTM PRO (BD, Biosciences) 
software. Once analysed, cells were incubated for 15 minutes with the 
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mitochondrial uncoupler CCCP (carbonyl cyanide m-chlorophenyl hydrazone) (10 
mM) to define the depolarized value. Results were expressed in arbitrary units. 
6. PROTEIN EXTRACTION 
6.1. Total protein extraction 
To obtain total cell protein extracts, cells were washed with cold PBS and lysed in 
RIPA buffer (1% sodium dodecylsulphate, 10 mM ethylene diamine tetraacetic 
acid (EDTA), 1 % v/v Triton Tx-100, 150 mM NaCl, 10 mM Na2HPO4 , pH 7.0), 
supplemented with phosphatase (1 mM Na3VO4 , 50 mM NaF) and protease (100 
µM phenylmethylsulfonyl fluoride (PMSF), 50 µg/ml aprotinine, 50 µg/ml 
leupeptine, 50 µg/ml pepstatin, 50 µg/ml anti-papain, 50 µg/ml amastatin, 50 
µg/ml bestatin and 50 µg/ml soybean trypsin inhibitor) inhibitor cocktail, and 
boiled for 5 minutes. Extracts were then centrifuged at 13,000 g for 10 minutes 
and the supernatant transferred to a new tube. 
6.2. Cytosolic and nuclear fractionation in vitro 
To obtain cytosolic and nuclear fractions from cell cultures, a previously reported 
protocol (Zancai et al., 2005) was used, with some modifications. This method 
first uses a mildly aggressive solution (Cytosolic buffer) that fragmentises cellular 
membranes maintaining the integrity of the nuclei, which are lysed using a more 





Cells were washed with cold PBS containing 1 mM MgCl2, harvested with 
Cytosolic buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 
NP-40 0.1%, v/v, 1.5 M sucrose and protease and phosphatase inhibitor cocktail, 
pH 7.9), triturated with a micropipette to promote cell lysis, left on ice for 30 
minutes and vortexed for 10 seconds. After checking the cell lysis under a light 
microscope, extracts were centrifuged at 830 g for 10 minutes and the cytosolic 
fraction (supernatant) was removed and boiled for 5 minutes. Lysis of the nuclei 
was performed by re-suspending the nuclear pellet in Nuclear buffer (50 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl mM, 0.5 mM NaCl, 1 mM EDTA, NP-40 
1%, v/v, and protease and phosphatase inhibitor cocktail, pH 7.9), triturated with a 
micropipette, left on ice for 1 hour, vortexed at maximum speed for 10 seconds, 
boiled for 5 minutes and sonicated for 5 minutes. 
Scheme 5: Cytosolic and nuclear fractionation in vitro. Cytosolic and nuclear fractions were obtained 
following a differential centrifugation protocol. 
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6.3. Cytosolic and nuclear fractionation ex vivo 
To obtain cytosolic and nuclear fractions from brain, liver, heart and kidney 
tissue, a previously reported protocol (Dimauro et al., 2012) was used. Fresh 
tissue (approximately 50 mg) was washed with cold PBS, minced on ice using 
sharp scissor and re-suspended in 500 µl of STM buffer (250 mM sucrose, 50 mM 
Tris-HCl, 5 mM MgCl2, protease and phosphatase inhibitor cocktail, pH 7.4) and 
homogenized for 1 minute on ice using a Teflon pestle attached to a Potter-
Elvehjem homogeniser set to 1,000 rpm. The homogenate was then inspected and 
if intact tissue was still evident, the homogenisation was repeated. The 
homogenate was decanted into a centrifuge tube and maintained on ice for 30 
minutes, vortexed at maximum speed for 15 seconds and then centrifuged at 800 g 
for 15 minutes. The pellet was labelled as P0 and kept on ice, the supernatant was 
labelled as S0 ad used for subsequent isolation of cytosolic fraction (Scheme 6).  
 
Scheme 6: Cytosolic and nuclear fractionation ex vivo. Cytosolic and nuclear fractions were obtained 
following a differential fractionation protocol. 
 
 59 
The pellet P0 (containing nuclei and debris) was re-suspended in 500 µl of STM 
buffer, vortexed at maximum speed for 15 seconds and then centrifuged at 500 g 
for 15 minutes. Subsequently the above step, the nuclear pellet was labelled as P1 
and kept on ice, while the supernatant S1 (containing cell debris) was discarded. 
To further increase the purity, P1 fraction was washed in 500 µl of STM buffer, 
vortexed at maximum speed for 15 seconds and then centrifuged at 1,000 g for 15 
minutes. The supernatant was discarded and the pellet was labelled as P2 and re-
suspended in 300 µl of NET buffer (20 mM HEPES, 1.5 mM MgCl2, 0.2 mM 
EDTA, 20% glycerol, 1% Triton-X-100, protease and phosphatase inhibitor 
cocktail, pH 7.9) using a pipette to triturate until homogeneous. Pellet P5 was 
vortexed at maximum speed for 15 seconds and incubated on ice for 30 minutes. 
This fraction containing the nuclei were lysed with 20 passages through a 
micropipette and sonicated for 5 minutes. The lysate was centrifuged at 9,000 g 
for 30 minutes and the resulting supernatant was the nuclear fraction. 
Cytosolic fraction was extracted from S0 by centrifugation at 800 g for 10 
minutes. The pellet was discarded and the supernatant S1 was centrifuged at 
11,000 g for 10 minutes. The pellet was discarded and the supernatant S2 
(containing cytosol and microsomal fraction) was precipitated in 500 µl of 100% 
cold acetone at -20ºC for at least 1 hour, followed by centrifugation at 11,000 g 
for 10 minutes. The supernatant was discarded and the pellet P3 was re-suspended 
in 300 µl of STM buffer and labelled as cytosolic fraction. 
6.4. Cytosolic and mitochondrial fractionation 
To obtain cytosolic and mitochondrial fractions from cell culture, a differential 
centrifugation protocol was used (Almeida et al., 1998). Cells grown in 145 cm2 
plates were collected in Mitochondria Isolation Buffer (MIB, 320 mM sucrose, 1 
mM potassium EDTA, 10 mM Tris-HCl and the protease and phosphatase 
inhibitor cocktail, pH 7.4). Cells were centrifuged at 600 g for 5 minutes and the 
pellet re-suspended in MIB. After a 18 stroke homogenization step in a Teflon 
pestle attached to a Potter-Elvehjem homogeniser, homogenate was centrifuged 
three times at 1,300 g for 10 minutes, keeping the supernatants in every step. The 
mitochondrial pellet resulted from the final centrifugation (at 17,000 g for 12 
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minutes) was re-suspended in RIPA buffer, and the supernatant, containing the 
cytosolic fraction, was kept on ice (Scheme 7). 
 
 
6.5. Protein concentration determination 
Protein concentration in samples was determined using the commercially 
available BCA (bicinchoninic acid) protein assay kit (Pierce). This method is 
based on the reduction of Cu2+ (blue) to Cu+ by the peptide bond. The amount of 
Cu2+ reduced is proportional to the amount of protein present in the solution. 
Next, two molecules of BCA chelate with each Cu+ ion, forming a purple-colored 
Scheme 7: Cytosolic and mitochondrial fractionation in vitro. Cytosolic and mitochondrial fraction were 
obtained following a differential fractionation protocol. 
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complex that strongly absorbs light at wavelength of 562 nm that was measured 
with a Multiskan Ascent (Thermo Electron Corp) spectrophotometer. Protein 
concentration was determined using a BSA standard curve. 
7. ELECTROPHORESIS AND PROTEIN 
IMMUNODETECTION (WESTERN BLOT) 
Extract of whole cells, cytosolic-, nuclear- and mitochondrial-fraction were 
obtained as previously described (see Section 6). Aliquots of the samples and a 
molecular weight marker (PageRulerTM Plus Prestained Protein Ladder, Thermo 
Scientific) were loaded in a sodium dodecyl sulfate (SDS) polyacrylamide gel 
(acrilamide/bisacrilamide 29/1; BioRad Laboratories S.A.) and subjected to 
vertical electrophoresis (MiniProtean, Bio-Rad). Proteins were transferred to 
nitrocellulose membranes (Hybond®, Amersham Biosciences), blocked with 5% 
w/v low-fat milk in TTBS (20 mM Tris, 500 mM NaCl, 0.1 % v/v Tween 20, pH 
7.5) for 1 hour at room temperature, and incubated with the primary antibody 
(Table 2) over night at 4ºC. As loading control b-Actin was used for whole cells, 
GAPDH for cytosolic fraction, Lamin-B for nuclear fraction and VDAC for 
mitochondrial fraction. 
The following day, membranes were washed 3 times with TTBS and incubated 
with the secondary antibody (Table 2), conjugated with the horseradish 
peroxidase (HRP), in 2% w/v BSA in TTBS for 1 hour at room temperature. 
Signal was detected with the enhanced chemiluminescence kit (Pierce, Thermo 
Scientific) by exposing membranes on a Fuji Medical X-Ray Film (Fujifilm). For 
quantification, auto radiographies were scanned and the bands were analyzed 
using image treatment software (NIH Image, Wayne Rasband, National Institutes 
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8. MITOCHONDRIA ISOLATION 
To obtain large quantities of isolated mitochondria in order to measure mCAT 
activity (see Section 9), a different centrifugation protocol was used (Acín-Pérez 
et al., 2008). Cells grown in 145 cm2 plates were washed with cold PBS, collected 
and centrifuged at 500 g for 5 minutes. The supernatant was discarded and the 
pellet was re-suspended in 1 ml of Buffer A (83 mM sucrose, 10 mM MOPS (3-
(N-morpholino)propanesulfonic acid, pH 7.2) and homogenized (10 strokes) in a 
Teflon pestle attached to a Potter-Elvehjem homogeniser. The same volume of 
Buffer B (250 mM sucrose, 30 mM MOPS, pH 7.2) was added to the sample and 
the homogenate was centrifuged at 1,000 g for 5 minutes to remove unbroken 
cells and nuclei. The pellet was discarded and the supernatant was centrifuged at 
12,000 g for 2 minutes. The supernatant was discarded and the pellet, which 
contains the mitochondrial fraction, was washed in 200 µl of Buffer C (320 mM 
sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4) and centrifuged at 12,000 g for 
2 minutes. The supernatant was discarded and the pellet, containing the washed 
mitochondria, was re-suspended in 200 µl of Buffer D (1 M 6-aminohexanoic 
acid, 50 mM Bis-Tris HCl, pH 7.0) (Scheme 8). Protein concentration was 




9. mCAT ACTIVITY MEASUREMENT 
mCAT activity was measured from isolated mitochondria according to a 
previously published protocol (Quintana-Cabrera and Bolaños 2013), with some 
modifications. The assay is based on the ability of mCAT to neutralize the 
exogenous hydrogen peroxide. Mitochondria were incubated with different 
hydrogen peroxide concentrations for different times; once the reactions were 
stopped, samples were incubated with a solution containing Fe2+, which is 
oxidized by hydrogen peroxide at Fe3+. The incubation solution also contains 
SCN-, which reacts with Fe3+ to form the orange complex FeSCN2+, which 
absorbs light at wavelength of 492 nm (Scheme 9). The value of the absorbance is 
directly proportional to the residual hydrogen peroxide concentration. 
Scheme 8: Isolation of mitochondria. Large quantities of mitochondria were isolated 





To determine the mCAT activity, 5 µg of mitochondria were incubated in a final 
volume of 50 µl of 0.1 M Phosphate Buffer (PB) pH 7.4 with 0, 25, 50 and 100 
µM hydrogen peroxide for 0, 5, 10, 15 and 20 minutes. Reactions were stopped 
using 37% HCl. Then, 3.2 mM (NH4)2Fe(SO4)2 (ammonium ferrous sulfate 
hexahydrate) and 180 mM KSCN (potassium thiocyanate) were added and the 
samples were incubated for 10 minutes at room temperature in the dark. The 
absorbance at 492 nm was measured using a Fluoroskan Ascent FL (Thermo 
Fisher) and the concentration of the residual hydrogen peroxide was calculated 
using a standard curve. 
Scheme 9: Evaluation of the mCAT activity. To determine the mCAT activity, a 




Astrocytes were grown on glass coverslips. At DIV15 they were fixed with 4% 
paraformaldehyde (v/v) in PBS for 20 minutes and washed with PBS. 
Subsequently, astrocytes were incubated in 5% goat serum, 1% BSA PBS-Tx 
0.2% for 1 hour at room temperature. Afterwards, they were incubated with the 
primary antibody (Table 3) in 2% goat serum, 1% BSA, PBS-Tx 0.2% overnight 
at 4ºC. The following day astrocytes were washed with PBS-Tx 0.2% and 
incubated with the secondary antibody (Table 3) and the nuclear marker DAPI 
(Sigma, Ref D9542, 1/10,000) in 2% goat serum, 1% BSA, PBS-Tx 0.2% for 1 
hour at room temperature. Subsequently, glass coverslips were placed on a glass 
slide using SlowFade® (Molecular Probes) in order to avoid fluorescence loss. 
Confocal microscopy images were obtained using a spinning disk confocal 
microscopy Olympus IX81 and processed with Adobe Photoshop cs5.5 software. 
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11. RNA PURIFICATION 
To obtain a total RNA fraction, the GeneluteTM Mammalian Total RNA kit 
(Sigma-Aldrich) was used. 
Cells were lysed with a solution of b-mercaptaethanol:Lysis Solution in 1:100 
proportion. The lysates were filtered through a Genelute Filtration Column and 
centrifuged at 16,000 g in order to eliminate cellular debris and discard the DNA. 
An equivalent 70% ethanol volume (prepared in DEPC (dyethyl pyrocarbonate) 
water RNase free) was added and the samples were vortexed. After that, the 
samples were passed to a Genelute Binding Column, which retains the RNA. The 
filtered was discarded and the column was washed with the Wash Solution 1. 
Once the RNA was separated, the column was treated with 100 U of DNAse I 
(Roche) for 15 minutes at room temperature in a buffer containing 400 mM Tris-
HCl, 100 mM NaCl, 60 mM MgCl2, 10 mM CaCl2, pH 7.9. To eliminate residual 
DNA, column was washed first with the Wash Solution 1 and then with the Wash 
Solution 2 Concentrate/ethanol. Finally, the total RNA was eluted with 50 µl of 
Elution Solution through a centrifugation at 16,000 g for 1 minute. 
To obtain a micro-RNA (miRNA) enriched fraction, the miRNeasy kit (Qiagen) 
was used. Cells were lysed with QIAzol Lysis reagent, homogenized by vortexing 
for 1 minute and left at room temperature for 5 minutes to promote the 
dissociation of nucleoprotein complexes. Subsequently, chloroform was added, 
the tube was vortexed for 15 seconds and left at room temperature for 3 minutes. 
After that, the tube was centrifuged at 12,000 g at 4ºC, The aqueous phase was 
transferred to a new tube and mixed with an equivalent 70% ethanol volume 
(prepared in DEPC water RNase free) and the tube was vortexed. The sample was 
then passed to an RNeasy Mini spin column, which retains the larger RNAs. The 
filtered containing the miRNA was passed to a new tube and mixed with 0.65 
volumes of 100% ethanol. The sample was passed to a RNeasy Mini spin column 
and the filtered was discarded. To eliminate residual impurities, the column was 
washed first with RWT buffer, then with RPE buffer and finally with 80% ethanol 
(prepared in DEPC water RNAse free). The spin column membrane was dried by 
centrifugation at 8,000 g for 2 minutes and the miRNA-enriched fraction was 
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eluted in 14 µl of RNAse free water through a centrifugation at 8,000 g for 1 
minute. 
Purified RNA concentration was measured using the UV-Vis Nanodrop 2000 
(Thermo Scientific). The absorbance ratio calculated between 260 and 280 nm 
(A260/A280), which determines the RNA purity, was 1.8 – 2. 
12. REAL TIME QUANTITATIVE POLYMERASE CHAIN 
REACTION 
Real Time quantitative Polymerase Chain Reaction (RT-qPCR) was used to 
evaluate the relative gene expression. This method compares target genes versus a 
housekeeping gene (b-actin in this case) of constant expression in the samples 
studied, at the same time that relativizes this expression to a control condition. 
Concentration of primers for the RT-qPCR was optimized, calculating the 
efficiency for every pair of primers. Efficiencies in the range 90-110% were 
considered optimal conditions. To achieve this, serial RNA dilutions were 
incubated with different primers concentrations. In the Table 4 they are shown the 
concentrations and the sequences of the primers used, following their 
optimization, for the different mRNA. This step is necessary to compare the 




To perform the RT-qPCR the commercial kit Power Sybr Green RNA-to-Ct 1-
Step kit (Applied Biosystems) was used, following the manufacture’s protocol. 
This kit allows the reverse transcription of the mRNA to cDNA and the following 
PCR in a unique step. 100 ng of purified RNA in a final volume of 20 µl were 
used. Every determination was performed in triplicate using the thermocycler 
Mastercycler ep Realplex (Eppendorf). 
RT-qPCR conditions were: 30 minutes at 48ºC (reverse transcription step), 10 
minutes at 95ºC (DNA polymerase activation step), 40 cycles of 15 seconds at 
95ºC (denaturalization step) followed by 1 minute at 60ºC (annealing and 
elongation steps). 
The value obtained for every reaction was the Ct (threshold cycle), which 
represents the cycle number at which the fluorescence generated within a reaction 
crosses the fluorescence threshold, a fluorescent signal significantly above the 
background fluorescence. For every gene studied, including the housekeeping 
Gene Forward sequence 5'  3' Concentration (μM)
 5'-ATGCAGGCCAACCGTCTATT-3' 5'-TGTCTGACTCATGCAGGTCT-3'




















Nox4 5'-TGCAGAGATATCCAGTCCTTCC-3' 5'-TCCCATCTGTTTGACTGAGG-3' 0.1
Nox1 5'-AAATTCCAGCGTGCCGACAA-3' 5'-AACCAGGCAAAGGCACCTGT-3' 0.1
Nox2 5'-ATGCAGGAAAGGAACAATGC-3' 5'-GTGCACAGCAAAGTGATTGG-3' 0.1
Table 4: Sequences and concentrations of primers used for the RT-qPCR. 6pgd: 6-phosphogluconate 
dehydrogenase; G6pd: Glucose-6-phoshate dehydrogenase; Gclc: Glutamate cysteine ligase, catalytic 
subunit; Gpx2: Glutathione peroxidase-2; Ho-1: Heme oxygenase-1; Nqo1: NAD(P)H dehydrogenase 
quinone-1; Nox1: NADPH-oxidase-1; Nox2: NADPH-oxidase-2; Nox4: NADPH-oxidase-4; Nrf2: Nuclear 
factor (erythroid-derived 2)-like 2; Prdx1: Peroxiredoxin-1; Trx1: Thioredoxin-1. 
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gene (b-actin), a Ct is obtained. DCt sample is the Ct value for any sample 
normalized to the endogenous housekeeping gene (b-actin). 
Comparative method of Ct (DDCt) relates the number of copies of mRNA between 
different conditions, which is obtained using the formula: 
2-[(Ct sample – Ct housekeeping gene) – (Ct control – Ct housekeeping gene)] 
Results are expressed as arbitrary unit (fold) between the control, to which is 
assigned the value of 1, and the sample condition. Expression levels equal to 1 
indicate no differences between the two conditions; lower levels to 1 indicate a 
decreased gene expression in the sample compared to the control condition; on the 
contrary, higher levels to 1 indicate an increased gene expression in the sample 
compared to the control. 
13. miRNA EXPRESSION ANALYSIS 
All the following techniques have been performed at the ADN Sequencing service 
of NUCLEUS, University of Salamanca. 
13.1. miRNA reverse transcription 
To perform the miRNA reverse transcription, 50 ng of miRNA-enriched fraction 
was mixed with 0.1 µl of 100 nM dNTP, 0.14 µl of RNase inhibitor (20 U/ µl), 
0.67 µl of reverse transcriptase (50 U/ µl), 1 µl RT-Buffer 1X and 4.5 µl of primer 
pool (mixed to allow a final concentration of 0.05X for hsa-miR-1 and hsa-miR-
206 and 0.5X for mmu-miR-202-5p) in a final volume of 10 µl. All reagents were 
purchased from Applied Biosystems. Samples were incubated for 5 minutes on 
ice, 30 minutes at 16ºC, 30 minutes at 42ºC and finally 5 minutes at 85ºC. 
13.2. Pre-PCR amplification 
Before the expression analysis of miRNA, the cDNA was pre-amplified. To do so, 
pre-PCR amplification reaction was done at 5 µl containing 2.5 µl TaqMan 
PreAmp Master Mix (2X), 1.25 µl of pooled TaqMan assay mix (0.2X each 
assay) and 1.25 µl of cDNA. The pre-amplification PCR was performed at one 
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cycle 95ºC for 10 minutes, 10 cycles at 95ºC for 15 seconds followed by 4 
minutes at 60ºC. All reagents were purchased from Applied Biosystems. 
13.3. miRNA expression analysis using 48.48 dynamic array 
Relative miRNA expression was evaluated using a 48.48 dynamic array (Fluidigm 
Corporation). This method compares target miRNA versus a miRNA endogenous 
control (mmu-miR-202-5p in this case) of constant expression in the samples 
studied, at the same time that relativizes this expression to a control condition. 
miRNA expression analysis was carried out using the 48.48 dynamic array 
(Fluidigm Corporation) following the manufacturer’s protocol. Specifically, a 5 µl 
of sample mixture was prepared for each sample containing 2.5 µl TaqMan 
Universal Master Mix (No UNG) (Life Technologies), 0.25 µl of 20X GE Sample 
Loading Reagent (Fluidigm Corporation) and 2.25 µl of pre-amplified cDNA. 
Then, 5 µl of Assay mix was prepared with 2.5 µl of 20X TaqMan miRNA assay 
(Thermo Scientific) and 2.5 µl of 2X Assay Loading Reagent (Fluidigm 
Corporation). An integrated fluidic circuit (IFC) controller was used to prime the 
fluidic array (chip) with control line fluid and then with samples and assay mixes 
in the appropriate inlets. After loading, the chip was placed in the BioMark HD 
Instrument for PCR at 96.5ºC for 10 minutes, followed by 40 cycles at 96ºC for 
15 seconds and 60ºC for 1 minute. Different miRNA expression was calculated 
using the comparative method of Ct (DDCt), as previously described in Section 12. 
Data were analysed with Fluidigm Real-Time PCR Software (Fluidigm 
Corporation). TaqMan assays used were mmu-miR-202-5p, hsa-miR-1 and hsa-
miR-206 (Thermo Scientific). 
14. GLUTATHIONE CONCENTRATION DETERMINATION 
To determinate the glutathione concentration, cells were washed with cold PBS 
and rapidly harvested with 1% w/v 5-sulfosalicylic acid with a cell scraper. An 
equal volume of 0.1 M NaOH was added to the same amount of cells for protein 
quantification. Cell lysates were centrifuged at 13,000 g for 5 minutes and the 
total glutathione concentration, which is the sum of reduced glutathione plus two-
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fold the oxidized (GSx = GSH + 2GSSG), was measured in the supernatant using 
a previously described protocol (Tietze 1969). The assay is based on the GSH 
(reduced glutathione) oxidation at expense of the DTNB (5,5'-dithiobis-(2-
nitrobenzoic acid) (Sigma-Aldrich) reduction to TNB (λmax=405 nm). The newly 
formed GSSG (oxidized glutathione) is regenerated to GSH through the 
enzymatic activity of the glutathione reductase, which need NADPH (H+) as a co-
factor. This is a cyclic reaction (Scheme 10), whose reaction rate is directly 
proportional to the GSx (total glutathione) concentration. 
 
 
This determination was realized in a 96-wells plate mixing 10 µl of the sample, 90 
µl of water and 100 µl of the buffer reaction (1 mM EDTA, 0.3 mM DTNB, 0.4 
mM NADPH, 1 U/ml glutathione reductase, prepared in 0.1 mM PB, pH 7.5). 
Increases of absorbance, following the reaction between GSH and DTNB, was 
measured using a Fluoroskan Ascent FL (Thermo Fisher) at 405 nm, every 15 
seconds during 2.5 minutes (10 iterations). 
GSx concentration was determined extrapolating the slopes to those obtained 
from a GSSG standard curve (0-50 µM) and the results were expressed as nmol 
GSx / mg protein. 
Scheme 10: GSx enzymatic determination. DTNB: 5,5'-dithiobis-(2-nitrobenzoic acid); 
GSH: reduced glutathione; NADP+: Nicotinamide Adenine Dinucleotide Phosphate; TNB: 5’-
thio-2-nitrobenzoic acid; GSSG: oxidized glutathione; NADPH: Nicotinamide Adenine 
Dinucleotide Phosphate, reduced form. 
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15. CASPASE-3 ACTIVITY DETERMINATION 
To evaluate cellular apoptosis, the activity of the enzyme Caspase-3 (CSP-3) was 
chose as apoptotic marker. For this purpose, Caspase 3 Assay Kit, Fluorimetric 
(Sigma-Aldrich) was used following the manufacture’s protocol. This assay is 
based on the hydrolysis of the peptide substrate Ac-DEVD-AMC (acetyl-Asp-
Glu-Val-Asp-7-amino-4-methylcoumarin) by CSP-3, resulting in the release of 
the fluorescent AMC (7-amino-4-methylcoumarin) moiety (Scheme 11). 
 
The excitation and emission wavelengths of AMC are 360 nm and 460 nm, 
respectively. The concentration of the AMC released can be calculated from a 
standard curve determined with defined AMC solutions. 
Cells were lysed with a Lysis Buffer (50 mM HEPES, 5 mM CHAPS, 5 mM 
DTT, pH 7.4) for 20 minutes on ice. Successively, Assay Buffer containing the 
Ac-DEVD-AMC substrate (20 mM HEPES, 2 mM EDTA, 0.1% CHAPS, 5 mM 
DTT, 16 µM Ac-DEVD-AMC, pH 7.4) was added, the solution was mixed well 
by pipetting and 200 µl was transferred to a 96 wells plate. The fluorescence was 
recorded for 2 hours at 20 minutes intervals at 37 ºC using a Fluoroskan Ascent 
FL (Thermo Scientific) (λexc=360 nm, λem=460 nm). CSP-3 activity was 
determined as AMC release rate extrapolating the slopes to those obtained from a 
AMC standard curve and the results were expressed as arbitrary unit (fold) 
between the control, to which is assigned the value of 1, and the sample condition. 
16. PENTOSE-PHOSPHATE PATHWAY (PPP) FLUX 
MEASUREMENT 
The PPP flux was measured in attached cells following a previously published 
protocol (Rodriguez-Rodriguez et al., 2013). This method determines the PPP 
Scheme 11: Caspase-3 activity determination. Ac-DEVD-AMC: acetyl-Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin; Ac-DEVD: acetyl-Asp-Glu-Val-Asp; AMC: 7-amino-4-methylcoumarin. 
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flux by determining the difference of 14CO2 produced from D-[1-14C]-glucose, 
metabolized both in the tricarboxylic acid cycle and in the PPP, and the 14CO2 
produced from D-[6-14C]-glucose, metabolized only in the tricarboxylic acid 
cycle, in the reactions catalyzed by isocitrate dehydrogenase and α-ketoglutarate 




Scheme 12A: Schematic representations of the fate of the radiolabeled carbons used for 
the PPP flux assessment. D-[1-14C]-glucose is decarboxylated in the reaction catalysed by 6-
phosphogluconate dehydrogenase. D-[6-14C]-glucose that enters PPP is transformed back into 
GAP or F6P in the non-oxidative branch of PPP. D-[6-14C]-glucose and D-[1-14C]-glucose 





To do so, cells were seeded in the bottom of 25 cm2 flasks. At DIV15 in culture, 
medium was replaced by 1.5 ml KRPG in presence of 0.5 µCi/ml of either D-[1-
14C]-glucose or D-[6-14C]-glucose. Before sealing the flask with a rubber cap, a 
1.5-ml Tube containing 0.8 ml of benzetonium hydroxide (Sigma-Aldrich) for 
14CO2 trapping was fixed inside the flask by holding it from the flask tab using a 
rib (Scheme 13).  
Scheme 12B: Schematic representations of the fate of the radiolabeled carbons used for 
the PPP flux assessment. Radiolabeled pyruvate, proceeding from D-[1-14C]-glucose or D-
[6-14C]-glucose enters TCA and is decarboxylated in the different turns of the cycle in the 




In order to ensure an adequate O2 supply throughout incubation period, the 
atmosphere of the flasks was gassed with an O2:CO2  (95:1) mixture for 20 
seconds, before the flasks were sealed and incubated in a thermostatic orbital 
shaker for 90 minutes. After the incubation period, reaction was stopped by 
adding 0.15 ml of 20% w/v perchloric acid and flasks were incubated for another 
90 minutes to allow 14CO2 trapping by the benzetonium hydroxide. The tubes 
were placed in a vial containing Optiphase HiSafe III (PerkinElmer) scintillating 
liquid, vortexed at maximum speed for 20 seconds and left to equilibrate 
overnight. The following day, counts per minute was measured using a Tri-Carb 
4810 TR (PerkinElmer) liquid scintillating analyser and results were expressed as 
nmol of glucose turned into 14CO2 per hour and per mg protein. 
The efficiency of 14CO2 trappping by the benzetonium hydroxide was determined 
to be a 75% (Rodriguez-Rodriguez et al., 2013). Total µCi in the tube where then 
measured for calculating the percentage of 14CO2 trapped, which was taken in 
account for the calculations. 
Scheme 13: Schematic representation of the method for PPP 
flux determination in attached cells. 
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17. NADPH/NADP+ RATIO DETERMINATION 
To determine the concentration of the nucleotides NADPH and NADP+, the 
commercial kit NADP/NADPH Assay Kit (Colorimetric) (Abcam) was used. The 
enzymes in the system specifically recognize NADP and NADPH in an enzyme 
cycling reaction.  
Cells were trypsinized and centrifuged at 500 g for 5 minutes. The supernatant 
was discarded and the pellet was re-suspended in 500 µl of NADP/NADPH 
Extraction Buffer and kept on ice for 10 minutes. Samples were then vortexed for 
10 seconds and centrifuged at 14,000 rpm for 5 minutes to remove insoluble 
material. The extracted NADP/NADPH supernatant was transferred to a new tube, 
labelled as NADPt (total NADP, containing NADPH and NADP+) and kept on 
ice. To determine NADPH only, 200 µl of NADPt was separated into a new tube 
and heated at 60 ºC for 30 minutes to decompose NADP+. The samples containing 
only NADPH were then cooled on ice and centrifuged 1 minute at 14,000 rpm.  
The determination was realized in a 96-wells plate mixing 50 µl of the sample in 
presence of 100 µl of the buffer reaction (98 µl NADP Cycling Buffer, 2 µl 
NADP Cycling Enzyme) and incubated 5 minutes at room temperature to convert 
NADP+ to NADPH. Then, 10 µl of NADPH Developer was added to each well 
and incubated for 2 hours at room temperature. The absorbance at 450 nm was 
measured using a Fluoroskan Ascent FL (Thermo Fisher). 
NADPt and NADPH concentration was determined using a NADPH standard 
curve (0-100 pmol/well). NADP+ concentration was calculated from the formula 
NADPt – NADPH = NADP+ 
18. de novo LIPOGENESIS FLUX MEASUREMENT 
To measure the flux of the de novo lipogenesis (DNL), a previously reported 
protocol (Tabernero et al., 1993) with some modifications was used. This method 
determines the DNL flux by determining the incorporation of 14C in the total 
lipidic fraction. To do so, astrocytes were seeded in 6 wells plate. At DIV15, 
medium was replaced by KRPG in the presence of 3 µCi/ml of D-[6-14C]-glucose 
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and cells were incubated in a thermostatic orbital shaker at 37ºC for 3 hours. After 
the incubation period, cells were washed twice with PBS, recollected and 
centrifuged at 500 g for 5 minutes. The supernatant was discarded and the pellet 
was re-suspended in 500 µl of a mixture chloroform/methanol (2:1, v/v) and 
incubated at -20ºC for 16 hours. Subsequently, 250 µl of 0.3% (w/v) NaCl 
saturated with chloroform were added, the samples were centrifuged at 1,500 g for 
15 minutes and the aqueous phase, containing the cellular hydro soluble 
components, was discarded. Later, this same process was repeated, this time using 
250 µl of 0.3% (w/v) NaCl saturated with chloroform and 180 µl of methanol. 
The resulting chloroformic phase was passed to a new tube. Every step was 
performed at 4ºC. An aliquot of 50 µl of the chloroformic phase containing the 
lipid fraction, was placed in a vial containing Optiphase HiSafe III (PerkinElmer) 
scintillating liquid, vortexed at maximum speed for 20 seconds and left to 
equilibrate overnight. The following day, counts per minute was measured using a 
Tri-Carb 4810 TR (PerkinElmer) liquid scintillating analyser and results were 
expressed as nmol of glucose incorporated in lipids per hour and per mg protein. 
19. STATISTICAL ANALYSIS 
All measurements were carried out at least in three different culture preparations 
or animals, and the results were expressed as the mean values ± SEM (Standard 
Error of the Mean). For the comparison between two groups of values, the 
statistical analysis of the results was performed by the Student’s t test. The 
statistical analysis was performing using the SPSS software. In all cases, p<0.05 










1. mCAT expression down-modulates endogenous mROS in 
MEFs 
Astrocytes, despite their major antioxidant defenses, produce higher 
mitochondrial reactive oxygen species (mROS) compared with neurons under 
basal conditions (Lopez-Fabuel et al., 2016). The vast majority of studies on 
ROS-mediated cell signalling have used a strategy based on increasing ROS, 
either by exogenous or endogenously-supplied ROS. However, this approach 
might mask the beneficial effects of mROS. In this work the alternative approach 
to down-modulate mROS abundance specifically is used. 
Several transgenic mouse models able to down-modulate mROS have been 
generated in the last decades. Nevertheless, every model presents a major 
disadvantage. The overexpression of mitochondrial superoxide dismutase 
(MnSOD) efficiently decrease the amount of superoxide, but it increases the 
concentration of hydrogen peroxide (Chen et al., 1998). Down-modulation of 
endogenous mitochondrial hydrogen peroxide has been achieved through the 
overexpression of peroxiredoxin-3 (Matsushima et al., 2006). The 
peroxiredoxin/thioredoxin complex is a very efficient system to convert hydrogen 
peroxide into water. However, to regenerate reduced peroxiredoxin, NADPH is 
required (Patenaude et al., 2005). The consumption of reducing equivalents will 
thus modify the NAPDH/NADP+ ratio, changing the redox state that could alter 
cellular metabolism. Recently, it was demonstrated that the expression of a 
mitochondrial form of the glutamate-cysteine ligase (mGCL) down-modulates 
mROS (Quintana-Cabrera et al., 2012). mGCL directs the biosynthesis of g-
glutamylcysteine (g-GC, the immediate glutathione precursor) to the 
mitochondria, where it efficiently detoxifies mROS acting as glutathione 
peroxidase-1 cofactor (Quintana-Cabrera et al., 2012). However, it consumes 
ATP, cysteine and glutamate, interfering in cellular metabolism. A clean manner 
to down-modulate mROS is the expression of a mitochondrial form of catalase 
(mCAT). A mCAT mouse model has been generated (Schriner et al., 2005). 
However, this mCAT model was generated by non site-directed insertion of the 
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construct, thus likely affecting the expression of other genes. Furthermore, this 
technique does not allow to control the number of copies inserted. 
Accordingly, we aimed to generate a new mCAT mouse by insertion of the 
construct in the Rosa26 locus of C57Bl/6 embryonic stem cells by homologous 
recombination. 
Preliminary studies were performed in immortalized MEFs transfected with the 
pIRES2eGFP-mCAT (henceforth mCAT) or the empty plasmid, in order to 
ascertain the correct expression of the construct. The data obtained show that cells 
transfected with mCAT express the HA tag (Figure 1A), and higher catalase 
abundance (Figure 1B) compared to MEFs transfected with the empty plasmid. 
 
 
Figure 1: HA occurrence and catalase abundance in transfected MEFs.  Immunoblot revealed that MEFs 
transfected with mCAT show increased abundance of catalase (A) and express the HA tag (B) compared to 
the empty plasmid. b-Actin was used as loading control. Data are expressed as mean ± S.E.M.; *p<0.05 
Student’s t-test; n=3 independent experiments. 
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Next, with the aim to establish whether mCAT is able to detoxify hydrogen 
peroxide, the functionality of the enzyme was investigated. The catalytic activity 
of mCAT was assessed in isolated mitochondria in presence of different 
concentrations of exogenous hydrogen peroxide. As shown in Figure 2, 
mitochondria isolated from MEFs expressing mCAT neutralize exogenous 
hydrogen peroxide faster than cells transfected with the empty plasmid. Analyzing 
these results, it seems that mCAT is not able to down-modulate endogenous 
mROS, considering that in absence of exogenous hydrogen peroxide there are no 
differences between mitochondria expressing mCAT and the empty plasmid. 
However, the colorimetric method used to measure mCAT activity is not sensitive 
enough to detect endogenous mROS levels. 
 
 
The release rate of mROS in basal conditions was then assessed using the Amplex 
Red, a non-fluorescent probe that is selectively oxidized by extracellular hydrogen 
peroxide to the fluorescent molecule resorufin in presence of the horseradish 
peroxidase. This assay is very sensitive and allows to detect hydrogen peroxide in 
the picomolar range (Mishin et al., 2010; Mohanty et al., 1997). First, the 
hydrogen peroxide release rate was measured in mitochondria isolated from 
Figure 2: mCAT expression increases mitochondrial hydrogen peroxide detoxification in MEFs. 
Incubation of isolated mitochondria with different concentrations of exogenous hydrogen peroxide for 
different time period shows that mCAT expression increases significantly the rate of hydrogen peroxide 
neutralization at all concentration used. In the absence of exogenous hydrogen peroxide, there were no 
differences between mitochondria expressing mCAT and the empty plasmid. Data are expressed as mean ± 
S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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transfected MEFs. As shown in Figure 3, mitochondria that express mCAT 
produce lower hydrogen peroxide release rate compared to the empty plasmid. 
Considering that hydrogen peroxide diffuses through biological membranes (Han 
et al., 2003), its mitochondrial production may affect the rest of the cell. As 
illustrated in Figure 3, the expression of mCAT down-modulates hydrogen 
peroxide release rate from whole cells too. Hence, mCAT is functional and its 
expression in MEFs is sufficient to down-modulate endogenous levels of mROS.  
 
 
2. Endogenous mROS modulate NRF2 abundance and activity in 
immortalized MEFs 
The cellular abundance and the consequent nuclear translocation of NRF2 is 
mainly controlled by the complex formed by the redox sensitive protein KEAP1 
and Cul3, which binds and ubiquitinates NRF2 for its proteasomal degradation 
(Itoh et al., 1999). Oxidation of three Cys residues on KEAP1 causes a 
conformational change on the KEAP1-Cul3 complex that does not allow the 
Figure 3: mCAT expression down-modulates endogenous mROS and ROS levels in transfected MEFs. 
Mitochondria and intact MEFs expressing mCAT show a ~0.4 fold lower hydrogen peroxide release rate 




ubiquitination and recycling of the complex (Baird et al., 2013). In this situation, 
de novo synthesized NRF2 can accumulate and translocate to the nucleus, where it 
up-regulates the transcription of its target genes (Baird et al., 2013). 
With the aim to investigate whether endogenous mROS are sufficient to activate 
the NRF2 pathway, NRF2 protein abundance was measured by immunoblot. As 
shown in Figure 4A, MEFs expressing mCAT express lower NRF2 levels 
compared to the empty plasmid. 
Afterwards, we aimed to ascertain whether NRF2 down-modulation affected the 
expression of antioxidant genes by analyzing the mRNA levels of three of its 
target genes. Using b-actin as housekeeping gene, the expression of the 
glutamate-cysteine ligase catalytic subunit (Gclc), heme oxygenase 1 (Ho-1) and 
NADPH quinone dehydrogenase 1 (Nqo1) were measured by RT-qPCR. As 
shown in Figure 4B the levels of Gclc, Ho-1, and Nqo1 were 18%, 30% and 44% 
lower in MEFs transfected with mCAT compared to the empty plasmid, 
respectively. 
These results indicate that endogenous mROS modulate the NRF2 protein 




3. mCAT expression down-modulates physiological endogenous 
mROS in primary astrocytes 
In light of the preliminary data obtained in immortalized MEFs, primary 
astrocytes were transfected with mCAT in order to ascertain whether its 
expression down-modulates endogenous mROS in primary glial cells too. 
Figure 4: mROS modulate NRF2 abundance and its transcriptional activity in MEFs. (A) mCAT 
expression decreases NRF2 abundance in MEFs. b-Actin was used as loading control. (B) mRNA levels of 
Gclc, Ho-1 and Nqo1 were significantly decreased in MEFs expressing mCAT when compared to the empty 
plasmid. b-actin was used as housekeeping gene. Data are expressed as mean ± S.E.M.; *p<0.05 Student’s t-
test; n=3 independent experiments. 
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Astrocytes transfected with mCAT show the HA tag, indicating the correct mCAT 
expression (Figure 5A). Considering that in primary astrocytes the efficiency of 
transfection is low (~30% of cells were transfected, compared to >70% MEFs 
transfected), cells expressing mCAT slightly decrease hydrogen peroxide release 
rate (~13%) compared to the empty plasmid (Figure 5B). Thus, the expression of 
mCAT down-modulates endogenous mROS levels in primary astrocytes. 
 
 
4. Generation of constitutive +/mCAT mouse 
Considering the preliminary results in transfected immortalized MEFs and 
primary astrocytes, we generated the Cre recombinase-inducible ROSA26-floxed 
knock-in mouse harboring the floxed-mCAT by homologous recombination. 
In order to express mCAT ubiquitously, mCATfloxed/+ mice were crossbred with 
(CMV)-Cre recombinase mice under a C57Bl/6 background, which yielded the 
C57Bl6+/mCAT mouse line (henceforth mCAT). The offspring was genotyped 
(Figure 6) and used to obtain +/mCAT immortalized MEFs and primary 
astrocytes. 
Figure 5: HA occurrence and ROS levels in transfected primary astrocytes. Primary astrocytes were 
transfected 24h before the experiments. (A) Immunoblot revealed that primary astrocytes transfected with 
mCAT express the HA tag. b-Actin was used as loading control. (B) Hydrogen peroxide production was 
lower in astrocytes expressing mCAT when compared to the empty plasmid. Data are expressed as mean ± 




5. mCAT constitutive expression in MEFs down-modulates 
hydrogen peroxide release 
In order to confirm the correct expression and the sub-cellular localization of 
mCAT construct, the occurrence of HA tag was evaluated in MEFs by 
immunoblot. First of all, detection of the HA tag was performed in the whole 
extract obtained from immortalized MEFs (Figure 7A). The results confirm that 
+/mCAT MEFs express the HA tag, while WT (or +/+) do not. Next, 
mitochondrial localization of the mCAT was confirmed. After a sub-cellular 
fractionation, HA tag detection was carried out in the cytosolic and in the 
mitochondrial fractions of MEFs (Figure 7B). As expected, only mitochondrial 
fraction obtained from +/mCAT MEFs expresses the HA tag. 
The following step was to confirm that the constitutive expression of mCAT 
down-modulates endogenous ROS levels. Using the Amplex Red probe, hydrogen 
peroxide release rate from intact MEFs was measured. As shown in Figure 7C, 
+/mCAT MEFs released hydrogen peroxide 43% slower than WT. 
These results confirm that mCAT is correctly localized in the mitochondria of 
+/mCAT MEFs and its constitutive expression down-modulates endogenous 
release of ROS. 
Figure 6: Example of a PCR. The genotype of the mice was determined by PCR. Wild type mice present 
only one band at 729 bp, while for the mCAT animals an additional band at 245 bp was detected. As controls, 




6. mCAT constitutive expression in primary astrocytes 
In light of the previous results confirming the correct expression and activity of 
mCAT in MEFs, the occurrence of mCAT was confirmed in primary astrocytes. 
First, the expression of HA tag and the abundance of catalase were detected by 
immunoblot in whole cell extracts. As expected, +/mCAT astrocytes showed 
higher (~6 fold) catalase abundance compared to the WT (Figure 8A) and they 
expressed the HA tag (Figure 8B). Subsequently, the mitochondrial localization 
of mCAT was confirmed. After a subcellular fractionation, HA tag was detected 
in mitochondria isolated from +/mCAT astrocytes (Figure 8C). However, a slight 
Figure 7: Constitutive mCAT expression decreases endogenous ROS release in MEFs. Expression of HA 
tag in MEFs that constitutively express mCAT was assessed by immunoblot in (A) whole cells and (B) 
cytosolic and mitochondrial fractions. HA tag was detected only in the +/mCAT MEFs and localized only in 
the +/mCAT mitochondria. b-Actin was used as loading control for the whole cells extract; GAPDH was 
used as loading control for the cytosolic fraction; VDAC was used as loading control for the mitochondrial 
fraction. (C) Intact cells expressing constitutively mCAT showed a decreased hydrogen peroxide production 




band corresponding to the HA tag was detected also in the cytoplasmic 




Mitochondrial localization of mCAT in primary astrocytes was further confirmed 
by immunofluorescence by confocal microscopy. To do so, heat shock protein-60 
(HSP-60) was used as mitochondrial marker. As expected, +/mCAT astrocytes 
express the HA tag, which co-localizes with HSP-60 (Figure 9). In contrast, WT 
astrocytes did not express HA. 
Figure 8: HA occurrence and catalase abundance in primary astrocytes. Immunoblot revealed that 
primary +/mCAT astrocytes show increased levels of catalase when compared to WT (A) and expressed the 
HA tag (B). After a subcellular fractionation, mitochondrial localization of mCAT was evaluated detecting 
the HA tag by immunoblot (C). b-Actin was used as loading control of the whole cell extract; GAPDH was 
used as loading control of the cytosolic fraction; VDAC was used as loading control of the mitochondrial 
fraction. Data are expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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Altogether, these results confirm that mCAT is correctly expressed in the 
mitochondria of +/mCAT astrocytes. 
 
 
7. Constitutive expression of mCAT efficiently detoxifies 
hydrogen peroxide and down-modulates endogenous ROS in 
primary astrocytes 
The following step was to confirm the functionality of mCAT and to corroborate 
whether its constitutive expression is sufficient to down-modulate endogenous 
mROS in primary astrocytes. 
Catalytic activity of mCAT was measured in mitochondria isolated from WT and 
+/mCAT primary astrocytes incubated with different concentrations of exogenous 
hydrogen peroxide. The results shown in Figure 10 demonstrate that 
mitochondria expressing mCAT neutralize exogenous hydrogen peroxide faster 
than WT cells. In the firsts 5 minutes of the assay, mCAT neutralized half of the 
exogenous hydrogen peroxide. In addition, after 20 minutes, the totality of 
exogenous hydrogen peroxide was completely neutralized by mCAT at all 
Figure 9: HA tag co-localizes with mitochondria in +/mCAT astrocytes. Confocal microscopy images 




concentrations tested. Nevertheless, as in transfected MEFs, it seems that 
according to this experiment, mCAT is not able to down-modulate ROS when no 
hydrogen peroxide was added. 
 
 
Accordingly, we next used two more sensitive probes, namely the Amplex Red 
and the MitoSox. 
Hydrogen peroxide analysis from isolated mitochondria and intact astrocytes was 
first performed using the Amplex Red dye. The result represented in Figure 11A 
indicates that, under basal conditions, both +/mCAT mitochondria and intact 
astrocytes release hydrogen peroxide slower than WT. Next, MitoSox Probe was 
used. This mROS-sensitive probe enters the mitochondria depending on the 
mitochondrial membrane potential (DYm), and the oxidized product is highly 
fluorescent. Differences in the DYm may lead to a different accumulation of the 
MitoSox in the mitochondria. Hence, it is necessary to disregard any difference in 
the DYm to correctly analyze and interpret the MitoSox results. Using the 
DilC1(5) probe, DYm was measured by flow cytometry and the results show that 
Figure 10: Constitutive mCAT expression increases mitochondrial hydrogen peroxide detoxification in 
primary astrocytes. Incubation of isolated mitochondria with different concentrations of exogenous 
hydrogen peroxide for different time periods shows that mCAT constitutive expression increases significantly 
the rate of hydrogen peroxide neutralization at all concentration used. In the absence of exogenous hydrogen 
peroxide, there were no differences between mitochondria expressing mCAT and WT. Data are expressed as 
mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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there are no significant differences between WT and +/mCAT astrocytes (Figure 
11B). Subsequently, MitoSox fluorescence was measured and the result indicates 




Altogether these results further indicate that mCAT is efficient at neutralizing 
exogenous hydrogen peroxide, and its constitutive expression in primary 
Figure 11: Constitutive mCAT expression down-modulates endogenous mROS and ROS in primary 
astrocytes. (A) Intact cells and isolated mitochondria constitutively expressing mCAT release hydrogen 
peroxide slower when compared to WT. (B) Assessment of DYm was performed by flow cytometry. WT and 
+/mCAT astrocytes do not show significant differences. (C) mROS measurement was performed by flow 
cytometry using the MitoSox Red dye. +/mCAT astrocytes present lower mROS when compared to WT. 
Data are expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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astrocytes is sufficient to down-modulate endogenous mROS. Furthermore, these 
changes in the redox environment in glial cells do not affect DYm. 
8. Down-modulation of endogenous mROS does not affect 
astrocytic survival 
Given that ROS modulate apoptosis (Circu and Aw, 2010), it was investigated 
whether the constitutive expression of mCAT in primary astrocytes exerted any 
effect on cellular survival. To do so, the activity of the enzyme caspase-3 (CSP-3), 
an effector of apoptosis (Elmore, 2007), was used. CSP-3 activity was measured 
in primary astrocytes under basal conditions and after a 4 hours treatment with 
100 µM etoposide, an apoptotic inducer. The results obtained indicate that under 
basal conditions, mCAT constitutive expression does not affect astrocytic survival 
(Figure 12). The treatment with etoposide increased ~3.5 fold the CSP-3 activity, 
but no differences between WT and +/mCAT astrocytes were observed. Taken 
together, these results indicate that down-modulation of endogenous mROS has 






9. Endogenous mROS modulate nuclear accumulation of NRF2 
in primary astrocytes and in vivo 
In order to investigate whether endogenous mROS modulate the NRF2 nuclear 
accumulation in astrocytes, a subcellular fractionation was performed. NRF2 
abundance was detected by immunoblot in the cytosolic and in the nuclear 
fraction of primary astrocytes. As shown in Figure 13, nuclei obtained from 
+/mCAT astrocytes show lower NRF2 abundance compared to the WT, whereas 
no differences were found in the cytosolic compartment.  
 
Figure 12: Down-modulation of endogenous mROS does not affect astrocytic survival. Activity of CSP-
3 was used as apoptotic marker. Under basal conditions, no differences were observed between WT and 
+/mCAT astrocytes. After a 4h treatment with 100 µM etoposide, activity of CSP-3 was increased ~3.5 fold, 
but still no differences between the two genotypes were detected. Data are expressed as mean ± S.E.M.; n.s 




This result was further confirmed by immunofluorescence. As illustrated in 
Figure 14, WT astrocytes show higher nuclear abundance (~17%) of NRF2 
compared to mCAT cells, as shown by Cy2-labeled NRF2 co-localization with 
nuclear staining DAPI. 
Figure 13: Down-modulation of endogenous mROS decreases NRF2 nuclear accumulation in primary 
astrocytes. Nucleus isolated from +/mCAT astrocytes showed a lower nuclear NRF2 accumulation. Lamin B 
was used as loading control of the nuclear fraction. GAPDH was used as loading control of the cytosolic 





Next, NRF2 levels were evaluated in the cytosolic and nuclear compartments of 
the brain, heart, liver and kidney obtained from WT or +/mCAT mice. 
Immunoblot revealed that brain from +/mCAT mice show lower nuclear and 
higher cytosolic abundance of NRF2 compared to WT (Figure 15A). a similar 
result was obtained in the heart, although the differences were less evident 
(Figure 15B). The hepatic cytosolic compartment did not show differences in 
NRF2 abundance, while a decrease was found in the nuclei of +/mCAT mice 
(Figure 15C). No differences were detected in the kidney (Figure 15D). 
Figure 14: mROS-weakened astrocytes show decreased NRF2 nuclear accumulation. Confocal 
microscopy images revealed that +/mCAT astrocytes present lower NRF2 co-localization with DAPI staining 
when compared to WT. Quantification of nuclear fluorescence was carried out in 120 cells. Data are 






These results show that down-modulation of physiological endogenous mROS in 
primary astrocytes leads to a decrease in the nuclear accumulation of NRF2. In 
addition, they suggest that mCAT is more efficient at decreasing physiological 
endogenous mROS in the brain and heart than in the liver and kidney.  
10. Endogenous mROS modulate NRF2 functional activity in 
primary astrocytes 
To investigate whether the decreased nuclear localization of NRF2 in +/mCAT 
astrocytes could affect its transcriptional activity, the mRNA levels of several 
NRF2 target genes were measured by RT-qPCR. The genes chosen were NADPH 
quinone dehydrogenase 1 (Nqo1), glutamate-cysteine ligase catalytic subunit 
(Gclc), glutathione peroxidase-2 (Gpx2), heme oxygenase 1 (Ho-1), thioredoxin-1 
(Trx1), nuclear factor (erythroid-derived-2)-like 2 (Nrf2), peroxiredoxin-1 
(Prdx1), 6-phosphogluconate dehydrogenase (6pgd) and glucose-6-phosphate 
dehydrogenase (G6pd). The firsts seven genes analyzed, had decreased mRNA 
levels in mCAT astrocytes, although the Prdx1 not in a significant manner 
(Figure 16). Surprisingly, the transcription of 6pgd and G6pd genes were up-
regulated in mROS-weakened astrocytes, suggesting the occurrence of another 
mechanism that modulates their transcription. 
Taken together, these results illustrate that endogenous mROS modulate the 
transcription levels of several NRF2 target genes. 
Figure 15: Constitutive mCAT expression in vivo modulates NRF2 subcellular localization. Immunoblot 
from in vivo samples reveals different cytosolic and nuclear NRF2 abundance. Cerebral (A) and cardiac (B) 
samples revealed higher cytosolic and lower nuclear NRF2 abundance in +/mCAT mice when compared to 
WT. The hepatic samples (C) show no differences in the cytosolic compartment, however NRF2 nuclear 
accumulation decreased in +/mCAT mice. Kidney (D) shows no differences of NRF2 abundance. Data are 




11. Down-modulation of endogenous mROS increases the 
abundance of pentose phosphate pathway (PPP)-related 
enzymes 
Glucose-6-phosphate dehydrogenase (G6PD) is the enzyme that catalyses the first 
and rate limiting step of the pentose phosphate pathway (PPP). In order to 
investigate whether the increased transcription of the G6pd gene leads to an 
increase of the G6PD protein levels, its abundance was studied by 
immunoblotting. As shown in Figure 17A, +/mCAT astrocytes express higher 
G6PD abundance compared to WT, which is coherent with the previously data 
obtained by the mRNA analysis. In addition, abundance of 6-phosphogluconate 
dehydrogenase (6PGD) was evaluated. 6PGD is the third enzyme involved in the 
Figure 16: Endogenous mROS modulate the transcription of several NRF2 target genes. Expression of 
several NRF2 target genes was evaluated by RT-qPCR using b-actin as housekeeping gene. Constitutive 
expression of mCAT leads to a decreased expression of several NRF2 target genes (Nqo1, Gclc, Gpx2, Ho-1, 
Trx1, Nrf2, Prdx1) and, surprisingly, a significant increase of 6pgd and G6pd genes in +/mCAT astrocytes 
compared with WT. Nqo1: NADPH quinone dehydrogenase 1; Gclc: glutamate-cysteine ligase catalytic 
subunit; Gpx2: glutathione peroxidase-2; Ho-1: heme oxygenase 1; Trx1: thioredoxin-1; Nrf2: nuclear factor 
(erythroid-derived-2)-like 2; Prdx1: peroxiredoxin-1; 6pgd: 6-phoshogluconate dehydrogenase; G6pd: 




oxidative branch of the PPP, where it catalyses the decarboxylation of 6-
phosphogluconate to ribulose-5-phosphate. This enzyme is fundamental in 
maintaining cellular homeostasis, because together with G6PD, they are the major 
producers of cytosolic NADPH (Wamelink et al., 2008). This co-enzyme plays a 
key role in the glutathione (GSH) homeostasis and lipogenesis by supplying the 
reduced equivalents necessary to reduce GSSG to GSH and for the de novo 
synthesis of lipids (Wamelink et al., 2008). In +/mCAT astrocytes, protein levels 
of 6PGD are higher than in WT (Figure 17B). 
 
 
Figure 17: Endogenous mROS down-modulation increases G6PD and 6PGD abundance in primary 
astrocytes. Immunoblot showed that mROS-weakened astrocytes present higher G6PD (A) and 6PGD (B) 
abundance when compared to WT. b-Actin was used as loading control. Data are expressed as mean ± 
S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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12. Down-modulation of endogenous mROS increases miR-1 and 
miR-206 expression in astrocytes 
Recently, an alternative regulation of the transcription of several PPP-related 
genes was discovered (Singh et al., 2013). This mechanism involves the histone 
deacetylase HDAC4, which accumulates in the nucleus when the two cysteine 
residues, Cys-667 and Cys-669, are in their reduced state (Ago et al., 2008). In 
this manner, HDAC4 represses the transcription of two microRNAs, miR-1 and 
miR-206, which degrade the newly synthesized mRNA of several PPP-related 
genes and HDAC4 itself (Singh et al., 2013). 
The increased G6pd and 6pgd mRNA levels that we observed are compatible with 
this mechanism. The results obtained so far show that +/mCAT astrocytes present 
lower ROS amount under basal conditions compared to the WT. In this less 
oxidant environment, HDAC4 cysteine resideus could be in their reduced state. In 
this scenario, HDAC4 would be localized in the nucleus repressing the 
transcription of miR-1 and miR-206, hence stabilizing G6PD and 6PGD mRNA. 
To investigate whether down-modulation of endogenous mROS in primary 
astrocytes regulates the subcellular localization of HDAC4, its abundance in 
whole cells and in the nuclear fraction was evaluated by immunoblotting. Both in 
whole cell extract (Figure 18A) and in the nuclear compartment (Figure 18B), 
+/mCAT astrocytes showed higher HDAC4 abundance compared to WT.  
Subsequently, miR-1 and miR-206 abundances were evaluated by RT-qPCR. The 
data obtained show that +/mCAT astrocytes express 15% and 30% less miR-1 and 
miR-206 abundances, respectively, compared to WT (Figure 18C). This result is 
consistent with the higher nuclear localization of HDAC4 in +/mCAT astrocytes 





Figure 18: Endogenous mROS down-modulation increases HDAC4 abundance and decreases miR-1 
and miR-206 expression. Immunoblot revealed that +/mCAT astrocytes express higher HDAC4 abundance 
both in whole cells (A) and in the nuclear fraction (B) when compared to WT. (C) RT-qPCR shows that 
mROS-weakened astrocytes express 15% and 30% less miR-1 and miR-206 respectively, when compared to 
WT. b-Actin was used as loading control for whole cells; lamin B was used as loading control for the nuclear 
compartment; mmu-miR-202 was used as endogenous control. Data are expressed as mean ± S.E.M.; *p<0.05 
Student’s t-test; n=3 independent experiments. 
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13. Down-modulation of endogenous mROS increases glucose flux 
through PPP 
In light of these results, the flux of glucose through the PPP was measured 
following a protocol optimized in our laboratory (Rodriguez-Rodriguez et al., 
2013). To do so, intact primary astrocytes were incubated in the presence of D-[1-
14C]-glucose or D-[6-14C]-glucose, and the 14CO2 released was quantitatively 
trapped and measured. 14CO2 released from D-[1-14C]-glucose reflects 6-
phosphogluconate decarboxylation by 6PGD plus acetyl-CoA decarboxylation at 
isocitrate dehydrogenase and α-ketoglurate dehydrogenase of the tricarboxilic 
acid (TCA). However, 14CO2 released from D-[6-14C]-glucose reflects acetyl-CoA 
decarboxylation at isocitrate dehydrogenase and α-ketoglurate dehydrogenase. 
Thus, the difference between 14CO2 released from D-[1-14C]-glucose and that 
from D-[6-14C]-glucose is used to estimate glucose oxidized through the PPP. As 
shown in Figure 19, mCAT astrocytes show a 40% increase in the flux of glucose 
oxidized through the PPP when compared to WT cells. 
 
 
A major function of PPP is to regenerate NADPH necessary for redox 
homeostasis and anabolic pathways (Wamelink et al., 2008). Given that down-
Figure 19: Glucose flux through the oxidative branch of the PPP is increased by the down-modulation 
of endogenous mROS. PPP rate was evaluated incubating intact astrocytes with radiolabelled glucose. 
mROS-weakened astrocytes showed a 40% increase of glucose oxidation via the PPP when compared to WT. 
Data are expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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modulation of astrocytic mROS increases the protein levels of G6PD and 6PGD, 
and increases the rate of the PPP, the NAPDH/NADP+ ratio was measured. 
Surprisingly, mROS-weakened astrocytes showed decreased NADPH/NADP+ 
ratio compared to WT (Figure 20A). One possible explanation is that +/mCAT 
astrocytes consume more NADPH compared to WT. Since lipid synthesis 
consumes NADPH (Wamelink et al., 2008), the de novo lipogenesis was 
measured. Intact astrocytes were incubated with D-[6-14C]-glucose for 3 hours, 
the lipid fraction was extracted and the radioactivity quantified. As shown in 
Figure 20B, the constitutive expression of mCAT does not alter the rate of the de 
novo lipogenesis in primary astrocytes. These results suggest that mROS deficient 
astrocytes consume more NADPH compared to WT, although these reducing 
equivalents do not seem to be used for the de novo lipogenesis. 
 
 
14. Endogenous mROS modulate extracellular superoxide 
production in primary astrocytes 
Recent evidences show that G6PD is found in close proximity with the ROS 
producer enzymes NADPH-oxidases (NOX) (Yang et al., 2016). This enzyme 
Figure 20: Endogenous mROS down-modulation decreases the NADPH/NADP+ ratio, however it does 
not affect the de novo lipogenesis rate. mROS-weakened astrocytes showed a significant decrease of the 
NADPH/NADP+ ratio (A) compared to WT, which does not affect the rate of de novo lipogenesis (B). Data 
are expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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family uses NADPH to produce superoxide or hydrogen peroxide, depending on 
the isoform. The interaction between G6PD (one of the major cytoplasmic 
NADPH producers) and NOXs may modulate downstream transduction signals. 
In addition, it was recently reported that NRF2 represses the expression of NOX2, 
while enhances NOX4 expression (Kovac et al., 2015; Wei et al., 2016), although 
the mechanism is unknown. Considering that +/mCAT astrocytes show lower 
NRF2 activity and more NADPH consumption compared to WT, the mRNA 
levels of NOX-1, -2, -4 were evaluated. The data obtained illustrate that +/mCAT 
astrocytes express higher levels of NOX1 and NOX2 mRNA (46% and 51%, 
respectively), while a decreased levels of NOX4 when compared with WT 
(Figure 21A). Considering that NOX1 and -2 produce extracellular superoxide, 
whereas NOX4 produces hydrogen peroxide, the extracellular superoxide release 
was determined. To do so, intact astrocytes were incubated with oxidized 
cytochrome c, which is reduced by superoxide. The reduced form of cytochrome c 
absorbs light at 550 nm, allowing its detection. As shown in Figure 21B, 
+/mCAT astrocytes release 20% more superoxide compared to WT. These results 
indicate that down-modulation of endogenous mROS in primary astrocytes 
increases the expression of NOX1 and NOX2, but decreases the levels of NOX4. 
This increase of the two NOX isoforms responsible for extracellular superoxide 
production is compatible with the observed increase of extracellular superoxide. 
Furthermore, the increase of NOX1 and NOX2 is consistent with the increased 
NADPH consumption observed in +/mCAT astrocytes. Nevertheless, the 
mechanism responsible of the increase of NOX1 and -2 and the decrease of 




15. Rescue of the NRF2 levels decreases extracellular superoxide 
release by primary astrocytes  
In order to corroborate that NRF2 deficiency leads to an increase in extracellular 
superoxide release through NOX1 and -2 activities, +/mCAT astrocytes were 
transfected with a constitutively active form of NRF2. This construct encodes for 
a NRF2 protein which directly translocates to the nucleus and up-regulates the 
transcription of its target genes. The plasmid was previously designed and 
validated in our laboratory (Jimenez-Blasco et al., 2015). The construct contains 
the human NRF2 sequence (1817 bp, access number NM_006164.3) fused at the 
5’ end with the green fluorescent protein (GFP). To obtain the phosphomimetic 
form (NRF2 PM), three residues (Thr395, Ser433 and Thr439) were substituted 
by aspartate by site-directed mutagenesis (Jimenez-Blasco et al., 2015). The 
resulting phosphomimetic NRF2 (NRF2 PM) accumulates and translocates to the 
nucleus of transfected cells (Jimenez-Blasco et al., 2015). We first confirmed the 
correct NRF2 expression by RT-qPCR and immunoblotting. As shown in Figure 
Figure 21: Endogenous mROS down-modulation modulate NOX expression and increased superoxide 
release. mROS-weakened astrocytes showed an increase of the NOX-1 and -2 expression, whereas a NOX-4 
decrease (A) when compared to WT, which increase production of extracellular superoxide (B). Data are 
expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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22A, +/mCAT astrocytes transfected with NRF2 PM express ~35-fold higher Nrf2 
mRNA abundance compared to the empty plasmid. Immunoblot analysis revealed 
two bands of NRF2, namely the constitutive (with a molecular weight of 100 
kDa) and the phosphomimetic, which is detected at 130 kDa. As expected, only 
astrocytes transfected with NRF2 PM showed two bands (Figure 22B).  
 
 
Subsequently, the mRNA levels of NOX1, -2 and -4 were measured in +/mCAT 
astrocytes transfected with NRF2 PM. The data obtained show that the 
transfection of +/mCAT astrocytes with NRF2 PM completely rescued the mRNA 
levels of NOX1, -2 and -4 compared with WT cells transfected with the empty 
plasmid (Figure 23A). Next, extracellular superoxide release was measured in 
order to ascertain whether NRF2 PM expression was sufficient to restore the basal 
values. As illustrated in Figure 23B, +/mCAT astrocytes released a 10% more 
extracellular superoxide compared to WT cells when transfected with the empty 
plasmid. However, no differences were found when +/mCAT cells were trasfected 
with NRF2 PM versus WT cells transfected with the empty plasmid. Taken 
Figure 22: NRF2 PM expression increased NRF2 abundance in +/mCAT astrocytes. (A) mRNA levels 
of NRF2 were measured by RT-qPCR using b-actin as housekeeping gene. mCAT astrocytes transfected with 
NRF2 PM show a ~35-fold higher Nrf2 expression when compared to the empty plasmid. (B) NRF2 protein 
abundance was evaluated by immunoblot. +/mCAT astrocytes transfected with NRF2 PM show a slightly 
increase of consitutive NRF2, as shown by the 100 kDa band, and they expressed an additional band at 130 
kDa, corresponding to NRF2 PM, when compared to the empty plasmid. b-Actin was used as loading control. 
Data are expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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together, these results confirm that NRF2 represses the expression of NOX1 and -
2, while it increases NOX4 in primary astrocytes. Furthermore, the rescue of 
NRF2 levels in +/mCAT glial cells restores basal release of extracellular 




16. Endogenous mROS modulate glutathione abundance in 
primary astrocytes via NRF2 
Glutathione (GSH), the most abundant thiol-containing antioxidant, is synthesized 
in two consecutive ATP-requiring steps, namely g-glutamate cysteine ligase 
(GCL) and glutathione synthase (GS), respectively (Dringen, 2000). The first step 
is the rate limiting, hence the expression and activity of GCL control the synthesis 
GSH. Down-modulation of endogenous mROS in astrocytes led to a decreased 
expression of the Gclc gene (Figure 16). In order to investigate whether this 
Figure 23: NRF2 PM expression in +/mCAT astrocytes restores basal expression of NOXs and 
extracellular superoxide release. mROS-weakened astrocytes expressing NRF2 PM show no differences of  
NOX1, -2 and -4 mRNA levels (A) and extracellular superoxide release (B) when compared with WT 
astrocytes transfected with the empty plasmid. b-actin was used as housekeeping gene. Data are expressed as 
mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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decreased Gclc transcription leads to a lower GSH synthesis in mROS-weakened 
astrocytes, GCL protein and the total GSH abundances were evaluated. 
Immunoblotting showed decreased GCL abundance in +/mCAT astrocytes 
compared to WT (Figure 24A). As expected, +/mCAT astrocytes showed a 
decrease (20%) of GSH concentration (Figure 24B).  
In order to investigate whether astrocytic mROS modulate GSH abundance 
through the NRF2 pathway, +/mCAT astrocytes were transfected with NRF2 PM. 
As expected, the expression of NRF2 PM increase GCL protein abundance in 
+/mCAT astrocytes (Figure 24C). Subsequently, total GSH concentration was 
measured. Consistent with the GCL increase, +/mCAT astrocytes transfected with 
NRF2 PM showed higher total GSH concentration (Figure 24D). 
Taken together, these results suggest that astrocytic endogenous mROS modulate 




Figure 24: mROS modulate GSH synthesis through the NRF2 pathway. (A) Immunoblot showed that 
+/mCAT astrocytes express lower GCL levels when compared to WT. (B) Measurement of GSH 
concentration showed that mROS-weakened astrocytes present a 20% decrease in total GSH when compared 
to WT. Transfection of mROS-weakened astrocytes with NRF2 PM increases GCL abundance (C) and GSH 
concentration (D), when compared to the empty plasmid. b-Actin was used as loading control. Data are 
expressed as mean ± S.E.M.; *p<0.05 Student’s t-test; n=3 independent experiments. 
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17. Neurons co-cultured with mROS-weakened astrocytes show 
less antioxidant defenses, and higher ROS release and 
apoptosis 
Previous works (Bolaños et al., 1996; Diaz-Hernandez et al., 2005; Dringen et al., 
1999) demonstrated that neurons depend on astrocytic supply of precursors for the 
de novo synthesis of GSH. Furthermore, it has been demonstrated that the 
increase of astrocytic NRF2 activity, increases GSH synthesis and export from 
glial cells (Jimenez-Blasco et al., 2015). In order to investigate whether down-
modulation of astrocytic endogenous mROS is deleterious for neurons, astrocyte-
neuron co-cultures were performed. To do so, astrocytes were plated in inserts 
with a semi-permeable membrane, while neurons were seeded in a multiwell 
plate. After three days, astrocytes-containing inserts were placed above neurons 
and co-cultured for four more days. Subsequently, inserts containing astrocytes 
were discarded and GSH concentration and hydrogen peroxide release were 
measured in neurons. 
As indicated in the Figure 25A, neurons co-cultured with +/mCAT astrocytes 
show a 27% decrease in total GSH concentration compared to neurons co-cultured 
with WT astrocytes. With the aim to ascertain whether this GSH deficit disrupts 
neuronal redox homeostasis, hydrogen peroxide was measured. As shown in 
Figure 25B, neurons had higher hydrogen peroxide production when co-cultured 
with mROS-weakened astrocytes. Taken together, these data confirm the 
importance of the GSH precursors supply from neighbour astrocytes for neuronal 
homeostasis. In addition, they strongly suggest that down-modulation of 




To investigate whether disruption of neuronal redox homeostasis affects survival, 
the abundance of the active form CSP-3 and its activity were evaluated as markers 
of apoptosis. Once discarded the inserts, the abundance of the 17 kDa CSP-3 
cleaved active fragment was detected. Immunoblot show that neurons express 
higher active CSP-3 when co-cultured with mCAT astrocytes under basal 
conditions (Figure 26A). This result was further confirmed by the measurement 
of CSP-3 activity, which was evaluated in co-cultured neurons under basal 
conditions or after a 4 hours treatment with 100 µM etoposide. AMC release, a 
marker of CSP-3 activity, was higher in neurons co-cultured with mROS-
weakened astrocytes in basal conditions (Figure 26B). After a 4 hours treatment 
with etoposide, CSP-3 activity was significantly increased in neurons; however, 
as shown in Figure 26B, the increase was higher in neurons co-cultured with 
mROS-weakened astrocytes compared with neurons co-cultured with WT 
astrocytes. These data suggest an increased vulnerability of neurons co-cultured 
with mROS-weakened astrocytes. In addition to the CSP-3 activity, DYm was 
evaluated as a marker of mitochondrial stress. The data obtained using the 
DilC1(5) dye show no differences in DYm in neurons co-cultured with WT or 
mCAT astrocytes (Figure 26C). Taken together, these results indicate that down-
Figure 25: Neurons co-cultured with mROS-weakened astrocytes show lower antioxidant defences and 
increased ROS levels. Incubation of neurons with +/mCAT astrocytes for four days decreases neuronal GSH 
pool (A) and leads to an increase of the hydrogen peroxide release rate (B) when compared to neurons co-




modulation of astrocytic endogenous mROS is deleterious for the neighbour 
neurons, although neuronal DYm is unaffected. 
 
 
Figure 26: Neurons co-cultured with mROS-weakened astrocytes show higher apoptosis and 
unaffected mitochondrial membrane potential. (A) Immunoblot showed that, under basal conditions, co-
culture of neurons with mROS-weakened astrocytes increases the abundance of the active fragment of CSP-3. 
b-Actin was used as loading control. (B) Incubation of neurons with mCAT astrocytes for four days shows a 
~0.5 fold and ~1.7 fold higher CSP-3 activation under basal condition and after a 4h treatment with 100 µM 
etoposide, respectively, compared to neurons co-cultured with WT astrocytes. (C) Neuronal DYm was 
unaffected by the presence of +/mCAT astrocytes. Data are expressed as mean ± S.E.M.; *p<0.05, n.s. 
p>0.05 Student’s t-test; n=3 independent experiments  
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18. Expression of NRF2 PM in mCAT astrocytes rescues the 
antioxidant defenses and survival of neurons 
To investigate whether astrocytic mROS modulate the neuronal redox 
homeostasis and survival via the NRF2 pathway, neurons were co-cultured with 
+/mCAT astrocytes previously transfected with NRF2 PM or with the empty 
plasmid. To do so, astrocytes were transfected at DIV11. On the following day, 
the inserts were washed, the medium replaced, and cells were co-cultured for 
three days. After this period, the inserts were discarded and total GSH 
concentration, hydrogen peroxide release and CSP-3 activity were measured in 
neurons. As previously reported, treatments that increase astrocytic GSH enhance 
neuronal GSH (Dringen et al., 2015; Jimenez-Blasco et al., 2015). With the aim 
to investigate whether NRF2 PM rescues neuronal GSH pool, total GSH 
concentration was measured in co-cultured neurons. As illustrated in Figure 27A, 
neurons co-cultured with +/mCAT astrocytes previously transfected with NRF2 
PM showed higher levels of GSH, reaching the values of neurons co-cultured with 
WT astrocytes (Figure 25A). Next, hydrogen peroxide release was measured. As 
depicted in Figure 27B, neurons co-cultured with mROS-weakened astrocytes, 
previously transfected with NRF2 PM, showed a ~40% decreased in hydrogen 
peroxide release when compared to neurons co-cultured with +/mCAT astrocytes 
transfected with the empty plasmid. Finally, to test whether astrocytic NRF2 PM 
expression rescues neuronal death, the activity of CSP-3 was evaluated. Figure 
27C illustrates that neurons co-cultured with mROS-weakened astrocytes 
expressing NRF2 PM had lower CSP-3 activity compared to neurons co-cultured 




Taken together, these results are consistent with previous work from our 
laboratory (Jimenez-Blasco et al., 2015) which demonstrates that the increase of 
the astrocytic NRF2 pathway leads to a boost of neuronal antioxidant defences 
and survival. In addition, they strongly suggest that endogenous astrocytic mROS 
modulate redox homeostasis and increase viability of neurons through the NRF2 
pathway. 
 
Figure 27: NRF2 PM expression in mROS-weakened astrocytes rescued antioxidant defences and 
survival of co-cultured neurons. (A) Neurons incubated for 3 days with +/mCAT astrocytes expressing 
NRF2 PM rescued their GSH pool and their hydrogen peroxide release (B). In addition, a slightly but 
significant increase of neuronal viability (C) was found in neurons co-cultured with +/mCAT astrocytes 










1. Expression of a mitochondrial form of catalase allows to 
investigate physiological roles of mROS 
Traditionally, ROS have been associated with oxidative stress and human 
diseases. However, given that clinical trials based on antioxidants have not been 
conclusive (Halliwell 2013; Heyland et al., 2013; Kamat et al., 2008; Snow et al., 
2010), the pathological role of ROS is questioned. 
To investigate the functions of ROS, the majority of studies have used strategies 
based on increasing ROS, either by exogenously or endogenously supplied ROS. 
However, this approach could mask the beneficial roles of endogenous ROS. 
Here, we implemented an alternative approach aimed to down-modulate 
endogenous mROS. Several mouse models designed to down-modulate 
endogenous mROS have already been described. However, they have side effects 
on metabolism (Chen et al., 1998; Matsushima et al., 2006; Quintana-Cabrera et 
al., 2012). The strategy used in this work to down-modulate endogenous mROS 
based on the expression of a mitochondrial form of catalase, which neutralizes 
hydrogen peroxide with minimal effect on metabolism. In fact, a mCAT mouse 
model has been previously described (Schriner et al., 2005). However, the 
conventional microinjection technique used to generate that model has two major 
drawbacks, namely a non site-directed insertion of the DNA construct and the 
impossibility to control the numbers of copies inserted. Hence, whether the effects 
observed are due to mCAT activity or to any unknown effect caused by gene 
expression disruption is uncertain. 
Accordingly, we generated a new mCAT mouse model in order to investigate the 
physiological roles of mROS. The mCAT construct was inserted in the Rosa26 
locus of C57Bl/6 of embryonic stem cells by homologous recombination. This 
technique inserts only one copy of the mCAT construct in a defined and safe 
locus. Furthermore, the model was generated based on the Cre-LoxP strategy, 




The results obtained in this work show that the newly generated mCAT mouse 
model is able to down-modulate endogenous mROS in primary astrocytes. 
Therefore, this is useful to investigate the biological roles of astrocytic mROS. 
Moreover, the mCAT floxed mouse model could be used to study the involvement 
of mROS in any tissue both in physiological and pathological circumstances. 
2. Endogenous mROS modulate redox homeostasis in primary 
astrocytes via the NRF2 pathway 
The NRF2 pathway is essential for redox homeostasis in the brain. However, its 
activity differs between the two most abundant cell types, neurons and astrocytes. 
Neurons show a repressed antioxidant defences because of the continuous NRF2 
protein destabilization (Bell et al., 2015; Jimenez-Blasco et al., 2015). In contrast, 
NRF2 is highly stable in astrocytes, which explains their robust antioxidant 
defences (Habas et al., 2013; Jimenez-Blasco et al., 2015). Nevertheless, the 
mechanism whereas astrocytic NRF2 is stabilized is still elusive. In this context, a 
recent study demonstrated that astrocytes produce severalfold higher mROS than 
neurons under basal conditions (Lopez-Fabuel et al., 2016). The physiological 
roles of these glial mROS production are, however, elusive. 
The results obtained in this work demonstrate that endogenous mROS in 
astrocytes maintain high the levels of NRF2 activation. Accordingly, high levels 
of NRF2 activity promote the expression of antioxidant systems that contribute to 
keep the robust antioxidant machinery of astrocytes. On the other hand, NRF2 
modulates the expression of the ROS-producer enzymes NADPH-oxidases in 
astrocytes. In particular, NRF2 represses the expression of NOX-1 and -2 and 
enhance NOX-4 expression, in good agreement with previous works (Kovac et 
al., 2015; Wei et al., 2016). The mechanism(s) whereby NRF2 modulates NOXs 
expression is unknown. It is tempting to speculate that the increase in extracellular 
superoxide production observed in mROS-weakened astrocytes could be a redox 
signal for neighbour neurons, indicating a altered astrocytic metabolism. 
To the best of our knowledge, this is the first evidence that endogenous mROS 
modulates the redox homeostasis via the NRF2 pathway in astrocytes. 
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Furthermore, considering that mCAT expression in brain, liver and heart 
decreases NRF2 nuclear abundance, our data strongly suggest that endogenous 
mROS modulate this pathway in vivo. 
3. Endogenous mROS modulate glucose flux through the pentose 
phosphate pathway (PPP) 
PPP is a metabolic pathway, a function of which in the adult brain is regenerating 
NADPH to contribute to cellular redox homeostasis. The data presented in this 
work show that down-modulation of endogenous mROS in astrocytes enhances 
the flux of glucose through the PPP. These data are in apparent contradiction with 
the widely-held notion that ROS activate PPP activity (Stincone et al., 2015). 
Thus, ROS, by activating NRF2, promote G6pd and 6pgd expression (Hayes and 
Dinkova-Kostova, 2014). However, in another work it has been shown that NRF2 
modulates the expression of PPP-related genes via an indirect mechanism 
involving epigenetic modifications (Singh et al., 2013).  
Here, we show that mROS-weakened astrocytes show a decreased NRF2 activity 
despite enhanced transcription of PPP-related genes. Our data suggest that mROS 
modulate the expression of G6PD and 6PGD by promoting nuclear localization of 
HDAC4, which represses the expression of miR-206. This miRNA targets G6PD 
and 6PGD mRNAs for degradation, leading to decreased protein levels. 
Altogether, these results demonstrate that endogenous mROS can modulate 
glucose metabolism in astrocytes. The suggested epigenetic mechanism is 
coherent with the study of Singh et al. (2013) and further demonstrate that G6pd 
and 6pgd are not direct NRF2 target genes. It will be very interesting to 
investigate if other metabolic pathways are also affected in mROS-weakened 
astrocytes, in order to have a better view on the role of mROS in the regulation of 
cell metabolism. 
4. Endogenous mROS are neuroprotective 
Oxidative stress is a hallmark of several neurodegenerative diseases. Accordingly, 
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ROS have always been considered as harmful species. However, the fact that 
astrocytes produce a considerable high amount of mROS (Lopez-Fabuel et al., 
2016), strongly suggests a physiological function of these mROS. 
Astrocytes protect co-cultured neurons from oxidative insults (Bélanger and 
Magistretti, 2009; Dringen, 2000; Wilson, 1997) by increasing the antioxidant 
defences through the supply of GSH precursors (Bolaños et al., 1996; Dringen et 
al., 1997). This phenomenon, which has been named as the astrocyte-neuron 
glutathione shuttle (Bolaños, 2016), is maintained by constitutively activation of 
NRF2 in astrocytes (Jimenez-Blasco et al., 2015). In fact, the notion that NRF2 
activation in astrocytes increases neuronal survival against an oxidative insult is a 
well known phenomenon, both in vitro (Jakel et al., 2007; Jimenez-Blasco et al., 
2015; Shih et al., 2003) and in rodent models of neurodegenerative diseases 
(Chen et al., 2009; Vargas et al., 2008). However, in these studies, astrocytic 
NRF2 activity was artificially increased by protein overexpression or 
pharmacological activation. Here, we further demonstrate that endogenous mROS 
play a major role at activating NRF2 in astrocytes, and through this mechanism 
exerts neuroprotection. A previous study suggested that subtoxic levels of 
astrocytic hydrogen peroxide failed to activate NRF2 and triggers NRF2-
independent processes that protected co-cultured neurons (Haskew-Layton et al., 
2010). However, these conclusions were questioned on the basis of the 
experimental design, which did not use appropriate techniques to evaluate 
astrocytic NRF2 activation (Bell et al., 2011). Moreover, subtoxic doses of 
hydrogen peroxide activated NRF2 in astrocytes (Bell et al., 2011). Whilst these 
data are in agreement with our results, the dose of hydrogen peroxide tested were 
~16 fold-higher than the physiological levels that we measured in primary 
astrocytes in our laboratory (Lopez-Fabuel et al., 2016). We therefore believe 
that, even at subtoxic concentrations of hydrogen peroxide, an aberrant redox 
signal might contribute to masking the neuroprotective role of endogenous 
astrocytic mROS. 
It should to be noted that rescue of NRF2 levels in mROS-weakened astrocytes 
only partially restored the survival of co-cultured neurons. These data suggest that 
endogenous mROS may modulate neuroprotective pathways besides NRF2. 
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Whether glycolysis, a fundamental metabolic route in the metabolic interactions 
between astrocytes and neurons (Pellerin and Magistretti, 1994), is affected in 
mROS-weakened astrocytes is an interessant possibility worth studying. 
The data obtained in this work further confirm that endogenous mROS play 
fundamental roles in maintaining cellular homeostasis, as observed in different 
tissues (Puente et al., 2014; Zhou et al., 2016). To the best of our knowledge, this 
work demonstrates for the first time that endogenous astrocytic mROS have a 
neuroprotective role. Furthermore, it can be speculated that clinical trials based on 
antioxidant strategy in patients suffering neurological disorders failed because 
antioxidants scavenge ROS unspecifically across the brain cell. We propose that 
this approach could be more beneficious if decreasing ROS specifically in 
neurons, and not in astrocytes that we show ROS are neuroprotective. These 
considerations should be taken into account for the design of new antioxidant 











In the light of the results presented in this Thesis, we have achieved the following 
conclusions: 
 
1. Here, we have partially characterized a novel mouse model conditionally 
expressing a mitochondrial-tagged isoform of catalase (mitoCatalase or 
mCAT) cDNA. This model was designed by our group, and externally 
generated specifically for this project, by targeted insertion of the mCAT 
sequence within the Rosa26 locus via homologous recombination in 
embryonic stem cells from C57Bl/6 mouse strain. The insertion was 
achieved such that in the resulting model the expression of the mCAT 
cDNA is under the control of the ubiquitous CAG promoter. A floxed 
(loxP flanked) transcriptional STOP cassette was incorporated between the 
mCAT sequence and the CAG promoter to allow the expression of the 
resulting transgene to be dependent upon the Cre recombinase 
(mCATfloxed/+). By breeding mCATfloxed/+ with the C57Bl/6 mice 
expressing Cre recombinase, it was obtained mice ubiquitously expressing 
mCAT (mCAT mouse). 
 
2. Cortical astrocytes in primary culture obtained from the mCAT mouse 
show a significant reduction in the production of endogenous (basal) 
mitochondrial reactive oxygen species (mROS). Taking advantage of this 
system, we show that endogenous mROS control the expression of 
antioxidant genes by up-regulating the activity of the nuclear factor 
(erythroid-derived 2)-like 2 (NRF2) transcriptional factor in astrocytes. In 
turn, NRF2 represses the production of extracellular ROS, likely by down-
modulating NADPH-dependent oxidases (NOXs) types -1 (NOX1) and -2 
(NOX2). 
 
3. Using cortical astrocytes in primary culture obtained from the mCAT 
mouse, we show that endogenous mROS regulates glucose oxidation 
through the pentose phosphate pathway (PPP). Thus, down-modulation of 
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endogenous mROS enhanced PPP activity through a mechanism likely 
mediated by the reduction of the redox-sensitive histone deacetylase 
HDAC4. When reduced, HDAC4 is constitutively active in the nucleus, 
where it represses the expression of miR-1 and miR-206, which in turn 
represses the mRNA abundances of G6PD and 6PGD. We show that 
mROS lowers the occurrence of HDAC4 in the nucleus, which leads to 
decreased miR-1 and miR206 abundances and enhanced G6PD and 6PGD 
expression and PPP activity. Therefore, in astrocytes, mROS keeps 
partially repressed the PPP activity thus representing, to the best of our 
knowledge, the first evidence connecting endogenous mROS production 
with the regulation of glucose metabolism. 
 
4. In experiments in which mCAT-derived astrocytes were co-cultured with 
wild type neurons, we show that mROS in astrocytes affects the redox 
status and survival of neurons. Thus, we show that endogenous mROS in 
astrocytes, by keeping NRF2 active, contributes to the sustaining of total 
glutathione abundance in neighbour neurons. Moreover, through this 
















La aparición del oxígeno en la atmósfera de la Tierra fue un evento crucial que 
promovió la evolución de los organismos aeróbicos, capaces de producir energía 
de una manera muy eficiente. Una de las consecuencias de esta mejora fue la 
aparición de nuevas moléculas reactivas derivadas del oxígeno denominadas 
especies reactivas de oxígeno (ROS, del inglés Reactive Oxygen Species). 
Los ROS incluyen, principalmente, anión superóxido (O2•-), peróxido de 
hidrógeno (H2O2) y radical hidroxilo (•OH). Estas especies presentan mayor 
reactividad química respecto al oxígeno y son capaces de desencadenar procesos 
tanto fisiológicos como patológicos. En condiciones normales, el nivel de los 
ROS celulares es constante en un equilibrio dinámico, y este equilibrio se modula 
mediante procesos celulares que producen y eliminan ROS (Zhang et al., 2016). 
Sin embargo, bajo ciertas circunstancias, la tasa de producción de ROS excede la 
capacidad de los sistemas antioxidantes para eliminarlos. Este exceso de ROS, 
comúnmente llamado estrés oxidativo o estrés redox, lleva a la oxidación de 
proteínas, ácidos nucleicos y lípidos (Poyton et al., 2009; Temple et al., 2005). De 
hecho, en las muestras cerebrales post mortem de enfermedades neurológicas se 
han encontrado huellas de estrés oxidativo en las áreas cerebrales dañadas 
(Cannon and Greenamyre 2013; Federico et al., 2012). Por lo tanto, el estrés 
oxidativo parece estar asociado a las enfermedades neurodegenerativas. Sin 
embargo, los ensayos clínicos basados en una estrategia antioxidante realizados 
hasta ahora en pacientes que padecen enfermedades neurodegenerativas no han 
sido fructíferos (Halliwell 2013; Heyland et al., 2013; Kamat et al., 2008; Snow et 
al., 2010), lo que podría sugerir que el exceso de ROS no tiene un papel 
patológico. Por el contrario, la idea de que los ROS modulan fisiológicamente 
vías de supervivencia ha recibido, sin embargo, poca o ninguna atención. 
Varios orgánulos dentro de la célula pueden generar ROS fisiológicamente. Estos 
incluyen las mitocondrias, el retículo endoplásmico y los peroxisomas. Además, 
varias enzimas, incluidas oxidasas y oxigenasas, generan ROS como parte de sus 
ciclos de reacción (Holmström and Finkel, 2014). Asimismo, la generación de 
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ROS es específica de especie, célula y tejido, y también depende del estado 
fisiopatológico de las células. Por estas razones, la identificación de la principal 
fuente intracelular de los ROS es compleja. 
Dentro del sistema nervioso central, las neuronas y los astrocitos, los dos tipos de 
células más abundantes en el cerebro, presentan un patrón diferencial de 
producción de los ROS mitocondriales (mROS), siendo las células gliales las que 
producen más mROS (López-Fabuel et al., 2016). Sin embargo, el papel 
fisiológico de esta producción de mROS por parte de los astrocitos aún se 
desconoce. 
Tradicionalmente, los ROS se consideran como especies no reguladas y nocivas, 
con dianas intracelulares aleatorias. Aunque este aspecto inespecífico, aleatorio y 
dañino de la biología de los ROS persiste, un creciente número de evidencias 
ahora sugiere que los ROS actúan como moléculas de señalización en varios 
procesos fisiológicos (D'Autréaux and Toledano, 2007; Holmström and Finkel, 
2014; Wang and Hai, 2016). Sin embargo, esta visión no está libre de 
controversia. Las especies reactivas de oxígeno, en particular el peróxido de 
hidrogeno, son segundos mensajeros capaces de modular rutas involucradas en la 
transcripción nuclear, diferenciación celular, muerte celular y envejecimiento, 
entre otros. Cabe destacar la importancia del factor de transcripción nuclear NRF2 
[nuclear factor (erythroid-derived-2)-like 2], el principal regulador de la respuesta 
antioxidante que está modulado por ROS. En condiciones basales, los niveles de 
NRF2 se mantienen bajos gracias a su degradación por parte del proteosoma 
mediada por el complejo formado por KEAP1 (Kelch-like ECH-associated 
protein 1) y CUL3 (Cullin 3) (Kobayashi et al., 2004). Actuando como un sensor 
de estrés redox, KEAP1 presenta múltiples tioles, cuya modificación lleva a un 
cambio conformacional de KEAP1 que conduce a la acumulación nuclear de 
NRF2 (Taguchi et al., 2011). Una vez en el núcleo, NRF2 promueve la 
transcripción de una plétora de genes implicados en la respuesta a diferentes tipos 
de estrés celulares (Taguchi et al., 2011). La ruta de NRF2 tiene un papel crucial 
en el cerebro, debido al hecho de que modula la transcripción de todas las enzimas 
involucradas en la homeostasis del glutatión, fundamental para mantener el estado 
redox de las neuronas. En el cerebro, los astrocitos son el reservorio principal de 
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GSH, mientras que las neuronas dependen del suministro de precursores de GSH 
por parte de las células gliales para sintetizarlo (Bolaños, 2016). Además de la 
regulación positiva de las defensas antioxidantes, recientemente se ha descubierto 
que NRF2 modula la homeostasis redox modulando la expresión de las NADPH 
oxidasas (NOXs), enzimas productores de ROS. La actividad de NRF2 reprime la 
expresión de la NOX2, mientras que aumenta la expresión de NOX4 (Kovac et 
al., 2015; Wei et al., 2016), aunque los mecanismos aún se desconocen. Estos 
enzimas producen ROS utilizando equivalentes reductores procedentes de 
NADPH, producidos mayoritariamente en la vía de las pentosas fosfato (PPP) 
gracias a la acción de la glucosa-6-fosfato deshidrogenasa (G6PD) y la 6-
fosfogluconato deshidrogenasa (6PGD) (Wamelink, et al., 2008). Esta ruta oxida 
la glucosa para producir ribosa-5-fosfato, necesaria para la síntesis de ácidos 
nucleicos, así como para regenerar NADPH para mantener la homeostasis redox y 
para ciertos procesos anabólicos (Riganti et al., 2012). 
2. HIPÓTESIS 
Los ROS han estado tradicionalmente asociados a situaciones de estrés redox e 
involucrados en la etiología de las patologías humanas, incluidas las 
enfermedades neurodegenerativas. Aunque los tratamientos con antioxidantes en 
modelos in vitro e in vivo de enfermedades neurodegenerativas han demostrado 
protección neuronal, la traslación a humanos no ha sido concluyente (Halliwell, 
2013; Heyland et al., 2013; Kamat et al., 2008; Snow et al., 2010), lo que 
cuestiona el papel patológico de los ROS. 
Resultados recientes de nuestro laboratorio muestran que, en condiciones basales, 
los astrocitos producen más ROS mitocondriales (mROS) en comparación con las 
neuronas (López-Fabuel et al., 2016). Esto parece ser una paradoja, considerando 
que los astrocitos expresan una robusta maquinaria antioxidante, gracias a una 
elevada actividad de la ruta NRF2, en comparación con las neuronas (Jimenez-
Blasco et al., 2015). Además, los astrocitos sustentan las defensas antioxidantes 
de las neuronas proporcionándoles los precursores del glutatión (GSH), gracias a 
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la acción de NRF2 en los astrocitos. Sin embargo, los mecanismos responsables 
de la alta actividad de la vía de NRF2 en los astrocitos aún se desconocen. 
Con estos antecedentes, nuestra hipótesis es que los mROS endógenos mantienen 
activa la ruta de NRF2 en los astrocitos contribuyendo a la supervivencia 
neuronal. 
3. OBJETIVOS 
Para abordar la hipótesis mencionada, nos hemos planteado los siguientes 
objetivos: 
 
1. Generar un modelo de ratón capaz de disminuir los niveles de mROS 
endógenos en astrocitos. 
 
2. Estudiar si los mROS endógenos modulan la homeostasis redox en los 
astrocitos. 
 
3. Estudiar si los mROS astrocíticos modulan la homeostasis redox y la 




1. Generación del ratón +/mCAT constitutivo 
Teniendo en cuenta los resultados preliminares en MEFs inmortalizados y 
astrocitos primarios transfectados, se generó el ratón inducible mitocatalasa 
(mCATfloxed/+), insertando la construcción mCAT en el locus Rosa 26 de células 
madre embrionarias de ratón con fondo C57Bl/6 por recombinación homóloga. 
Además, entre el fuerte promotor CAG y la mCAT, se insertó un cassette con la 
señal STOP floxeado. 
Con el fin de expresar mCAT de forma ubicua, los ratones mCATfloxed/+ se 
cruzaron con ratones (CMV)-Cre recombinasa bajo un fondo C57Bl/6, lo que 
produjo la línea de ratón C57Bl6+/mCAT (en adelante mCAT). La descendencia se 




2. Expresión constitutiva de la mCAT en los astrocitos primarios 
La presencia de la mCAT se confirmó en los astrocitos primarios. Primero, la 
expresión del epítopo HA y la abundancia de la catalasa se detectaron mediante 
transferencia de tipo Western en extractos de células enteras. Como era de 
Figura 1: Ejemplo de un gel de PCR. El genotipo de los ratones fue determinado por PCR. Los animales 
wild type presentan sólo una banda a 729 bp, mientras que en los mCAT aparece una banda adicional a 245 
bp. Como controles se utilizó DNA procedente de la cola de los ratones parentales.  
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esperar, los astrocitos +/mCAT mostraron una mayor abundancia de la catalasa, 
de unas 6 veces, en comparación con los WT (Figura 2A) y expresaron el epítopo 
HA (Figura 2B). Posteriormente, se confirmó la localización mitocondrial de la 
mCAT. Así, después de un fraccionamiento subcelular, se detectó HA en las 
mitocondrias aisladas de los astrocitos +/mCAT (Figura 2C). Sin embargo, se 
detectó también una pequeña banda correspondiente a HA en el compartimento 
citosólico de los astrocitos +/mCAT, lo que probablemente refleja la proteína 
recién sintetizada. En conjunto, estos resultados confirman que la mCAT se 
expresa correctamente en las mitocondrias de los astrocitos +/mCAT. 
 
Figura 2: Presencia del epítopo HA y abundancia de la catalasa en astrocitos primarios. El análisis de la 
transferencia de Western reveló que los astrocitos +/mCAT tienen niveles más altos de catalasa respecto a los 
WT (A) y presentan HA (B). Después de un fraccionamiento subcelular, la localización mitocondrial de HA 
se analizó mediante transferencia de Western (C). Se utilizó b-actina como control de carga del extracto total, 
GAPDH como control de carga citosólico y VDAC como control de carga mitocondrial. Los datos son 
expresados como la media ± SEM; *p<0,05 test t-Student; n=3 experimentos independientes. 
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3. La mCAT constitutiva destoxifica eficientemente el peróxido 
de hidrogeno y disminuye los niveles de los ROS endógenos en 
los astrocitos primarios 
El siguiente paso fue confirmar la funcionalidad de la mCAT y corroborar si su 
expresión constitutiva es suficiente para disminuir los niveles de mROS 
endógenos en astrocitos primarios. 
La actividad catalítica de la mCAT se midió en mitocondrias aisladas de astrocitos 
primarios WT y +/mCAT incubados con diferentes concentraciones de peróxido 
de hidrogeno exógeno. Los resultados mostrados en la Figura 3 demuestran que 
las mitocondrias que expresan mCAT neutralizan el peróxido de hidrógeno 
exógeno más rápidamente que las células WT. Después de 20 minutos, la 
totalidad del peróxido de hidrógeno exógeno se neutralizó por completo mediante 
la acción de la mCAT a todas las concentraciones de peroxido de hidrogeno 
utilizadas. No obstante, parece que la mCAT no es capaz de disminuir los noveles 
de los ROS en ausencia de peróxido de hidrógeno. En este sentido, hay que tener 
en cuenta que el método colorimétrico utilizado para medir la actividad de la 






Por esta razón, se utilizaron dos sondas más sensibles: Amplex Red y MitoSox. Se 
midió la liberación de peróxido de hidrógeno por parte de las mitocondrias 
aisladas y de los astrocitos intactos con la sonda Amplex Red. El resultado 
mostrado en la Figura 4A indica que, en condiciones basales, tanto las 
mitocondrias +/mCAT como los astrocitos intactos liberan menos peróxido de 
hidrógeno respecto a los WT. A continuación, se utilizó la sonda MitoSox. Esta 
sonda sensible a mROS penetra en la mitocondria en función del potencial de 
membrana mitocondrial (Dym), por lo que diferencias en Dym podrían alterar la 
acumulación mitocondrial de MitoSox. Por lo tanto, es necesario monitorizar 
Dym. Usando la sonda DilC1(5), Dym se determinó por citometría de flujo y los 
resultados demuestran ausencia de diferencias significativas entre astrocitos WT y 
+/mCAT (Figura 4B). Posteriormente, se midió la fluorescencia de MitoSox y el 
resultado indica que los astrocitos +/mCAT presentan una menor abundancia de 
mROS (~20%) en comparación con los WT (Figura 4C). 
Figura 3: La expresión constitutiva de la mCAT aumenta la destoxificación mitocondrial del peróxido 
de hidrogeno en astrocitos primarios. La incubación de mitocondrias aisladas con diferentes 
concentraciones de peróxido de hidrogeno exógeno durante diferentes tiempos mostró que la expresión 
constitutiva de la mCAT aumenta de manera significativa la velocidad de destoxificación del peróxido de 
hidrogeno a todas las concentraciones testadas. En ausencia de peróxido de hidrogeno, no se han encontrado 
diferencias entre las mitocondrias que expresan la mCAT y los WT. Los datos son expresados como la media 
± SEM; *p<0,05 test t-Student; n=3 experimentos independientes. 
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En conjunto, estos resultados muestran que mCAT eficientemente neutraliza el 
peróxido de hidrógeno exógeno, y que su expresión constitutiva en astrocitos 
primarios es suficiente para disminuir los niveles de los mROS endógenos. 
Además, estos cambios en el entorno redox en las células gliales no afectan al 
Dym. 
 
Figura 4: La expresión constitutiva de la mCAT disminuye los niveles de mROS y ROS endógenos en 
astrocitos primarios. (A) Células enteras y mitocondrias aisladas que expresan constitutivamente la mCAT 
liberan menos peróxido de hidrogeno respecto a los WT. (B) La medición del Dym ha sido analizado 
mediante citometría de flujo. No se encontraron diferencias entre los astrocitos WT y +/mCAT. (C) El 
análisis de los mROS ha sido realizado por citometrá de flujo utilizando la sonda MitoSox Red. Los astrocitos 
+/mCAT tienen menos mROS respecto a los WT. Los datos son expresados como la media ± SEM; *p<0,05 
test t-Student; n=3 experimentos independientes. 
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4. Los mROS endógenos modulan la acumulación nuclear y la 
actividad funcional de NRF2 en astrocitos primarios 
Para investigar si los mROS endógenos modulan la acumulación nuclear de NRF2 
en astrocitos, realizamos fraccionamiento subcelular y la abundancia de NRF2 se 
detectó mediante transferencia tipo Western en las fracciones citosólica y nuclear. 
Como se muestra en la Figura 5A, los núcleos obtenidos a partir de astrocitos 
+/mCAT presentan una menor abundancia de NRF2 en comparación con los WT, 
mientras que no se encontraron diferencias en el compartimento citosólico. 
Para investigar si la disminución de la localización nuclear de NRF2 en astrocitos 
+/mCAT podría afectar a su actividad transcripcional, los niveles de mRNA de 
varios genes diana de NRF2 se midieron mediante RT-qPCR. Los genes elegidos 
fueron NADPH-quinona deshidrogenasa 1 (Nqo1), glutamato-cisteína ligasa 
subunidad catalítica (Gclc), glutatión peroxidasa-2 (Gpx2), hemo-oxigenasa 1 
(Ho-1), tiorredoxina-1 (Trx1), nuclear factor (erythroid-derived-2)-like 2 (Nrf2), 
peroxiredoxina-1 (Prdx1), 6-fosfogluconato deshidrogenasa (6pgd) y glucosa-6-
fosfato deshidrogenasa (G6pd). Los primeros siete genes analizados mostraron 
menores niveles de mRNA en astrocitos mCAT, aunque Prdx1 no de manera 
significativa (Figura 5B). Sorprendentemente, la abundancia de los transcritos de 
los genes 6pgd y G6pd era superior en astrocitos +/mCAT, lo que sugiere la 
existencia de un mecanismo particular de control de su expresión. 
En conjunto, estos resultados muestran que los mROS endógenos modulan la 






5. La disminución de los niveles de mROS endógenos aumenta la 
abundancia de los enzimas de la PPP 
La glucosa-6-fosfato deshidrogenasa (G6PD) cataliza el primer paso limitante de 
la vía de las pentosas fosfato (PPP). Con el fin de investigar si el aumento de la 
transcripción del gen G6pd conlleva un aumento de la proteína G6PD, se estudió 
Figura 5: La disminución de los mROS endógenos modula la acumulación nuclear de NRF2 y su 
actividad. (A) Los núcleos aislados de los astrocitos +/mCAT mostraron una menor acumulación nuclear de 
NRF2. Se utilizó GAPDH como control de carga citosólica y Lamina B como control de carga nuclear. (B) 
La expresión de varios genes diana de NRF2 se evaluó por RT-qPCR. Se utilizó b-actina como housekeeping 




su abundancia mediante transferencia tipo Western. Como se muestra en la 
Figura 6A, los astrocitos +/mCAT expresan una mayor abundancia de G6PD en 
comparación con los WT. Además, se evaluó la abundancia de 6-fosfogluconato 
deshidrogenasa (6PGD). La 6PGD cataliza la tercera reacción de la fase oxidativa 
del PPP, consistente en la descarboxilación del 6-fosfogluconato formando 
ribulosa-5-fosfato. Este enzima es fundamental en el mantenimiento de la 
homeostasis redox celular, porque junto con G6PD, es el principal sistema 
regenerador del NADPH citosólico (Wamelink et al., 2008). Este coenzima juega 
un papel clave en la homeostasis del glutatión (GSH) al suministrar los 
equivalentes reductores necesarios para reducir GSSG a GSH (Wamelink et al., 
2008). En astrocitos +/mCAT, los niveles de proteína de 6PGD son más altos que 
en los WT (Figura 6B). 
 
Figura 6: La disminución de los mROS endógenos aumenta la abundancia de G6PD y 6PGD en 
astrocitos primarios. El análisis de la transferencia de Western mostró que los astrocitos +/mCAT tienen una 
mayor abundancia de G6PD (A) y 6PGD (B) respecto a los WT. Se utilizó b-Actina como control de carga. 
Los datos son expresados como la media ± SEM; *p<0,05 test t-Student; n=3 experimentos independientes.  
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6. La disminución de los niveles de los mROS endógenos aumenta 
la expresión de miR-1 y miR-206 
Recientemente se ha puesto de manifiesto un mecanismo de regulación alternativa 
de la transcripción de varios genes relacionados con la vía PPP (Singh et al., 
2013). Este mecanismo está mediado por la histona deacetilasa HDAC4, que se 
acumula en el núcleo cuando los dos residuos de cisteína, Cys-667 y Cys-669, 
están en su estado reducido (Ago et al., 2008). De esta manera, HDAC4 reprime 
la transcripción de dos microRNA, miR-1 y miR-206, los cuales degradan el 
mRNA recién sintetizado de varios genes relacionados con la vía PPP, además del 
propio HDAC4 (Singh et al., 2013). 
El aumento de los niveles de los mRNA de G6pd y 6pgd que hemos observado es 
compatible con este mecanismo. Puesto que los astrocitos +/mCAT presentan un 
entorno menos oxidante, los residuos de cisteína de HDAC4 podrían estar en su 
estado reducido. De ser así, HDAC4 estaría localizado en el núcleo reprimiendo la 
transcripción de miR-1 y miR-206, lo que conllevaría una estabilización de los 
mRNA de G6PD y 6PGD. Para dilucidar esta hipótesis, la abundancia de HDAC4 
en la fracción nuclear se evaluó mediante transferencia tipo western. Los 
resultados revelan que la abundancia de HDAC4 en el núcleo es mayor en los 
astrocitos +/mCAT que en los WT (Figura 7A). Para confirmar estos resultados, 
evaluamos las abundancias de los miR-1 y 206 mediante RT-qPCR. Los datos 
obtenidos muestran que las abundancias de los miR-1 y 206 en los astrocitos 






7. La disminución de los niveles de los mROS endógenos aumenta 
el flujo de glucosa hacia la PPP 
Con objeto de dilucidar si los incrementos en las abundancias de mRNA y 
proteína de G6PD y 6PGD correlacionan con un aumento en el flujo de glucosa a 
través del PPP, a continuación determinamos la velocidad de esta vía metabólica 
utilizando un protocolo optimizado en nuestro laboratorio (Rodríguez-Rodríguez 
et al., 2013). Como se muestra en la Figura 8A, el flujo de glucosa oxidada a 
través de la vía PPP es un 40% mayor en los astrocitos mCAT  que en los WT. 
Figura 7: La disminución de los mROS endógenos aumenta la abundancia nuclear de HDAC4 y 
disminuye la expresión de miR-1 y miR-206. El análisis de la transferencia tipo Western mostró que los 
astrocitos +/mCAT presentan una mayor abundancia nuclear de HDAC4 (A) respecto a los WT. Se utilizó 
Lamina B como control de carga nuclear. (B) El análisis por RT-qPCR reveló que los astrocitos +/mCAT 
expresan menos miR-1 y miR-206 respecto a los WT. Se utilizó miR-202 como control interno. Los datos son 
expresados como la media ± SEM; *p<0,05 test t-Student; n=3 experimentos independientes. 
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Una de las funciones principales de la vía PPP es la regeneración del NADPH 
necesario para mantener la homeostasis redox y otras vías anabólicas (Wamelink 
et al., 2008). Dado que la disminución de los mROS astrocíticos aumenta los 
niveles de G6PD y 6PGD junto con la tasa de PPP, se midió la razón 
NAPDH/NADP+. Sorprendentemente, los astrocitos +/mCAT mostraron una 
razón NAPDH/NADP+ menor qua la de los WT (Figura 8B). Este resultado se 
podría explicar por un mayor consumo de NADPH en los astrocitos +/mCAT, 
entre otras posibles razones. 
 
8. Los mROS endógenos modulan la producción de superóxido 
extracelular en los astrocitos 
En estudios muy recientes se ha observado que la G6PD se encuentra muy 
próxima a los enzimas productores de ROS, NADPH-oxidasas (NOX) (Yang et 
al., 2016). Esta familia de enzimas utiliza NADPH para producir superóxido o, 
según la isoforma, peróxido de hidrógeno. Además, recientemente se ha 
demostrado que NRF2 reprime la expresión de NOX2, mientras que aumenta la 
expresión de NOX4 (Kovac et al., 2015; Wei et al., 2016), aunque se desconoce 
Figura 8: La disminución de los mROS endógenos aumenta flujo de la glucosa oxidada a través de la 
PPP. (A) El flujo de la PPP fue evaluado incubando los astrocitos con glucosa marcada radioactivamente. 
Las células +/mCAT mostraron un incremento de la oxidación de la glucosa a través de la PPP respecto a los 
WT. Sin embargo, los astrocitos +/mCAT presentan una menor razón NADPH/NADP+ comparados con los 




el mecanismo. Considerando que los astrocitos +/mCAT muestran una menor 
actividad de NRF2 y, probablemente, más consumo de NADPH en comparación 
con los WT, decidimos evaluar los niveles de mRNA de NOX1, -2, -4. Los datos 
obtenidos ilustran que los astrocitos +/mCAT expresan niveles más altos de 
mRNA de NOX1 y NOX2 (46% y 51%, respectivamente), mientras que 
disminuyen los niveles de NOX4 en comparación con los WT (Figura 9A). 
Teniendo en cuenta que NOX1 y -2 producen superóxido extracelular, mientras 
que NOX4 produce peróxido de hidrógeno, se determinó la liberación de 
superóxido extracelular. Como se muestra en la Figura 9B, los astrocitos 
+/mCAT liberan un 20% más de superóxido extracelular en comparación con los 
WT. Estos resultados indican que la disminución de los mROS endógenos en 
astrocitos primarios aumenta la expresión de NOX1 y NOX2, pero disminuye los 
niveles de NOX4. Este aumento de las dos isoformas de NOX responsables de la 
producción de superóxido extracelular es compatible con el aumento observado de 
este ROS. Además, el aumento de NOX1 y NOX2 es consistente con el aumento 
en el consumo de NADPH observado en los astrocitos +/mCAT. Sin embargo, se 






9. El rescate de los niveles de NRF2 disminuye la liberación de 
superóxido en los astrocitos 
Con el fin de corroborar que la deficiencia de NRF2 conduce a un aumento en la 
liberación de superóxido extracelular a través de la actividad de las NOX1 y -2, 
los astrocitos +/mCAT se transfectaron con un cDNA codificante para una forma 
fosfomimética de NRF2 (NRF2 PM). Esta isoforma de NRF2 se transloca 
directamente al núcleo e incrementa la transcripción de sus genes diana. El 
plásmido se diseñó y se validó previamente en nuestro laboratorio (Jimenez-
Blasco et al., 2015). 
Primero confirmamos la correcta expresión de NRF2 mediante RT-qPCR y 
transferencia de tipo Western. Como se muestra en la Figura 10A, los astrocitos 
+/mCAT transfectados con NRF2 PM expresan unas 35 veces más mRNA de 
Nrf2 en comparación con el plásmido vacío. La transferencia de tipo Western 
reveló dos bandas de NRF2, concretamente la constitutiva (con un peso molecular 
de 100 kDa) y la fosfomimética, que se detecta a 130 kDa. Como era esperable, 
Figura 9: Los mROS endógenos modulan la expresión de las NOXs y la liberación del superóxido 
extracelular. Los astrocitos +/mCAT presentan una mayor expresión de las NOX-1 y -2, mientras una 
disminución de la NOX-4 respecto a los WT (A), lo que lleva a un aumento de la liberación del superóxido 




sólo los astrocitos transfectados con NRF2 PM mostraron dos bandas (Figura 
10B). 
 
Posteriormente, los niveles de mRNA de NOX1, -2 y -4 se midieron en astrocitos 
+/mCAT transfectados con NRF2 PM. Los datos obtenidos muestran que la 
transfección de astrocitos +/mCAT con NRF2 PM restableció los niveles de 
mRNA de NOX1, -2 y -4 en comparación con las células WT transfectadas con el 
plásmido vacío (Figura 11A). A continuación, se midió la liberación de 
superóxido extracelular con el fin de determinar si la expresión de NRF2 PM era 
suficiente para restablecer los valores basales. Como se ilustra en la Figura 11B, 
los astrocitos +/mCAT liberaron un 10% más de superóxido extracelular en 
comparación con las células WT cuando se transfectaron con el plásmido vacío. 
Sin embargo, no se encontraron diferencias entre las células +/mCAT 
transfectadas con NRF2 PM frente a las células WT transfectadas con el plásmido 
vacío. En conjunto, estos resultados confirman que NRF2 reprime la expresión de 
NOX1 y -2, mientras que aumenta NOX4 en astrocitos. Además, el rescate de los 
Figura 10: La expresión de NRF2 PM aumenta la abundancia de NRF2 en los astrocitos +/mCAT. (A) 
Se midieron los niveles de expresión de Nrf2 mediante RT-qPCR, utilizando b-actina como housekeeping 
gene. Los astrocitos +/mCAT transfectados con NRF2 PM muestran una expresión ~35 veces mayor respecto 
a las células transfectadas con el plásmido vacío. (B) El análisis de la transferencia tipo Western mostró que 
los astrocitos +/mCAT transfectados con NRF2 PM tienen un pequeño incremento de la expresión de la 
forma constitutiva de NRF2, como se aprecia en la banda de 100 kDa, y expresan una banda adicional a 130 
kDa que corresponde a NRF2 PM, respecto a las células transfectadas con el plásmido vacío. Los datos son 
expresados como la media ± SEM; *p<0,05 test t-Student; n=3 experimentos independientes. 
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niveles de NRF2 en los astrocitos +/mCAT restaura la liberación basal de 
superóxido extracelular, lo cual sugiere que los mROS modulan la liberación de 
ROS extracelular a través de un mecanismo mediado por NRF2. 
 
10. Los mROS endógenos modulan la abundancia del glutatión en 
astrocitos primarios a través de la vía NRF2 
El glutatión (GSH) se sintetiza en dos pasos consecutivos, ATP-dependientes, 
catalizados por la glutamato cisteína ligasa (GCL) y glutatión sintasa (GS), 
respectivamente (Dringen, 2000). El primer paso es el limitante, razón por la cual 
la expresión y actividad de GCL controlan la síntesis de GSH. La disminución de 
los mROS endógenos en astrocitos conlleva una menor expresión del gen Gclc 
(Figura 5B). Con el fin de investigar si esta disminución de la transcripción del 
gen Gclc conduce a una menor síntesis de GSH en astrocitos +/mCAT, se 
evaluaron las abundancias de la proteína GCL y de GSH total. La transferencia de 
tipo Western mostró una disminución de la abundancia de la GCL en astrocitos 
+/mCAT en comparación con los WT (Figura 12A). Como era esperable, los 
Figura 11: La transfección de los astrocitos +/mCAT con NRF2 PM restablece la expresión basal de las 
NOXs y la liberación del superóxido. Los astrocitos +/mCAT que expresan NRF2 PM no muestran 
diferencia en la expresión de NOX1, -2 y -4 (A) ni en la liberación de superóxido extracelular (B) respecto a 
los WT transfectado con plásmido vacío. Se utilizó b-actina como housekeeping gene. Los datos son 
expresados como la media ± SEM; *p<0,05 test t-Student; n=3 experimentos independientes. 
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astrocitos +/mCAT mostraron una disminución (20%) de la concentración de 
GSH (Figura 12B). 
Con el fin de investigar si los mROS astrocíticos modulan la abundancia de GSH 
a través de la ruta NRF2, los astrocitos +/mCAT se transfectaron con NRF2 PM. 
Como se observa en la Figura 12C, la expresión de NRF2 PM aumenta la 
abundancia de la proteína GCL en astrocitos +/mCAT. Posteriormente se midió la 
concentración total de GSH. Coherentemente con el aumento de la GCL, los 
astrocitos +/mCAT transfectados con NRF2 PM mostraron una concentración de 
GSH total mayor (Figura 12D). En conjunto, estos resultados sugieren que los 






Figura 12: Los mROS endógenos modulan la síntesis del GSH a través de la vía NRF2. (A) El análisis de 
la transferencia de tipo Western muestra que los astrocitos expresan una menor cantidad de GCL respecto a 
los WT. (B) La medición de los niveles de glutatión mostró que los astrocitos +/mCAT tienen una menor 
cantidad de GSH respecto a los WT. La transfección de los astrocitos +/mCAT con NRF2 PM aumenta la 
abundancia de la GCL (C) y la concentración de GSH (D) respecto al plásmido vacío. Se utilizó b-Actina 




11. Las neuronas co-cultivadas con astrocitos +/mCAT presentan 
menos defensas antioxidantes, un aumento de la liberación de 
ROS y más apoptosis 
Con el fin de investigar si la disminución de los mROS endógenos astrocíticos 
altera la homeostasis redox y supervivencia de las neuronas, se realizaron co-
cultivos de astrocitos y neuronas. Como se presenta en la Figura 13A, las 
neuronas co-cultivadas con astrocitos +/mCAT muestran una disminución del 
27% en la concentración total de GSH en comparación con las neuronas co-
cultivadas con astrocitos WT. Con el objetivo de determinar si este déficit de 
GSH altera la homeostasis redox neuronal, se midió el peróxido de hidrógeno. 
Como aparece en la Figura 13B, las neuronas produjeron más peróxido de 
hidrógeno cuando se co-cultivaron con astrocitos +/mCAT. Para averiguar si estos 
cambios en las defensas antioxidantes afectan a la supervivencia neuronal, se 
midió la actividad de la caspasa-3 (CSP-3) como marcador de apoptosis en 
neuronas co-cultivadas en condiciones basales o tras un tratamiento con 100 µM 
de etopósido, un activador de la apoptosis. La liberación de AMC, marcador de la 
actividad de la CSP-3, fue mayor en neuronas co-cultivadas con astrocitos 
+/mCAT en condiciones basales (Figura 13C). Después de un tratamiento de 4 
horas con etopósido, la actividad de CSP-3 aumentó significativamente en las 
neuronas; sin embargo, como se muestra en la Figura 13C, el aumento fue mayor 
en neuronas co-cultivadas con astrocitos +/mCAT en comparación con neuronas 
co-cultivadas con astrocitos WT. 
En conjunto, estos datos confirman la importancia del suministro de precursores 
de GSH de los astrocitos para la homeostasis neuronal. Además, sugieren que la 
disminución de los niveles de mROS endógenos astrocíticos altera la homeostasis 





12. La expresión de NRF2 PM en los astrocitos +/mCAT 
restablece las defensas antioxidantes y la supervivencia de las 
neuronas 
Para investigar si los mROS astrocíticos modulan la homeostasis redox y la 
supervivencia neuronal a través de la ruta NRF2, se co-cultivaron las neuronas 
con astrocitos +/mCAT previamente transfectados con NRF2 PM o con el 
plásmido vacío. Posteriormente se determinaron la concentración total de GSH, la 
liberación de peróxido de hidrógeno y la actividad de CSP-3 en las neuronas. 
Figura 13: Las neuronas co-cultivadas con astrocitos +/mCAT muestran una disminución en las 
defensas antioxidantes y una incrementada liberación de ROS y apoptosis. La incubación de las neuronas 
con astrocitos +/mCAT durante 4 días disminuye el pool neuronal de GSH (A), lo que lleva a un aumento de 
la liberación de ROS (B) y a una mayor activación apoptótica respecto a las neuronas co-cultivadas con 




Como se ilustra en la Figura 14A, las neuronas co-cultivadas con astrocitos 
+/mCAT previamente transfectados con NRF2 PM mostraron niveles más altos de 
GSH, alcanzando los valores de neuronas co-cultivadas con astrocitos WT 
(Figura 13A). A continuación se midió la liberación de peróxido de hidrógeno y, 
tal como se representa en la Figura 14B, las neuronas co-cultivadas con astrocitos 
+/mCAT, previamente transfectadas con NRF2 PM, mostraron una disminución 
del ~40% en la liberación de peróxido de hidrógeno respecto a las neuronas co-
cultivadas con astrocitos +/mCAT transfectados con el plásmido vacío. 
Finalmente, para corroborar si la expresión de NRF2 PM en los astrocitos rescata 
la muerte neuronal, se evaluó la actividad de CSP-3. La Figura 14C muestra que 
las neuronas co-cultivadas con astrocitos +/mCAT que expresan NRF2 PM tenían 
una menor actividad de CSP-3 en comparación con las neuronas co-cultivadas con 
astrocitos transfectados con el plásmido vacío. 
En conjunto, estos resultados son consistentes con el trabajo previo de nuestro 
laboratorio (Jimenez-Blasco et al., 2015) que demuestra que el aumento de la vía 
NRF2 en los astrocitos lleva a un aumento de las defensas antioxidantes y de la 
supervivencia neuronales. Además, nuestros datos demuestran que los mROS 
astrocíticos endógenos modulan la homeostasis redox y aumentan la viabilidad de 






La expresión de una forma mitocondrial de la catalasa permite 
estudiar el papel fisiológico de los mROS 
Tradicionalmente, el exceso de ROS ha sido asociado a estrés oxidativo y 
enfermedades humanas. Sin embargo, los ensayos clínicos basados en 
antioxidantes no han sido concluyentes (Halliwell, 2013; Heyland et al., 2013; 
Figura 14: La expresión de NRF2 PM en los astrocitos +/mCAT restablece las defensas antioxidantes y 
la supervivencia de las neuronas co-cultivadas. La expresión de NRF2 PM en los astrocitos +/mCAT 
restablece los niveles de GSH (A) y disminuye la liberación de ROS (B) por parte de las neuronas co-
cultivadas, respecto al plásmido vacío. Además, se incrementa levemente, pero de manera significativa, la 
viabilidad neuronal tras el co-cultivo de las neuronas con los astrocitos +/mCAT que expresan NRF2 PM 
comparado con el plásmido vacío. Los datos son expresados como la media ± SEM; *p<0,05 test t-Student; 
n=3 experimentos independientes. 
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Kamat et al., 2008; Snow et al., 2010), lo que cuestiona un papel patológico para 
los ROS. 
Por otro lado, para investigar las funciones de los ROS, la mayoría de los estudios 
anteriores utilizan estrategias basadas en su aumento, ya sea por vías exógenas o 
endógenas. Sin embargo, este enfoque podría enmascarar los papeles beneficiosos 
de los ROS endógenos. En este trabajo, presentamos un enfoque alternativo 
consistente en la disminución de los niveles de mROS endógenos. Varios modelos 
de ratones diseñados con este fin ya han sido descritos. Sin embargo, tienen 
efectos secundarios sobre el metabolismo (Chen et al., 1998; Matsushima et al., 
2006; Quintana-Cabrera et al., 2012). La estrategia utilizada en este trabajo para 
disminuir los mROS endógenos está basada en la expresión de una forma 
mitocondrial de la catalasa, la cual neutraliza el peróxido de hidrógeno con un 
efecto mínimo sobre metabolismo. De hecho, se ha descrito previamente un 
modelo de ratón mCAT (Schriner et al., 2005). Sin embargo, la técnica de 
microinyección convencional utilizada para generar ese modelo tiene dos 
inconvenientes principales: una inserción del constructo de DNA no dirigida y la 
imposibilidad de controlar el número de copias insertadas. Por lo tanto, es incierto 
si los efectos observados se deben a la actividad de mCAT o a cualquier efecto 
desconocido causado por la alteración de la expresión génica. 
En consecuencia, diseñamos un modelo de ratón mCAT para investigar los 
papeles fisiológicos de los mROS. La construcción mCAT se insertó en el locus 
Rosa26 de células madre embrionarias de ratón con fondo C57Bl/6 mediante 
recombinación homóloga. Esta técnica inserta sólo una copia de la construcción 
mCAT en un locus definido. Además, el modelo se generó basado en la estrategia 
Cre-LoxP, que permite controlar la expresión de mCAT in vivo de una manera 
específica del tejido y controlada por tiempo. 
Los resultados obtenidos en este trabajo muestran que este modelo de ratón 
mCAT es capaz de disminuir los niveles de los mROS endógenos enlos astrocitos 





Los mROS endógenos modulan la homeostasis redox en los 
astrocitos primarios a través de la vía NRF2 
La ruta NRF2 es esencial para la homeostasis redox en el cerebro. Sin embargo, 
su actividad difiere entre los dos tipos de células más abundantes, neuronas y 
astrocitos. Las neuronas muestran las defensas antioxidantes reprimidas debido a 
la desestabilización continua de la proteína NRF2 (Bell et al., 2015; Jiménez-
Blasco et al., 2015). Por el contrario, NRF2 es altamente estable en los astrocitos, 
lo que explica sus robustas defensas antioxidantes (Habas et al., 2013; Jiménez-
Blasco et al., 2015). No obstante, aún se desconoce el mecanismo según el cual 
NRF2 se estabiliza en astrocitos. En este contexto, un estudio reciente demostró 
que los astrocitos producen más mROS que las neuronas en condiciones basales 
(López-Fabuel et al., 2016). Sin embargo, las funciones fisiológicas de esta 
producción glial de mROS no se conocen. 
Los resultados obtenidos en este trabajo demuestran que los mROS endógenos en 
los astrocitos mantienen altos los niveles de activación de NRF2, promoviendo la 
expresión de sistemas antioxidantes que así contribuyen a mantener su robusta 
maquinaria antioxidante. Por otro lado, NRF2 modula la expresión de los enzimas 
productores de ROS, NADPH-oxidasas, en astrocitos. En particular, NRF2 
reprime la expresión de NOX-1 y -2 y aumenta la expresión de NOX-4, de 
acuerdo con trabajos previos (Kovac et al., 2015; Wei et al., 2016). El mecanismo 
(s) conforme al cual NRF2 modula la expresión de las NOXs es desconocido. Se 
puede especular que el aumento en la producción de superóxido extracelular 
observado en los astrocitos que contienen menos mROS podría ser una señal 
redox para las neuronas vecinas, lo que indicaría una alteración del metabolismo 
astrocítico. 
Hasta donde sabemos, ésta es la primera evidencia de que los mROS endógenos 
modulan la homeostasis redox a través de la ruta NRF2 en los astrocitos. 
 
Los mROS endógenos modulan el flujo de la glucosa hacia la PPP 
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La PPP es una ruta metabólica cuya función principal en el cerebro adulto es 
regenerar NADPH para contribuir a la homeostasis redox celular. Los datos 
presentados en este trabajo muestran que la disminución de los mROS endógenos 
en astrocitos aumenta el flujo de la glucosa a través de la vía PPP. Estos datos 
están en aparente contradicción con la noción ampliamente difundida de que los 
ROS, al activar NRF2, promueven la expresión de G6pd y 6pgd aumentando la 
actividad de la PPP (Hayes and Dinkova-Kostova, 2014; Stincone et al., 2015). 
Sin embargo, se ha demostrado que NRF2 modula la expresión de genes 
relacionados con la vía PPP a través de un mecanismo indirecto involucrando 
modificaciones epigenéticas (Singh et al., 2013). 
En este trabajo mostramos que los astrocitos que presentan menos mROS 
muestran una actividad NRF2 disminuida a pesar de la aumentada transcripción 
de genes relacionados con la vía PPP. Nuestros datos sugieren que los mROS 
modulan la expresión de G6PD y 6PGD al promover la localización nuclear de 
HDAC4, que reprime la expresión de miR-206. Este miRNA se une a los mRNAs 
G6PD y 6PGD para su degradación, lo que lleva a la disminución de los niveles 
de proteína. 
En conjunto, estos resultados demuestran que los mROS endógenos pueden 
modular el metabolismo de la glucosa en los astrocitos. El mecanismo epigenético 
sugerido es coherente con el estudio de Singh et al. (2013) y demuestra una vez 
más que G6pd y 6pgd no son genes diana de NRF2. Sería muy interesante 
investigar si otras vías metabólicas también se ven afectadas en los astrocitos 
+/mCAT, con el fin de tener una visión más amplia del papel de los mROS en la 
regulación del metabolismo celular. 
 
Los mROS endógenos son neuroprotectores 
El estrés oxidativo es una característica distintiva de varias enfermedades 
neurodegenerativas. Así, los ROS han sido siempre considerados como especies 
dañinas. Sin embargo, el hecho de que los astrocitos produzcan una cantidad 
considerable de mROS (López-Fabuel et al., 2016) sugiere una función 
fisiológica de estos mROS. 
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Los astrocitos protegen a las neuronas co-cultivadas de los daños oxidativos 
(Bélanger and Magistretti, 2009; Dringen, 2000; Wilson, 1997) al aumentar las 
defensas antioxidantes a través del suministro de precursores de GSH (Bolaños et 
al., 1996; Dringen et al., 1997). Este fenómeno, que ha sido denominado 
lanzadera de glutatión astrocito-neurona (Bolaños, 2016), se mantiene mediante la 
activación constitutiva de NRF2 en astrocitos (Jimenez-Blasco et al., 2015). De 
hecho, la idea de que la activación de NRF2 en los astrocitos aumenta la 
supervivencia neuronal frente a un daño oxidativo es un fenómeno bien conocido, 
tanto in vitro (Jakel et al., 2007; Jiménez-Blasco et al., 2015; Shih et al., 2003) 
como en modelos animales de enfermedades neurodegenerativas (Chen et al., 
2009; Vargas et al., 2008). Sin embargo, en estos estudios, la actividad de NRF2 
en astrocitos se vio aumentada artificialmente por su sobreexpresión o su 
activación farmacológica. En este trabajo, demostramos que los mROS endógenos 
juegan un papel importante en la activación de NRF2 en astrocitos, y a través de 
este mecanismo ejercen neuroprotección. Un estudio previo sugirió que niveles 
subtóxicos de peróxido de hidrógeno astrocítico no activan NRF2 y desencadenan 
procesos independientes de NRF2 que protegen las neuronas co-cultivadas 
(Haskew-Layton et al., 2010). Sin embargo, estas conclusiones fueron 
cuestionadas (Bell et al., 2011). Además, las dosis subtóxicas de peróxido de 
hidrógeno utilizadas activan NRF2 en astrocitos (Bell et al., 2011). Si bien estos 
datos concuerdan con nuestros resultados, la dosis de peróxido de hidrógeno 
probada fue unas 16 veces mayor que los niveles fisiológicos que observamos en 
astrocitos en nuestro laboratorio (López-Fabuel et al., 2016). Por lo tanto, 
creemos que incluso utilizando concentraciones subtóxicas de peróxido de 
hidrógeno, se podría desencadenar una señal redox aberrante que podría 
enmascarar el papel neuroprotector de los mROS astrocíticos endógenos. 
Cabe destacar que el rescate de los niveles de NRF2 en astrocitos mCAT sólo 
restauró parcialmente la supervivencia de las neuronas co-cultivadas. Estos datos 
sugieren que los mROS endógenos pueden modular otras rutas neuroprotectoras 
además de NRF2. Una posibilidad interesante que merece la pena estudiar es si la 
glucólisis, una ruta metabólica fundamental en las interacciones metabólicas entre 
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los astrocitos y las neuronas (Pellerin and Magistretti, 1994), se ve afectada en los 
astrocitos que presentan menos mROS. 
Los datos obtenidos en este trabajo confirman una vez más que los mROS 
endógenos desempeñan papeles fundamentales en el mantenimiento de la 
homeostasis celular, como se observa en diferentes tejidos (Puente et al., 2014; 
Zhou et al., 2016). Este trabajo demuestra por primera vez que los mROS 
astrocíticos endógenos tienen un papel neuroprotector. Además, se puede 
especular que los ensayos clínicos basados en la estrategia antioxidante en 
pacientes que padecen enfermedades neurológicas no han sido concluyentes 
debido a que los antioxidantes eliminan los ROS de forma inespecífica en todas 
las células cerebrales. Proponemos que este enfoque podría ser más beneficioso si 
se disminuyen los ROS específicamente en las neuronas, y no en los astrocitos 
que demostramos ser neuroprotectores. Estas consideraciones deben tenerse en 
cuenta para el diseño de nuevas terapias antioxidantes en el futuro. 
6. CONCLUSIONES 
A la luz de los resultados presentados en esta Tesis, hemos obtenido las siguientes 
conclusiones: 
1. Hemos caracterizado parcialmente un nuevo modelo de ratón que expresa 
condicionalmente una isoforma mitocondrial de la catalasa (mitoCatalasa 
o mCAT). Este modelo ha sido diseñado por nuestro grupo, y se generó 
externamente y específicamente para este proyecto, mediante la inserción 
dirigida de la secuencia mCAT en el locus Rosa26 de células madre 
embrionarias de la cepa C57Bl/6 de ratón mediante recombinación 
homóloga. La inserción se logró de tal manera que, en el modelo 
resultante, la expresión del cDNA de la mCAT está bajo el control del 
promotor ubicuo CAG. Se insertó un cassete de STOP transcripcional 
floxeado (flanqueado con loxP) entre la secuencia mCAT y el promotor 
CAG para permitir que la expresión del transgén resultante dependa de la 
recombinasa Cre (mCATfloxed/+). Al cruzar mCATfloxed/+ con los ratones 
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C57Bl/6 que expresan la recombinasa Cre de forma ubicua, se obtuvieron 
ratones que expresan constitutivamente la mCAT (ratón mCAT). 
 
2. Los astrocitos corticales primarios obtenidos del ratón mCAT muestran 
una reducción significativa en la producción de especies reactivas de 
oxígeno mitocondriales endógenas (basales) (mROS). Aprovechando este 
sistema, demostramos que los mROS endógenos controlan la expresión de 
genes antioxidantes mediante la regulación positiva de la actividad de 
NRF2 [nuclear factor (erythroid-derived 2)-like 2] en los astrocitos. A su 
vez, NRF2 reprime la producción de ROS extracelulares, reprimiendo la 
expresión de las NADPH-oxidasas (NOX) tipo -1 (NOX1) y -2 (NOX2). 
 
3. Utilizando astrocitos corticales primarios obtenidos del ratón mCAT, 
demostramos que los mROS endógenos regulan la oxidación de la glucosa 
a través de la vía de las pentosas fosfato (PPP). De hecho, la disminución 
de los mROS endógenos aumentó la actividad de PPP a través de un 
mecanismo mediado por la reducción de la histona desacetilasa 4 
(HDAC4) sensible a ROS. En su estado reducido, HDAC4 es 
constitutivamente activa en el núcleo, donde reprime la expresión de miR-
1 y miR-206, que a su vez reprimen las abundancias de los mRNAs de 
G6PD y 6PGD. Aquí demostramos que los mROS disminuyen la 
acumulación de HDAC4 en el núcleo, lo que lleva a la disminución de la 
abundancia de miR-1 y miR206, y aumenta la expresión de G6PD y 6PGD 
junto con la actividad de la vía PPP. Por lo tanto, en los astrocitos, los 
mROS mantienen parcialmente reprimida la actividad de la PPP, 
representando la primera evidencia que conecta la producción endógena de 
mROS con la regulación del metabolismo de la glucosa. 
 
4. En experimentos en los que los astrocitos mCAT se co-cultivaron con 
neuronas WT, mostramos que los mROS de los astrocitos afectan el estado 
redox y la supervivencia de las neuronas. Así, los mROS endógenos de los 
astrocitos, al mantener NRF2 activa, contribuyen al mantenimiento de la 
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abundancia total de glutatión en las neuronas. Además, a través de este 
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Lois, Aoife, Nathalie, Michel e Cécile per le trasferte a Dublino e Siena tra pubs 
irlandesi e feste di contrada. 
Grazie a Gerard e Laura per aver reso speciale i tre mesi a Dublino, tra una 
(eterna) chiacchierata post pranzo e una birra al canale. 
Grazie al Añover Vacioplast Salamanca, soprattutto ad Andrés, Chucky, Palotes, 
Daniel, Mapache, Mario, Bekele, Pablo, Miguel, Boria, Huesines, Popi, Nate, 
Roberto e Rodri per avermi tenuto un minimo in forma in una squadra dove ciò 
che più importa sono il pusse e il buon ambiente. Il basket è qualcosa di superfluo. 
Grazie alla Gatta, che mi riempie di amore incondizionato ogni volta che rientro a 
casa. 
Grazie alla mia famiglia, che nonostante negli ultimi quattro anni ci siamo visti 
meno di un mese, mi sono sempre stati vicino. È grazie a voi che sono arrivato fin 
qui. 
Grazie a Emilie per avermi seguito in questa avventura charra. Grazie per esserci 
sempre stata ad ascoltare le mie lamentele e sfoghi, a correggere le mie bozze e a 
rincuorarmi nei momenti tristi. Tu meglio di tutti conosci lo sforzo e i sacrifici 
fatti per questa Tesi e sai che è anche tua. Adesso non sappiamo quello che ci 
aspetterà, ma sappiamo che lo affronteremo assieme. 
Infine, grazie a me stesso, per non aver mai mollato e aver continuato nonostante 
le difficoltà. Una volta finito il dottorato, il futuro è ancora più incerto e 
parafrasando il Sommo poeta: 
 
 
“(Quasi) Nel mezzo del cammin di nostra vita, 
mi ritrovai per una selva oscura 
ché la diritta via era smarrita.” 
 
